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Abstract 
 
The gut microbiota play a pivotal role in the onset and development of obesity and 
cardiometabolic disorders. Obese subjects exhibit significant gut microbial changes, 
including enrichment for bacterial genes associated with the degradation of tryptophan, 
which is converted by gut bacteria into indoles. Indoles act as signalling molecules in 
the microbial-mammalian crosstalk; however, their human targets and mechanisms are 
not fully understood. In particular, the human kinome remains an unexplored 
repertoire. The overall hypothesis of this work is that indoles bind human kinases, 
impact signalling pathways and interfere with cellular processes relevant for obesity 
and cardiometabolic diseases, thus acting as chemical messengers in the microbiome-
kinome crosstalk. Gut microbial degradation of tryptophan converges to the production 
of indoxyl sulfate and indole-3-acetate. Using 1H NMR profiling, indoxyl sulfate was 
found to be positively correlated with adiposity and plasma levels of leptin; its effect 
was further confirmed in vitro, where it increased both lipid accumulation and leptin 
production. A high-throughput kinase screening revealed that indoxyl sulfate has 
kinome-wide effects and was subjected to a network analysis to connect its pro-
adipogenic effect. Kinase screening and molecular docking analysis suggest that 
another indolic compound, indole-3-acetate, inhibits VEGFR-2 - a kinase-linked 
receptor essential for angiogenesis and involved in several cardiometabolic disorders 
(e.g. atherosclerosis, diabetes, and hypertension). This inhibition was validated in vitro 
by demonstrating that indole-3-acetate reduces the phosphorylation of VEGFR-2 and 
downstream AKT signalling in endothelial cells. Consistently, indole-3-acetate 
inhibited endothelial cell migration and tube formation, which are required for 
angiogenesis in vitro, and decreased vascular network formation in an in vivo 
angiogenesis model. Altogether, this study unravels a unique microbiome-kinome 
crosstalk by demonstrating that specific gut microbiota-generated indoles can impact 
adipogenesis (indoxyl sulfate) and angiogenesis (indole-3-acetate), two key processes 
in obesity and cardiometabolic disorders. 
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Chapter 1 
Introduction 
 
Obesity is a well-established risk factor for various medical conditions, including 
type 2 diabetes, dyslipidaemia and arterial hypertension (Gelber, et al., 2007; Shamai, 
et al., 2011; Speliotes, et al., 2010); it is also an independent risk factor for 
cardiovascular disease (CVD), the leading cause of mortality worldwide (WHO, 2016). 
Due to the close relationship between obesity and its co-morbidities, these conditions 
are often referred to collectively as cardiometabolic disorders.  
 
A growing body of evidence supports that the gut microbiota play a critical role 
on the onset and development of cardiometabolic disorders. This complex microbial 
community communicates with its mammalian host via a range of signalling molecules, 
that can lately impact obesity and CVD (Delzenne and Cani, 2011; Xu and Gordon, 
2003). In this chapter, the basic mechanisms and aetiology of obesity and CVD will be 
revisited, as well as the concept of gut microbial metabolites - in particular the indoles 
- as signalling molecules that, by binding human targets and activating signalling 
pathways, influence human health and disease.  
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1. Obesity and cardiometabolic diseases 
1.1 Obesity 
 
Obesity is one of the most important public health problems of the 21st century. 
In 2014, worldwide prevalence of obesity and overweight was, respectively, 13% and 
39%, comprising over 1.9 billion individuals (WHO, 2016). Although initially 
considered a public health problem of high-income countries only, the prevalence of 
obesity has also steadily increased in low and middle-income countries, assuming 
pandemic proportions (WHO, 2016). 
 
Obesity is a well-established risk factor for type 2 diabetes, dyslipidaemia, 
arterial hypertension, musculoskeletal disorders and cancer (Anandacoomarasamy, et 
al., 2008; Chen, et al., 2012; Dougan, et al., 2015; Gelber, et al., 2007; Genkinger, et 
al., 2011; Ma, et al., 2013; Shamai, et al., 2011; Speliotes, et al., 2010; Wang and Xu, 
2014). Obesity also contributes greatly to cardiovascular-related mortality, both as an 
independent risk factor and due to its association with other cardiovascular risk factors 
(Hubert, et al., 1983). 
 
The disability associated with obesity affects the individual’s quality of life and 
predisposes them to increased frailty (Blaum, et al., 2005). The social and economic 
impact of obesity has also steadily increased in the last few decades. In Europe, obesity 
is now estimated to account for more than 12 million years lost due to ill-health 
(disability-adjusted life years (DALYs)) (Ezzati M, 2004) and to cost more than 59 
billion euros per year (OECD, 2012). As a leading cause of disability, morbidity, 
mortality and healthcare costs, strategies to reduce obesity rates are considered a 
priority for health care organisations worldwide (Cuschieri and Mamo, 2016).   
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1.1.1 Clinical assessment of obesity  
 
Obesity is defined as an excessive accumulation of fat mass, as consequence of 
the imbalance between energy intake and energy expenditure. In obese patients, fat 
mass is mostly compartmentalised in two body locations: the abdominal region (central 
fat mass) and the limbs (peripheral fat mass). Central fat mass, comprising visceral 
adipose tissue and abdominal subcutaneous fat, has a positive association with CVD 
(Despres, et al., 2008; Phillips and Prins, 2008). Peripheral fat mass, especially 
gluteofemoral fat, might be less atherogenic, due to a lower fatty acid turnover and a 
different hormonal production profile (Ferreira, et al., 2004; Frayn, 2002). 
 
Several measurements have been proposed to assess obesity. The Body Mass 
Index (BMI), defined as the ratio between weight (in kg) and the square of height (in 
m2) (Keys, et al., 1972), is one of the most extensively used. According to the World 
Health Organisation, individuals with a BMI of 30 kg/m2 or higher are classified as 
obese, while those with values between 25 kg/m2 and 29.9 kg/m2 are considered 
overweight (WHO, 2016). BMI measurements are simple, inexpensive and non-
invasive; however, their sensitivity and predictive power have been questioned (Pories, 
et al., 2010; Romero-Corral, et al., 2008). It is important to note that BMI is a 
surrogate marker based on a mathematical estimation, not a direct measurement of 
the individual’s fat mass (Shah and Braverman, 2012). Consequently, it incorporates 
the contribution of other body components such as muscle mass and bone mass. As an 
example, high BMI can be observed in individual with muscular hypertrophy; while 
patients with sarcopenic obesity (increased adiposity in the presence of decreased lean 
mass) may exhibit normal BMI values (Donini, et al., 2013). Some authors propose 
that obesity would be better described by central obesity anthropometric measures 
(e.g. waist circumference, waist-to-hip ratio and waist-to-height ratio) (Wells and 
Fewtrell, 2006).  
 
Recently, more advanced techniques have allowed the direct quantification of 
both the individual’s fat mass (FM) and the fat-free mass (FFM) (e.g. densitometry, 
dual energy X ray absorptiometry (DEXA)). These methods provide direct 
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quantification of FM, and do not rely on predictive models based on anthropometric 
measurements, thus being more accurate than BMI (Wells and Fewtrell, 2006).  
 
1.1.2 Obesity, insulin resistance and metabolic syndrome 
 
Obesity is a major risk factor for several chronic metabolic complications, 
including type 2 diabetes, dyslipidaemia and arterial hypertension (Alberti, et al., 
2005). Each 1-unit increase in an individual’s BMI value increases by 8% the risk of 
incident arterial hypertension over 14.5 years (Gelber, et al., 2007). Obesity is also an 
independent risk factor for type 2 diabetes; it is estimated that the risk increases 
between 4.5 and 9% for every kilogram of weight gained (Ford, et al., 1997). Higher 
BMI values are associated with a deleterious lipid profile, characterised by increased 
levels of triglycerides and reduced levels of high-density lipoprotein (HDL) cholesterol 
(Shamai, et al., 2011) The epidemiological clustering of obesity with other metabolic 
disorders led to the introduction of the concept of “metabolic syndrome”, a predictive 
marker for the risk of type 2 diabetes and CVD (Despres, et al., 2008; Kim and Reaven, 
2004). According to the latest guidelines of the International Diabetes Federation 
(IDF), metabolic syndrome is diagnosed in the presence of central obesity (BMI  30 
kg/m2 or, if below, increased waist circumference, defined by ethnicity specific values), 
plus one of the following criteria: raised plasma glucose, raised systolic blood pressure, 
raised total cholesterol or reduced HDL cholesterol (IDF, 2005). 
 
 Obesity plays a central role in the onset of the metabolic syndrome: the 
accumulation of adipose tissue triggers local inflammatory responses and the release of 
cytokines that desensitise insulin signalling pathways in peripheral tissues, leading to 
insulin resistance (Bonder, et al., 2016). Consequently, the plasma concentration of 
glucose increases, and pancreatic -cells respond by increasing the production of insulin 
(hyperinsulinemia) (Benson, 2016). Eventually, the inability of the pancreatic β-cells 
to produce sufficient insulin leads to the transition from insulin resistance to type 2 
diabetes (Jeffery, et al., 2012). Insulin resistance also reduces the uptake of circulating 
lipids and increases lipolysis, increasing the concentration of circulating lipids and 
ultimately promoting dyslipidaemia (Atarashi, et al., 2013; Sender, et al., 2016). 
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1.1.3 Basic mechanisms of obesity and energy homeostasis 
 
Obesity develops as a result of energy intake in excess of energy expenditure; as 
a consequence, excess energy is stored in adipocytes in the form of triglycerides (TG). 
For most organisms, the main energy source is glucose; however, free fatty acids (FFA) 
and amino acids can also be used as alternative energy sources.  
 
 Dietary carbohydrates are digested into monosaccharides (mainly glucose), 
which are transported from the intestine to various tissues for energy production 
(Towle, et al., 1997). In most tissues, the major pathway for adenosine triphosphate 
(ATP) production is the metabolism of glucose into pyruvate (glycolysis) (Han, et al., 
2016; Pilkis, et al., 1988). In mitochondria-rich tissues, pyruvate enters the 
mitochondrial matrix and is converted into acetyl-CoA, which is then incorporated in 
the tricarboxylic acid cycle (TCA) (Figure 1). The TCA cycle generates not only 
guanosine triphosphate (GTP), an energy equivalent of ATP, but also reduced 
nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide 
(FADH2) that act as electron carriers for the process of electron transport chain-
oxidative phosphorylation, thus generating ATP (Han, et al., 2016). 
 
In case of energy surplus, excessive glucose is metabolised into Acetyl-CoA, 
which is then used for FFA synthesis via lipogenesis (Kersten, 2001; Towle, et al., 
1997) (Figure 1). FFA are esterified with glycerol, producing triglycerides that are 
stored in adipose tissue, liver and peripheral tissues (Towle, et al., 1997). Excess 
glucose can also be stored in the liver in the form of glycogen, a secondary energy 
source (glycogenesis) (Pilkis, et al., 1988).  
 
Energy storage is tightly controlled by glucoregulatory hormones, amongst 
which insulin is the main one (Giugliano, et al., 2008). In state of energy excess, insulin 
secretion increases and promotes glucose uptake by the cell, lipogenesis and 
glycogenesis, thus favouring energy storage (Giugliano, et al., 2008). Conversely, 
during fasting, there is a combined hormonal effect to increase glucose availability: 
insulin secretion is reduced and the production of glucagon, a hormone with opposite 
effects to insulin, increases (Aronoff, et al., 2004; Giugliano, et al., 2008). Glucagon 
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promotes the degradation of glycogen (glycogenolysis) in  liver and muscle (Han, et 
al., 2016). 
 
 
 
 
 
 
Figure 1. Overview of glucose, free fatty acid and amino acid metabolism. 
The three pathways share common metabolites that converge into the tricarboxylic acid (TCA) cycle.  
Glucose, amino acid and free fatty acid metabolic pathways share several common metabolites that 
converge into the TCA cycle (Rodwell, et al., 2015). Acetyl-CoA, pyruvate and other intermediary 
metabolites activate the TCA cycle, producing reduced coenzymes (i.e. NADH, FADH2). These 
coenzymes are further re-oxidised by oxidative phosphorylation, producing ATP that is finally used as 
an intracellular energy source. Asn: Asparagine, Asp: Aspartate, Ile: Isoleucine, Leu: Leucine, Phe: 
Phenylalanine, TG: triglycerides; Tyr: Tyrosine, Val: Valine). Designed based on information from 
(Rodwell, et al., 2015). 
 
 
 
 
In muscle, glycogenolysis provides an immediate source of glucose-6-phosphate 
for glycolysis, leading to the production of pyruvate (Han, et al., 2016). In hepatocytes, 
the main purpose of glycogenolysis is the release of glucose into the systemic circulation 
to be used by other cells. In this case, hepatic glucose-6-phosphatase removes the 
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phosphate group, and free glucose exits the cell via glucose transporter 2 (GLUT2) 
facilitated diffusion channels (van Schaftingen and Gerin, 2002). During fasting, 
glucagon also increases circulating glucose by increasing lipolysis, thus producing FFA 
that undergo -oxidation and produce acetyl-CoA (Miles and Jensen, 1993; Oscar, 
1991). 
 
As mentioned above, to avoid low glycaemic levels amino acids can also be used 
as secondary energy sources. Dietary protein breakdown by digestive enzymes 
generates peptides that enter enterocytes via peptide transporters; inside the 
enterocytes, peptides are converted into amino acids that finally enter systemic 
circulation (Rodwell, et al., 2015). Following nitrogen removal, most of the carbon 
atoms present in amino acids skeletons are degraded into TCA cycle intermediates, 
pyruvate and acetyl-CoA (Jungas, et al., 1992). Glucogenic amino acids (and other 
non-carbohydrate carbon substrates, e.g. pyruvate, glycerol) can also generate glucose 
via gluconeogenesis., a metabolic pathway taking place in liver and, to a lesser extent, 
in renal cortex (Jungas, et al., 1992) (Figure 1).  
 
Glucose, amino acid and free fatty acid metabolic pathways share several 
common metabolites that converge into the TCA cycle (Rodwell, et al., 2015). Acetyl-
CoA, pyruvate and other intermediary metabolites activate the TCA cycle (Figure 1), 
producing reduced coenzymes (i.e. NADH, FADH2). These coenzymes are further re-
oxidised by oxidative phosphorylation, producing ATP that is finally used as an 
intracellular energy source. 
 
Changes in glucose, FFA or amino acid metabolism promote significant 
disruption to physiological energy homeostasis. Excess glucose availability induces a 
deregulation of insulin action, in which cells fail to respond to this hormone and do 
not uptake glucose efficiently (insulin resistance) (Muoio and Newgard, 2008). As 
consequence, plasma levels of glucose increase (hyperglycaemia) and the energy surplus 
is stored in the form of TG (Unger, et al., 2010). 
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1.1.4 The multifactorial aetiology of obesity 
 
Although there is growing knowledge of the metabolic pathways involved in 
obesity, its causes are not completely understood. Most evidence suggests obesity has 
a multi-factorial aetiology, comprising genetic, environmental and epigenetic factors 
(Bleich, et al., 2008).  
 
To date, more than 50 genetic variants associated with obesity have been 
identified in genome-wide association studies (GWAS) (Herrera, et al., 2011; Leon-
Mimila, et al., 2013), including genes involved in the TCA cycle, glycolysis and 
inflammatory signalling (Cheung, et al., 2006). The obese (ob) gene and its product 
leptin are involved in the regulation of both appetite and energy expenditure in the 
mouse (Zhang, et al., 1994), but the frequency of this mutation is extremely rare in 
human populations (“syndromic obesity”) (Pi-Sunyer, et al., 1999). FTO, the first gene 
associated with non-syndromic obesity in humans, interacts through a noncoding 
region with the promoter of two homeobox genes (IRX3 and IRX5) which modulate 
obesity and body mass composition (Gerken, et al., 2007; Wahlen, et al., 2008). 
However, the combined contribution of all genetic variants only accounts for a small 
proportion of body weight variation; also, while the prevalence of obesity has steadily 
increased over the last three decades, genetic background has not changed greatly 
(Herrera, et al., 2011; Leon-Mimila, et al., 2013; Speliotes, et al., 2010). Altogether, 
these facts suggest that the growing prevalence of obesity is more likely to be explained 
by environmental changes and lifestyle factors rather than host genetics.  
 
Sedentary habits and high-carbohydrate, high-fat diets are known to promote a 
disproportion between energy intake and expenditure, resulting in increased body FM 
(WHO, 2016). Environmental stimuli can also trigger epigenetic mechanisms (e.g. 
histone acetylation, DNA methylation) that regulate the expression of genes involved 
in energy homeostasis (Musri and Parrizas, 2012). Interactions between environmental  
cues and epigenetic mechanisms associated with increased adiposity have been 
described for various genes, including MCR4, FTO, PPAR and POMC (Choy, et al., 
2010; Gerken, et al., 2007; Plagemann, et al., 2009; Widiker, et al., 2010). 
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Recently, the gut microbiota - a complex microbial community consisting of 
trillions of non-pathogenic commensal organisms living in a symbiotic relationship with 
its human host - have been suggested to play a pivotal role in obesity and its related 
metabolic co-morbidities (Delzenne and Cani, 2011). This perspective will be further 
explored in Section 2.3. Gut microbial changes in obesity and cardiovascular disease. 
 
1.2 Cardiovascular diseases 
 
Obesity is also an independent risk factor for CVD, a broad group of pathologies 
comprising vascular retinopathy, vascular nephropathy, peripheral artery disease, 
arterial hypertension, stroke and coronary artery disease (CAD) (Hubert, et al., 1983) 
(Figure 2). In 2013, CVD was the leading cause of death worldwide with a total of 
17.9 million deaths. CAD accounted for 80% and 75% of deaths in males and females, 
respectively (Brestoff and Artis, 2013). 
 
1.2.1 Clinical assessment of cardiovascular diseases 
 
CVD share a common mechanism: atherosclerosis (Guyton and Hall, 2005). The 
visualisation and characterisation of atherosclerosis in living patients is now possible 
by the use of several techniques. Amongst them, the echographic assessment of the 
intima media thickness assessment is particularly useful to detect the presence of 
atherosclerosis and predict the risk of acute events in high-risk patients (Al-Waiz, et 
al., 1987; Dolphin, et al., 1997). Coronary atherosclerosis can be further characterised 
by angiography (Craciun and Balskus, 2012), computed tomography (Al-Waiz, et al., 
1992) or resonance magnetic imaging (Al-Waiz, et al., 1987). 
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Figure 2. Cardiovascular complications associated with obesity and metabolic disorders. 
Both through a positive association with cardiometabolic risk factors and as an independent risk factor, 
obesity is associated with deleterious cardiovascular diseases. Designed using Servier Medical Art 
elements. 
 
1.2.2 Basic mechanisms of cardiovascular diseases: the role of 
atherosclerosis 
 
Atherosclerosis is a pathological process of the vascular endothelium, a 
monolayer of vascular endothelial cells that lines the entire circulatory system (Guyton 
and Hall, 2005) (Figure 3). This pathological process is the common underlying cause 
of several cardiovascular diseases, including stroke and coronary heart disease. 
 
The atherosclerotic process starts with the adhesion of leukocytes to the 
endothelial monolayer, followed by migration into the intima layer and, finally, 
maturation into macrophages (Libby, et al., 2011; Lusis, 2000). Macrophages are able 
to uptake lipid, leading to the formation of the initial atherosclerotic lesions - the “fatty 
streaks” (Guyton and Hall, 2005). The combined effect of several mechanisms 
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Figure 3. Trilaminar vascular structure. 
Arterial and venous vessels comprise three layers, at a macroscopic level. The innermost layer (also 
called intima) includes the endothelium, a monolayer of vascular endothelial cells. The midlle layer (also 
called media) contains mostly smooth muscle cells; it is separated from the other layers by the internal 
and external elastic membranes. The outermost layer  (also called adventitia) consists of fibroblasts and 
collagen fibers. Designed using Servier Medical Art elements. 
 
 
 
(i.e. migration of smooth muscle cells, increased synthesis of extracellular components, 
inflammation and oxidative stress) contributes to the progression of the lesion 
(Forstermann, et al., 2017; Hansson, 2005; Libby, et al., 2002). The last step of the 
natural history of atherosclerosis is thrombosis (Lusis, 2000). When the plaque 
ruptures, the tissue factors in its interior are exposed to the coagulation components 
present in the blood, triggering the formation of a thrombus that occludes the vascular 
lumen (Lusis, 2000). The blood flow is progressively limited by the increasing size of 
the atherosclerotic plaque, leading to stable angina, unstable angina and, if the blood 
flow is critically compromised, myocardial infarction and death (Guyton and Hall, 
2005). 
 
Atherosclerosis is closely linked to angiogenesis, the mechanism of formation of 
new blood vessels (Barger and Beeuwkes, 1990). However, the association is complex 
and likely dependent on the stage of the disease (Khurana, et al., 2005). Adventitial 
angiogenesis allows atherosclerotic plaques to develop beyond a critical thickness point, 
  
46 
by supplying them with oxygen and nutrients (Barger and Beeuwkes, 1990). In line 
with these results, associations between neovascularisation and the extent of the 
atherosclerotic plaque have been found in both primate and human studies (Kamat, et 
al., 1987; Williams, et al., 1988; Zhang, et al., 1993). In later stages of the disease, an 
increased neovascular network renders plaques more fragile and prone to rupture, 
leading to plaque destabilisation, luminal occlusion and, finally, acute coronary 
syndromes (Barger and Beeuwkes, 1990). A study involving 269 patients with 
advanced atherosclerotic lesions found a strong correlation between microvessel 
formation and plaque rupture (Moreno, et al., 2004). Moulton et al (1999) 
demonstrated that angiogenesis inhibitors (endostatin and TNP-470) are able to reduce 
the area of the plaque by 85% and 70%, respectively. Nevertheless, the authors 
cautiously point out that this effect may be due to non-specific effects of the compounds 
used (Moulton, et al., 1999). Interestingly, preclinical studies suggest that, after 
myocardial infarction, angiogenesis could actually have a beneficial effect by enhancing 
post-ischemic restorative revascularisation.  (Aicher, et al., 2005; Melo, et al., 2004). 
However, clinical trials have failed to demonstrate this beneficial effect and most of 
the current evidence globally supports that angiogenesis has a pro-atherogenic effect 
(Celletti, et al., 2001; Heeschen, et al., 2001). 
 
It is important to note that obesity also contributes to several basic mechanisms 
of atherosclerosis, thus explaining the epidemiological clustering of both conditions. 
First, by inducing profound hemodynamic changes, obesity indirectly increases 
metabolic demand, cardiac workload and ventricular pressure and increased blood 
pressure (Collis, et al., 2001; Ku, et al., 1994). The latter is associated with shear stress 
and oxidative stress, which promote endothelial dysfunction and contribute to the 
progression of the atherosclerotic plaque (Dharmashankar and Widlansky, 2010). 
Adipose tissue is not an inert energy storage tissue; conversely, it has an active role as 
the largest endocrine organ in humans, synthesising a range of products that impact 
the development and progression of CAD (Coelho, et al., 2013). Obese patients exhibit 
increased levels of pro-inflammatory cytokines (tumour necrosis factor- (TNF-) and 
interleukin-6 (IL-6)); IL-6 also increases the hepatic production of C-reactive protein 
(CRP), which enhances the uptake of low-density lipoprotein (LDL) cholesterol by 
macrophages in the atherosclerotic plaque (Mehta, et al., 2007). Finally, obesity creates 
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a pro-angiogenic environment (Miyazawa-Hoshimoto, et al., 2003). The expansion of 
the FM requires a simultaneous increase of the supporting vascular network, to provide 
an adequate supply of oxygen and nutrients (Cao, 2007). Therefore, adipose tissue 
expresses several growth factors that promote the formation of new blood vessels 
(angiogenesis), including fibroblast growth factor (FGF), placental growth factor 
(PIGF) and vascular endothelial growth factor (VEGF), the main regulator of 
angiogenesis and vascular endothelial cell function (Cao, 2007). Consistently, in human 
studies, BMI and visceral fat area measurements are positively correlated with VEGF 
concentrations (Miyazawa-Hoshimoto, et al., 2003), thus creating a pro-angiogenic – 
and consequently, pro-atherogenic – drive in these patients. 
 
1.2.3 The multifactorial aetiology of cardiovascular diseases 
 
Most evidence suggests that atherosclerosis has a multi-factorial aetiology, 
comprising both environmental and genetic factors. As previously mentioned, obesity 
is an independent risk factor for cardiovascular mortality (Engeland, et al., 2003); 
interestingly, children with higher BMI exhibit an increased risk of CVD in adulthood, 
highlighting the impact of early life programming on long-term cardiovascular 
outcomes (Baker, et al., 2007). Diabetes is also associated with a 2- to 3-fold increase 
in the likelihood of developing CVD (Fox, et al., 2004). Similarly, both systolic and 
diastolic blood pressure have a continuous and positive association with CVD outcomes 
(Stamler, et al., 1993). In individual aged between 50 and 70 years, an increment of 20 
mm Hg in systolic blood pressure was shown to double the risk of CVD (Lewington, 
et al., 2002). There is also a strong relationship between serum total cholesterol and 
cardiovascular risk (Stamler, et al., 1993). While, LDL cholesterol, the principal 
lipoprotein transporting cholesterol in the blood, is positively associated with CVD 
(Kannel, et al., 1979), HDL cholesterol levels are inversely correlated with coronary 
risk (Gordon, et al., 1989). 
  
Several environmental factors have also been implicated in CVD outcomes. A 
high consumption of processed meats increases CVD-related mortality, possibly due to 
increased salt intake (Gauch, 2003). Conversely, decreasing the consumption of 
saturated fat reduces this risk by 17% (Tzoulaki, et al., 2014). Moderate physical 
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activity (150 minutes of moderate physical activity each week) was shown to reduce 
the risk of CAD (Engin, 2017). Smokers have an increased risk of myocardial infarction 
or sudden death; importantly, the risk is proportional to the number of cigarettes 
smoked daily (Doyle, et al., 1962). Exposure to air pollutants, especially particulate 
matters, is also linked to high values of intima media thickness and an increased risk 
acute CVD events (Eckers, et al., 2016). 
 
To date, the genetic contribution to atherosclerosis seems to be mostly related 
to genes associated with lipid metabolism. APOE polymorphisms have been linked to 
atherosclerosis and hypercholesterolemia (Borrel, et al., 2017). APOE deficiency in 
mice results in a profound susceptibility to atherosclerosis; however, the same effect is 
not observed in humans (Borrel, et al., 2017). Common variants of LIPC, 
APOC3/A4/A5 and Apo(a) loci influence, respectively, the levels of HDL, triglycerides 
and lipoprotein(a) levels (Cohen, et al., 1999; Kinexus, 2017; Lustig, 2003). Both LIPC, 
and APOC3/A4/A5 loci seem to influence plasma lipoprotein(a) size, a known risk 
marker for CAD (Lustig, 2003). However, the estimated heritability of CAD is only 
between 40% and 60% (Lusis, 2000). As for all complex diseases, the phenotype of 
atherosclerosis is likely a product of many genes with small effects, modified by the 
environment and epigenetic effects. 
 
Recently, the gut microbiota was also proposed to contribute to the 
pathogenesis of CVD (Jonsson and Backhed, 2017). This perspective will be further 
explored in Section 2.3. Gut microbial changes in obesity and cardiovascular disease. 
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2. The gut microbiota  
 
A growing body of evidence supports that the gut microbiota, a complex 
microbial community inhabiting the human gut, plays a pivotal role in the 
development of obesity, metabolic diseases and CVD (Delzenne and Cani, 2011; Xu 
and Gordon, 2003).  
 
This section describes contributors to the gut microbiota, as well as changes 
observed in the composition in the context of obesity and CVD. The contribution of 
the healthy gut microbiota in relation to host barrier function, immunomodulation, 
metabolism and signalling is also discussed. Basic concepts of cell signal sensing and 
signal transduction are revisited, and exemplified with several cases of gut microbial 
metabolites that act as ligands for G-coupled protein receptors (GPCR) and nuclear 
receptors. Finally, the human kinome (i.e. the complete set of protein kinases encoded 
by the human genome) is introduced as an unexplored target for gut microbial 
metabolites. 
 
2.1  Composition of the gut microbiota  
 
For millions of years, humans have co-evolved in a symbiotic relationship with 
their microbial communities – termed the microbiota. Although many anatomical 
regions (e.g. skin, vaginal mucosa, respiratory system, oral cavity) harbour specific 
microbial populations, the digestive tract is by far the most populated system of the 
human body, home to the gut microbiota (Kim, et al., 2013). 
 
The gut microbiota consist of approximately 100 trillion of microbes, a number 
of the same order than the number of human cells (Sender, et al., 2016). The gut 
microbiome is the collective designation for the more than 10 million microbial genes 
coded by the gut microbiota (Backhed, et al., 2005; Li, et al., 2014). At the kingdom 
level, the gut microbiota are predominately bacteria; however, archaea, fungi and 
viruses are also present (Lozupone, et al., 2012). At the phylum level, more than 50 
different phyla of bacteria have been identified; amongst those, only four are dominant: 
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Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria (Arumugam, et al., 
2011). The relative proportion between phyla (in particular, the 
Firmicutes:Bacteroidetes ratio) was initially suggested to be especially relevant for 
human health; however, it was demonstrated that the gut Bacteroidetes/Firmicutes 
balance may not be a significant attribute of an individual’s gut microbiome; 
conversely, individuals carry a ‘personal equilibrium’ among Bacteroidetes and a group 
of temporally variable Firmicutes  (Lloyd-Price, et al., 2017) (Further details in Section 
2.3. Gut microbial changes in obesity and cardiovascular disease). 
 
At the genus level, cluster analysis revealed the existence of three distinct 
bacterial profiles, designated enterotypes (Arumugam, et al., 2011). The identification 
of each enterotype is based on the predominance of one of three main genera: 
Bacteroides (phylum Bacteroidetes), Prevotella (phylum Bacteroidetes) or 
Ruminococcus (phylum Firmicutes) (Arumugam, et al., 2011; Knights, et al., 2014).  
 
Although the classification into enterotypes provides an appealing framework to 
describe gut bacterial variation, the collapse of the continuous metagenomic bacterial 
variability into three discrete clusters remains a matter of debate (Jeffery, et al., 2012; 
Knights, et al., 2014). As the abundance of dominant taxa is a continuous gradient, 
predictive models based on the taxon-relative abundances have been suggested to be 
more effective as disease biomarkers than enterotype-based models (Knights, et al., 
2014). Also, enterotype-based models should be used carefully in cases in which specific 
bacteria (or bacterial genes) are associated with health or disease, as they may mask 
within-cluster variation of individual strains. In these cases, the use of single-effect 
models is likely to be more powerful as disease biomarkers (Knights, et al., 2014).  
 
The gut microbiota have also been profiled by quantitative metagenomics 
regarding their microbial genes, which seems to be an indicator for human health 
(Further details in Section 2.3. Gut microbial changes in obesity and cardiovascular 
disease). Several proxies and diversity indexes have been used, including the total 
bacterial gene count, microbial gene abundance (i.e. the number of different types of 
genes in a given sample, rarefaction at 6 or 7 M genes), the Chao1 index (based upon 
the number of rare classes found in a sample) and the Shannon index (that accounts 
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for both abundance and evenness of the species present (Le Chatelier, et al., 2013; 
Santacruz, et al., 2010) (Tuomisto, 2010). 
 
Finally, the composition of the gut microbiota varies across different segments 
and niches of the digestive trait (latitudinal variation). While the stomach and small 
intestine are sparsely populated, the luminal contents of the colon harbour a complex 
and densely populated bacterial ecosystem with up to 1012 cells/gram of intestinal 
content (Gill, et al., 2006). Intestinal pH and oxygen gradients influence the spatial 
distribution of the microbiota. Colon pH is mildly acidic in the proximal colon and 
more neutral distally; several Firmicutes species are more tolerant to acidic pH, thus 
exhibiting a competitive advantage in these conditions (Flint, et al., 2012). The colonic 
lumen is highly anaerobic and most colonic bacteria are strict anaerobes, mostly due 
to the consumption of available oxygen by facultative anaerobes (Flint, et al., 2012). 
In the colon, bacterial composition also varies between the mucosa and the crypts 
(longitudinal variation) (Swidsinski, et al., 2005) (Figure 4). The spatial relationship 
between the gut microbiota and the colonic epithelium may explain the differential 
responses (e.g. inflammation) promoted by specific bacterial groups (Swidsinski, et al., 
2005). 
 
 
 
Figure 4. Longitudinal variation of the microbial composition in human distal gut. Based on 
information taken from (Swidsinski, et al., 2005) and designed using Servier Medical Art graphic 
elements. 
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2.2 Host and environmental factors affecting gut microbial 
ecology 
 
The composition of the gut microbiota is a complex and polygenic trait, 
influenced by both intrinsic and extrinsic factors (e.g. diet, lifestyle) (Benson, et al., 
2010; Goodrich, et al., 2014). Furthermore, it experiences changes as a function of the 
host’s age (O' Toole and Jeffery, 2015). In this section, the impact of these factors 
across the life course will be described. 
 
Genetic factors 
 
Initial evidence suggesting a host genetic effect comes from studies showing that 
family members often share similar gut microbiota patterns (Tims, et al., 2013; 
Turnbaugh, et al., 2009). Although these similarities could be an effect of a shared 
environment, the effect of host genetic factors was reinforced in twin studies showing 
that microbiomes of monozygotic twins share more similarities than the ones of 
dizygotic twins (Benson, 2016; Bonder, et al., 2016; Goodrich, et al., 2016; Goodrich, 
et al., 2014). Specific gene-microbiota interactions were also identified: Nod2, for 
instance, was shown to be essential for the development of the gut microbiota 
(Rehman, et al., 2011); other genes were specifically associated with the abundance of 
certain genera, such as FUT2 and Bifidobacteria (Wacklin, et al., 2011). 
 
Early life 
 
The effect of environmental factors in the gut microbial ecology starts in utero. 
The identification of bacteria in the placenta and amniotic fluid of healthy newborns 
has challenged the widely accepted dogma that the placenta keeps foetuses sterile 
during pregnancy (Rodriguez, et al., 2015). Bacterial transmission during pregnancy 
was unequivocally demonstrated by the oral administration of a genetically labelled 
Enterococcus species to pregnant mice, followed by its identification in the amniotic 
fluid and in the first stool of the offspring, called meconium (Jimenez, et al., 2005). 
Human meconium also harbours a microbial ecosystem (Jimenez, et al., 2008), mostly 
dominated by Proteobacteria and Actinobacteria (Eckburg, et al., 2005). During the 
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first years of life the diversity of the gut microbiota increases, due to the emergence 
and subsequent dominance of Firmicutes and Bacteroidetes (Eckburg, et al., 2005). 
Several environmental factors are known to influence the development of the gut 
microbiota during childhood, including the mode of delivery (i.e. eutocic delivery versus 
caesarean section) (Jakobsson, et al., 2014; Salminen, et al., 2004) and breastfeeding 
(Fallani, et al., 2010). By 2-5 years of age, the ecology of the gut microbiota is fully 
developed, resembling that observed in adults both in terms of composition and 
diversity (Koenig, et al., 2011).  
 
Adult life 
 
Although the gut microbial ecosystem is relatively stable during adulthood, diet 
changes its composition (Faith, et al., 2013; Rodriguez, et al., 2015). Antibiotic 
treatment, even for short periods, can destabilise microbial ecology and affect metabolic 
programming, impacting long-term health (Cox, et al., 2014). Long-term dietary 
interventions are associated with the frequency of certain enterotypes: for example, 
carbohydrate-rich diets are associated with the Prevotella enterotype, whilst diets rich 
in animal protein and fat are linked to a higher prevalence of Bacteroides (Wu, et al., 
2011). Dietary supplements (e.g. sweeteners, prebiotics) and drugs (e.g. metformin) 
are also able to modify the gut microbiota, modulating both its ecology and functions 
(Forslund, et al., 2015; Suez, et al., 2014).  
 
Advanced age 
 
The ageing process also results in gradual changes in the gut microbiota over 
time (O' Toole and Jeffery, 2015). Subjects aged 65 years or older show different phyla 
proportions, with increased contribution of Bacteroides spp. (Claesson, et al., 2011) 
and reduced abundance of Prevotella (Jeffery, et al., 2016). It is important to note, 
however, that microbiota of elderly subjects exhibit extreme variability that can be 
explained by external factors (e.g. diet, exercise, medication and cohabitation patterns) 
(Claesson, et al., 2012). Frail elderly subjects exhibit a loss of diversity in the core 
microbiota groups and increased abundance of members of the order Clostridiales 
(Biagi, et al., 2010; Jeffery, et al., 2016). Further studies will shed light on whether 
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these changes are a consequence of the natural decline of general health, or if they are 
associated with specific co-morbidities in elderly subjects (Rodriguez, et al., 2015). 
 
2.3 Gut microbial changes in obesity and cardiovascular disease 
 
Over the last decades, studies have highlighted the critical role of the gut 
microbiota in the onset and development of obesity and CVD (Delzenne and Cani, 
2011; Jonsson and Backhed, 2017; Xu and Gordon, 2003).  
 
Gut microbial changes in obesity 
 
One of the first studies in the field demonstrated that transplanting gnotobiotic 
mice with the gut microbiota from an obese subject induced the development of the 
obese phenotype (Turnbaugh, et al., 2006). Similarly, transferring the gut microbiota 
of mice that underwent bariatric surgery into gnotobiotic mice also decreased body 
weight and fat mass (Liou, et al., 2013).  
 
Genetically obese mice (ob/ob) show an increase in Firmicutes and a decrease 
in Bacteroidetes, a phenotype that seems to be associated with more efficient energy 
extraction from dietary compounds (Turnbaugh, et al., 2006). These results were 
further replicated in various mouse models of obesity, most of them reporting an 
association between obesity, increased levels of Firmicutes and decreased levels of 
Bacteroidetes (Hildebrandt, et al., 2009; Murphy, et al., 2010; Turnbaugh, et al., 2008). 
In humans, obesity was also associated with a lower Bacteroidetes/Firmicutes ratio 
(Ley, et al., 2006). Cani et al (2007) demonstrated that a high-fat diet also profoundly 
affects the gut microbiota, decreasing the abundance of Bacteroides-like mouse 
intestinal bacteria, the [Eubacterium] rectale-Blautia coccoides group and 
Bifidobacterium spp. (Cani, et al., 2007). The less abundant phylum Proteobacteria is 
also increased in overweight patients (Santacruz, et al., 2010). 
 
A critical aspect of the microbial changes observed in obesity is an increase on 
the permeability of the gut barrier. Various mouse models of obesity are characterised 
by increased gut permeability and changes in the expression of tight-junction proteins 
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(e.g. claudin, occludin and zonula occludens 1) (Brun, et al., 2007; Cani, et al., 2008; 
Cani, et al., 2009; de La Serre, et al., 2010; Turner, 2009). As a consequence of increased 
intestinal permeability, obese patients exhibit a 2- to 5-fold increase in plasma levels 
of the microbiota-derived lipopolysaccharide (LPS), a component of the bacterial wall 
of Gram-negative bacteria (such as Escherichia, Klebsiella, Salmonella, Serratia spp.) 
with pro-inflammatory properties (Cani, et al., 2007; Cani, et al., 2007). The increase 
in the levels of LPS (which contributes to metabolic endotoxemia) dysregulates the 
inflammatory status of the host and triggers both weight gain and type 2 diabetes 
(Cani, et al., 2007). The association between high-fat diet, LPS levels, obesity and type 
2 diabetes has been further validated in several human studies (Amar, et al., 2008; 
Erridge, et al., 2007) (Pussinen, et al., 2011) and functional and compositional changes 
were also observed in the gut metagenomes of type 2 diabetes women, including 
enrichment of Clostridiales (Karlsson, et al., 2013).  
 
Functional analyses revealed that the microbiome from lean and obese twins 
express differences on the transcription of more than 300 enzymes (Ridaura, et al., 
2013). These data highlight that the relationship between the gut microbiota and 
metabolic parameters is complex and incorporates not only the impact of different 
taxa, but also different metabolic functions and resulting metabolites (Cani, 2014). 
Addressing this topic, some studies examined the impact of gene richness (i.e. the 
number of genes in the gut microbiome), a proxy marker for the diversity of microbial 
metabolic functions. Le Chatelier et al (2013) demonstrated that lower bacterial gene 
abundance (i.e. gene count) was associated with increased adiposity and deleterious 
metabolic outcomes (e.g. insulin resistance and inflammation) (Le Chatelier, et al., 
2013). Interestingly, dietary intervention was partially able to positively affect 
microbial gene richness (Cotillard, et al., 2013).  
 
Individuals with high gene count have a higher abundance of microbial anti-
oxidative stress genes and a higher genomic potential to produce short-chain fatty 
acids, which have been associated with metabolic beneficial outcomes (Le Chatelier, et 
al., 2013). Conversely, individuals with increased adiposity and low gene count exhibit 
a higher genomic potential for -glucuronide degradation and metabolism of aromatic 
amino acids (e.g. tryptophan) (Le Chatelier, et al., 2013). Upon bacterial metabolism, 
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tryptophan is degraded into a range of compounds designated indoles (Further details 
in the production of indoles and their impact in cardiometabolic health are provided 
in Section 2.5. The microbial mammalian signalling axis and Section 3. Indoles as a 
key family of gut microbial metabolites).   
 
Gut microbial changes in cardiovascular disease 
 
Both local and distant gastrointestinal infections can promote a pro-
inflammatory response, thus aggravating plaque development. There is a well-
established association between periodontal disease and CVD (Trevisan and Dorn, 
2010). Oral or intravenous administration of oral bacteria (i.e. Porphyromonas 
gingivalis and Aggregatibacter actinomycetemcomitans) promotes an increase in the 
size of atherosclerotic lesions in mouse models (Hayashi, et al., 2011).  
 
Patients with symptomatic atherosclerosis also harbour changes in their gut 
microbiome (Karlsson, et al., 2012). Using shotgun sequencing, Karlsson et al (2012) 
demonstrated that patients with stenotic carotid plaques have an enrichment of the 
genus Collinsella, while health controls were enriched in Roseburia and Eubacterium 
(Karlsson, et al., 2012). Further functional analyses revealed that patients with 
atherosclerosis had higher levels of genes encoding peptidoglycan and a depletion of 
phytoene dehydrogenase (Karlsson, et al., 2012). Patients with CAD exhibit an 
increased abundance of Bacteroides, Clostridium, and Lactobacillales (Emoto, et al., 
2017; Emoto, et al., 2016) 
 
Finally, the gut microbiota can influence atherosclerosis via the production of 
specific compounds that exhibit either beneficial (e.g. short-chain fatty acids (SCFA)) 
or harmful effects (e.g. trimethylamine-N-oxide (TMAO)). The mechanisms through 
which SCFA benefit cardiometabolic health are unclear but might involve systemic 
anti-inflammatory effects. TMAO promotes vascular inflammation, enhances platelet 
activation and thrombosis risk and its levels are an independent predictor of the 
presence of diffuse atherosclerotic lesions (Seldin, et al., 2016; Senthong, et al., 2016; 
Zhu, et al., 2016). The effects of TMAO are also thought to be, as least partially, 
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mediated by an inhibition of reverse cholesterol transport (Koeth, et al., 2014; Warrier, 
et al., 2015). 
 
2.4 Functions of the gut microbiota in health 
 
To better understand the impact of gut microbial changes in obesity and CVD, 
it is important to revisit the basic functions of the ‘healthy’ gut microbiota. Having 
evolved in a symbiotic relationship with its mammalian host, this microbial community 
performs a range of functions with wide-ranging effects on human physiology (Figure 
5).  
 
Barrier function 
 
The gut microbiota play a developmental role in early life, stimulating the 
formation of intestinal microvilli (Lloyd-Price, et al., 2017). During life, the gut 
microbiota are involved in the maintenance of the gut barrier, a layer of epithelial 
intestinal cells connected by junctional complexes (tight junctions, adherens junctions 
and desmosomes) (Groschwitz and Hogan, 2009) (Figure 5). While Bacteroides 
thetaiotaomicron induces the expression of proteins involved in the maintenance of 
desmosomes (Lutgendorff, et al., 2008), components of the bacterial cell wall were 
shown to contribute to the maintenance of tight junctions (Cario, et al., 2007). 
Unsurprisingly, germ-free mice exhibit marked changes in gut barrier structure, 
including reduced intestinal surface area and lower epithelial regeneration (Banasaz, 
et al., 2002; Gordon and Bruckner-Kardoss, 1961).  
 
Immunomodulation  
 
Immunomodulation is another important role of the gut microbiota (Figure 5). 
Gnotobiotic mice show an impaired development of immune organs (e.g. spleen and 
lymph nodes) (Bauer, et al., 1963) and lower levels of serum immunoglobulins (IgG1 
and IgG2) (Benveniste, et al., 1971). In fact, the gut microbiota are involved in the 
development of intestinal and systemic immune systems throughout the host’s life, 
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including the maturation of precursor lymphoid cells and IgA plasmocytes and the 
production of circulating cytokines (Brestoff and Artis, 2013; Franchi, et al., 2012; 
Geuking, et al., 2011; Rivollier, et al., 2012; Suzuki, et al., 2010). Gut microbiota, in 
particular Clostridia strains, promote the accumulation of T regulatory cells (TReg) 
(Atarashi, et al., 2013; Atarashi, et al., 2011). 
 
Figure 5. Functions of the healthy gut microbiota. 
Amongst the known functions of the gut microbiota, three aspects are particularly important: gut barrier 
homeostasis, immunomodulation and metabolic functions. 
 
 
Metabolism of dietary compounds 
 
The gut microbiota is also involved in the metabolism of various dietary 
compounds (Figure 5). Amongst these, products of the metabolism of carbohydrates, 
amino acids, bile acids and choline seem to be particularly relevant for obesity and 
cardiometabolic health (Chilloux, et al., 2016). Therefore, its production will be 
described in further detail.   
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The saccharolytic fermentation of indigestible fibre by the gut microbiota 
produces a range of SCFA (e.g. formate, acetate, propionate, butyrate, isobutyrate, 
valerate, isovalerate). The majority of the butyrate fraction is produced by 
Faecalibacterium prausnitzii, Eubacterium rectale and Eubacterium hallii (Seldin, et 
al., 2016). Propionate can be produced by a range of bacteria, including Negativicutes, 
Verrucomicrobia, Bacteroidetes and Lachnospiraceae (Hoyles, et al., 2017). 
Likewise, the gut microbiota is also able to metabolise bile acids: primary bile 
acids (cholic acid and chenodeoxycholic acid) synthesised by the liver enter the 
enterohepatic circulation where they are deconjugated, hydroxylated, oxidized and 
epimerized by the gut bacteria (e.g. Lactobacillus spp.) to form secondary bile acids 
(Hoyles, et al., 2017). Similarly, gut microbial species also degrade macronutrients; in 
particular, bacteria carrying operons encoding cutC and cutD are able to degrade 
choline into trimethylamine (TMA), which is further detoxified into TMAO by hepatic 
flavin-monooxygenase (FMO3) (Al-Waiz, et al., 1987; Al-Waiz, et al., 1992; Craciun 
and Balskus, 2012; Dolphin, et al., 1997). Gut archaea also play a role in choline 
metabolism, as genes for utilising TMA were found in Methanomassiliicoccales (Borrel, 
et al., 2017).  
Finally, the gut microbiota also contributes to the degradation of amino acids.  
Tyrosine and phenylalanine can be degraded into 4-cresol, via 4-hydroxyphenylacetate, 
by Clostridioides (formerly Clostridium) difficile and certain Lactobacillus strains 
(Santacruz, et al., 2010; Senthong, et al., 2016). Finally, tryptophan can be converted 
into indoles by tryptophanase-containing bacteria (Sasaki-Imamura, et al., 2011), 
leading to the production of indoles. 
Gut microbial metabolites can be used as energetic and nutritional sources or, 
importantly, act as signalling molecules in the microbial mammalian crosstalk. This 
signalling function is particularly important in the context of obesity and 
cardiometabolic diseases and will be explored in further detail in the next section. 
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2.5 The microbial-mammalian signalling axis 
2.5.1 Gut microbial metabolites as signalling molecules 
 
The concept of the “microbial-mammalian signalling axis” proposes that the gut 
microbiota communicate with its human host via microbial metabolites, i.e. signalling 
molecules that bind human targets and initiate cellular responses (Figure 6).  
 
 
 
 
Figure 6. The microbial-mammalian signalling axis. (Chilloux, et al., 2016) 
(Reprinted with permission, Licence Agreement in Appendix)   
 
2.5.2 Types of receptors involved in cell signalling 
 
Cell signalling is a key biological process through which extracellular signals are 
converted into cellular responses. This basic mechanism controls cell growth, 
proliferation and, importantly, cell metabolism (Gerhard, 2008). Cell signalling 
involves three steps: 1) a receptor molecule that perceives the extracellular stimulus, 
2) a transducer and 3) an effector (Tuteja, 2009). 
 
Receptors can be classified in four types, according to their mechanisms: ligand-
gated ion channels, (GPCR, nuclear receptors and kinase-linked receptors. 
 
Ligand-gated ion channels belong to a family of transmembrane ion channel 
proteins that incorporate a ligand-binding site (Valbuena and Lerma, 2016). Upon 
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ligand binding, the channel opens and ions (e.g. Na+, Ca2+ and/or Cl-) flow across the 
cell membrane inducing changes in the electrical properties of the cell within 
milliseconds (Valbuena and Lerma, 2016). GPCR are transmembrane proteins coupled 
to guanine nucleotide-binding proteins (G-proteins).  
 
G-proteins are heterotrimeric complexes consisting of G, G and G subunits 
(Qin, et al., 2011). When a GPCR recognises a given ligand, the receptor undergoes 
conformational changes; G binds a molecule of GTP and separates from the remaining 
subunits, exposing sites on the free G-G complex for interaction with other molecules 
and activating the G-protein (Qin, et al., 2011). The activated G-protein can interact 
directly with an ion channel or activate/inhibit an enzyme that promotes the release 
of second messengers (e.g. cyclic adenosine monophosphate (cAMP), cyclic guanosine 
monophosphate (cGMP), inositol triphosphate (IP3), diacylglycerol (DAG)), that link 
to a number of different effectors (e.g. phospholipase C and D, adenylate cyclase 
(Valbuena and Lerma, 2016; Yang and Xia, 2006).  
 
Nuclear receptors are intracellular receptors consisting of a binding-domain and 
a DNA-binding domain. Upon ligand binding, the receptor undergoes conformational 
changes and enters the nucleus, where it interacts directly with DNA and alters gene 
expression, ultimately affecting protein synthesis (in hours). 
 
Finally, kinase-linked receptors comprise a ligand-binding extracellular domain 
coupled to intracellular kinase domain (Cohen, 2002). Upon ligand binding, the kinase 
domain catalyses the transfer of phosphate moiety from high-energy donors (e.g. ATP) 
to target molecules (Figure 7). Kinases catalyse the reaction by orienting both the 
substrate and the phosphoryl group within their active site, thus increasing the rate of 
the reaction. Moreover, they commonly use positively charged amino acid residues (e.g. 
serine, threonine), which further stabilise the transition by interacting with the 
phosphate groups (Cohen, 2002). Subsequently, adapter molecules bind to the 
phosphorylated residues and initiate downstream signalling cascades of cytoplasmic 
molecules (Hubbard, 2004).  
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Figure 7. General reaction catalysed by kinases. 
 
 
The major signalling pathways are the cAMP-dependent pathway, the 
IP3/DAG pathway and the MAPK/ERK pathway (Gerhard, 2008). In humans, the 
cAMP-dependent pathway works by activating protein kinase A; cellular responses are 
cell-specific, depending on the cAMP-dependent protein kinase. The IP3/DAG 
pathway starts with the cleavage of phosphatidylinositol 4,5 bisphosphate (PIP2) into 
DAG and IP3. IP3 diffuses through the cytosol and binds calcium channels, increasing 
the cytosolic concentration of calcium and promoting a cascade of changes in 
intracellular activity. Calcium and DAG activate the protein kinase C (AKT). Finally, 
the MAPK/ERK pathway usually links cell surface receptors to intracellular responses 
leading to the binding of growth factors through a range of complex protein 
components and interactions (Orton, et al., 2005).  
 
These signalling cascades often interact with each other, thus allowing 
coordinated cellular responses (Papin, et al., 2005). At the molecular level, these 
responses involve changes in gene transcription or translation, as well as post-
translational protein changes. Such responses are the basic mechanism controlling cell 
growth, proliferation, metabolism and many other processes (Gerhard, 2008; Hubbard, 
2004). To date, most research has examined the role of gut microbial metabolites as 
ligands for GPCR and nuclear receptors. 
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Gut microbial metabolites as GPCR ligands 
 
SCFA act as ligands for several GPCR receptors, including Free Fatty Acid 
Receptor 2 (FFAR2) and Free Fatty Acid Receptor 3 (FFAR3); the activation of these 
receptors inhibits cAMP production, respectively, via Gi and Gi/q (Bindels, et al., 
2013). FFAR2 activation supresses the accumulation of adipose tissue and decreases 
insulin sensitivity in peripheral tissues, while increasing it in liver and muscle (Kimura, 
et al., 2013). Conversely, FFAR3 activation increases leptin secretion, a hormone with 
anorexigenic properties (Xiong, et al., 2004). Butyrate, a SCFA, is also able to bind 
the receptor GPR109A, initiating anti-inflammatory responses (reduced production of 
TNF- and monocyte chemoattractant protein-1 (MCP1)) (Digby, et al., 2012; 
Thangaraju, et al., 2009).  
 
Gut microbial metabolites as nuclear receptor ligands 
 
Gut microbial metabolites were also shown to bind nuclear receptors. Bile acids 
bind the nuclear receptor Farnesoid X Receptor (FXR), which is involved in both 
glucose and lipid homeostasis (e.g. gluconeogenesis, HDL-cholesterol, very low density 
lipoproteins (VLDL) and TG) (Thomas, et al., 2008). Bile acids metabolised by the 
gut microbiota, such as lithocholic acid, are able to activate the Pregnane X Receptor 
(PXR) that protects against liver toxicity (Tuomisto, 2010). Altogether, these 
examples demonstrate how the identification of the pharmacological targets can 
provide a deeper understanding of the mechanistic basis underlying the association 
between the gut microbiota and cardiometabolic outcomes. 
 
2.5.3 The human kinome as an unexplored target repertoire 
 
Over the past two decades, kinases have become one of the most intensively 
studied protein classes in the target and drug discovery, with 46 drugs approved by 
the U.S. Food and Drug Administration (FDA) (Flint, et al., 2012; Goodrich, et al., 
2016). Consisting of 518 kinases, the human kinome represents a broad repertoire of 
signal transduction triggers for human homeostasis and metabolism (Cohen, 2002; 
Manning, et al., 2002). According to PhosphoNET, the world’s largest repository of 
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known and predicted information on human phosphorylation sites, the human kinome 
has 144,424 experimentally-confirmed phosphosites, amongst which 56.0% are serine 
phosphosites (Kinexus, 2017). However, in the context of gut microbial targets, this 
class of receptors remains mostly unexplored.  
 
2.6 Indoles as a key family of gut microbial metabolites 
 
Indoles are gut microbial metabolites produced from dietary tryptophan and 
consistently reported in human biofluids. In this section, we address in further detail 
their bacterial production, as well as the gaps in knowledge on their human targets 
and relevance for obesity and cardiometabolic disorders, therefore providing the 
rationale for this study. 
 
2.6.1 Gut bacterial production and transport of indoles 
 
Indoles are heterocyclic compounds produced from dietary tryptophan upon 
microbial degradation (Figure 8). The production of indoles from tryptophan depends 
on gut bacteria; consistently, their production is reduced by the use of antibiotics (Sun 
et al., 2013) or modulated by probiotics (Xu, Hu, & Wang, 2002). Indoles are absorbed 
in the colon, thus entering systemic circulation. Whilst indole seems to diffuse across 
cell membranes without the aid of a specific transporter (Sender, et al., 2016), the 
absorption for other indolic compounds has not been clearly described. 
 
Although several studies evaluated the impact of single species in the production 
of indoles, the contribution of the gut microbiota, as a whole complex ecosystem, 
remains unclear. To date, no studies have systematically addressed the relative 
contribution of mammalian and/or microbial metabolism to the production of these 
compounds. 
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Figure 8. Generation of indoles from tryptophan by gut bacteria. 
Tryptophan can be directly converted to indole through the activity of bacterial tryptophanase (present 
in the major member of the gut microbiome Bacteroides thetaiotaomicron, but also Proteus vulgaris 
and Escherichia coli, amongst others) (DeMoss and Moser, 1969). Indole can be conjugated in the liver 
to form indoxyl sulfate (DeMoss and Moser, 1969). Clostridium spp. and Lactobacillus spp. are able to 
deaminate tryptophan, producing indole-3-pyruvate, indole-3-lactate, indole-3-acetate and 3-
methylindole (Jensen, et al., 1995) (Wikoff, et al., 2009). 
 
2.6.2 Relevance of indoles to obesity and cardiovascular health 
 
Indoxyl sulfate has been associated with cardiovascular mortality (Barreto et 
al., 2009) and various deleterious vascular outcomes. In endothelial cells, it induces 
oxidative stress by modifying the balance between pro- and anti-oxidant mechanisms, 
stimulating the release of endothelial micro-particles and diminishing endothelial-
healing ability (Faure et al., 2006); it also aggravates cardiac fibrosis and 
cardiomyocyte hypertrophy by increasing oxidative stress (Yisireyili et al., 2013). 
Indole-3-propionate is involved in inflammatory mechanisms and in the maintenance 
of intestinal barrier integrity (Cheng, Shah, & Gonzalez, 2012; Venkatesh et al., 2014; 
Zelante et al., 2013). Most pro-inflammatory and pro-oxidative effects of indoles in 
vascular endothelial cells are thought to be mediated by the aryl hydrocarbon receptor 
(AHR) (Ito, et al., 2016; Jin, et al., 2014). This ligand-activated transcription factor 
forms a nuclear heterodimer with the AHR nuclear translocator protein to activate 
genes involved in the signalling of nuclear factor-erythroid 2-related factor-2 (Nrf2), 
p53 (TRP53), retinoblastoma (RB1), and NF-B (Jin, et al., 2014). 
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In 2013, it was demonstrated for the first time that obese patients show higher 
numbers of genes associated with the degradation of tryptophan, suggesting that 
circulating indoles may also be increased in obesity (Le Chatelier, et al., 2013); 
however, to date, no study in adults has demonstrated this association. Recently, a 
study in a paediatric cohort firstly reported for that obese children  present a higher 
production of indoxyl sulfate, as well as a higher abundance of genes involved in the 
production of this metabolite (Zhang, et al., 2015). 
 
The putative targets and signalling pathways mediating the effect(s) of indoles 
in adipocytes and their mechanism of action on energy metabolism remain unclear. 
AHR expression is progressively decreased and eventually lost during adipocyte 
differentiation (Shimba, et al., 2003), making it an unlikely modulator of lipid 
accumulation. The identification of these targets is, therefore, critical to understand 
the molecular crosstalk underlying the putative impact of indoles in obesity and CVD.  
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3. A combined metabonomic and cell-based strategy to 
investigate the interactions between obesity and gut 
microbial metabolites 
 
A range of high-throughput technologies (i.e. genomics, transcriptomics, 
proteomics) have been used to provide an integrated perspective on human health and 
disease (Tyers and Mann, 2003; Wang, et al., 2009). However, since these methods 
focus on the impact of individual genes or proteins, they explain only a small proportion 
of the etiopathology of complex phenotypes such obesity and cardiometabolic disorders.  
 
The study of the metabolites contained in human biofluids (collectively 
designated as the human metabolome) has emerged as a more promising alternative 
(Nicholson, et al., 2008; Wishart, et al., 2007). The human metabolome provides a 
global picture of human physiology, where gene expression, protein translation, 
epigenetics and environmental stimuli converge into an altered metabolic signature or 
metabotype (Gavaghan, et al., 2000). Furthermore, exploratory metabolic phenotyping 
captures systems-level information, reflecting the effect of genetic and environmental 
cues on the microbial-mammalian symbiotic system (Holmes, et al., 2011; Holmes, et 
al., 2008; Nicholson, et al., 2002; Nicholson, et al., 2005). Is important to note that the 
metabolic response of living systems is not constant over time; conversely, it is affected 
by both external factors and genetic modification. The quantitative measurement of 
this dynamic multiparametric response has been coined metabonomics (Lindon, et al., 
2003; Lindon, et al., 2004; Nicholson, et al., 2002; Nicholson, et al., 1999).  
 
The two most important analytical approaches in metabonomics are mass 
spectrometry (MS) and nuclear magnetic resonance spectroscopy (1H NMR) (Markley, 
et al., 2017; Nicholson, et al., 2011). 1H NMR spectroscopy has several advantages, 
mostly related to its high reproducibility and easy sample preparation (Dona, et al., 
2014; Dumas, et al., 2006; Keun, et al., 2002; Nicholson, et al., 1995). This analytical 
method produces high-density data that can be further analysed by multivariate 
statistical analysis and pattern recognition methods (Lindon and Nicholson, 2008; 
Nicholson, et al., 2002; Nicholson, et al., 1999; Smolinska, et al., 2012).  
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Both MS and 1H NMR can be run in either untargeted or targeted mode. 
Untargeted profiling encompasses the quantification of as many metabolites as possible 
in a single biological sample; therefore, this mode does not require an a priori 
hypothesis and is frequently used to discover novel markers or metabolic associations. 
The main disadvantage of this mode includes eventual difficulties in the identification 
and quantification of a given metabolite, as the method is not optimised for individual 
compounds (Tzoulaki, et al., 2014). Conversely, targeted mode requires a previously 
defined hypothesis and can be optimized to quantify metabolites of interest. Semi-
targeted analysis is frequently used to perform the measurement of a class or group of 
metabolites (e.g. bile acids, phenolics) (Tzoulaki, et al., 2014).  
 
Metabolic phenotyping of obese and lean subjects has been used to highlight 
the contribution of mammalian metabolites involved in energy metabolism processes, 
such as the TCA cycle and lipid and amino acid homeostasis (Elliott, et al., 2015). 
The role of the microbial-mammalian interaction was also emphasised by various 1H 
NMR-based studies focusing on the development of obesity and cardiometabolic 
disorders (Calvani, et al., 2010; Dumas, et al., 2017; Elliott, et al., 2015; Nicholson, et 
al., 1984) In particular, the Intercontinental Study in Macronutrients in Arterial 
Pressure showed that BMI is linked to five gut microbial-host co-metabolic pathways, 
including choline degradation, protein colonic putrefaction and the production and 
excretion of hippurate (Elliott, et al., 2015). Indoles, particularly indoxyl sulfate, have 
been consistently detected in metabonomic studies (Garcia-Perez, et al., 2012; 
Heinzmann, et al., 2012; Zhang, et al., 2015). 
 
It is important to note that metabonomic data are particularly useful to identify 
significant associations between metabolites and genetic, environmental or microbial 
cues, but they are not sufficient to generate causal inferences. Nevertheless, the 
associations found in metabolic profiling can be particularly useful for leveraging 
further experimental designs, thus moving from correlations to causation. With respect 
to microbial-mammalian signalling, the establishment of causality requires the 
demonstration of a direct effect either in vitro and/or in vivo, complemented by the 
clarification of the targets and signalling pathways involved. 
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Therefore, in this project, 1H NMR-based metabolic profiling was combined with 
high-throughput kinase screening, cell-based and molecular studies, and in vivo 
validations, to provide a comprehensive assessment of the role of indoles in obesity and 
cardiometabolic disorders.  
 
4. Scope of the thesis: hypothesis and aims 
 
The gut microbiota plays a pivotal role in obesity and cardiometabolic diseases.  
Obese subjects exhibit significant gut microbial changes, including higher numbers of 
microbial genes associated with the degradation of tryptophan, which is converted by 
tryptophanase-containing bacteria into indoles (Le Chatelier, et al., 2013). A recent 
study in a paediatric cohort reported a positive association between obesity and indoxyl 
sulfate levels (Zhang, et al., 2015); however, no studies have validated this finding. 
Furthermore, the human targets, signalling pathways and cellular responses putatively 
involved in this effect remain unexplored.  
 
The overall hypothesis of this work is that gut microbial metabolites - and in 
particular indoles - bind to human kinases, impact signalling pathways and interfere 
with cellular processes relevant to obesity and cardiometabolic disorders, thus acting 
as chemical messengers in the microbiome-kinome crosstalk. 
 
The specific aims of this project included: 
1. To systematically describe the contribution of the gut microbiota to the 
production of indoles (Chapter 3); 
2. To characterise the contribution of indoles to the metabolic signature of 
obesity (Chapter 4); 
3. To identify novel pharmacological targets for indoles in the human kinome 
(Chapter 5 and Chapter 6); 
4. To validate the role of indoles in vitro and in vivo (Chapter 5, Chapter 7 
and 8). 
 
An overview of the structure of this thesis is provided in Figure 9. 
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Chapter 2 
General Methodology  
 
Several methodologies were applied in order to address the specific aims of this 
project. In order to systematically describe the contribution of the gut microbiota to 
the production of indoles (Chapter 3), a combined approach using network analysis 
and the Basic Local Alignment Search Tool (BLAST) was used. The contribution of 
indoles to the metabolic signature of obesity and cardiometabolic disorders (Chapter 
3) was investigated using a 1H NMR-based metabonomic approach. The potential 
targets of indoles in the human kinome were subsequently screened by a high-
throughput kinase screening using KdSELECT technology; molecular docking analyses 
were used to further characterise the nature of the interactions (Chapter 5 and Chapter 
6). Finally, the roles of indoxyl sulfate and indole-3-acetate were investigated in two 
different cell lines, by using a combination of cell-based and molecular approaches 
(Chapter 4 and Chapter 7). The anti-angiogenic effect of indole-3-acetate was validated 
in vivo using a subcutaneous Matrigel plug model (Chapter 8). 
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1. Cell lines and cell-based assays 
 
In this PhD, two different cell lines (3T3-L1 and HUVEC) were used to validate 
the effect of indoles in in vitro-based assays. 
 
1.1. 3T3-L1 
 
3T3-L1 is a secondary cell line extensively used as an in vitro model to study 
lipogenesis, due to its ability to differentiate into mature adipocytes (Poulos, et al., 
2010). Derived from murine fibroblasts obtained from Swiss 3T3 embryos, 3T3-L1 cells 
exhibit a similar cellular morphology to fibroblasts, during proliferation (Green and 
Kehinde, 1975; Green and Meuth, 1974). However, after reaching confluence, 
proliferation is inhibited; at this stage, upon the addition of pro-adipogenic compounds 
(insulin, dexamethasone and 3-isobutyl-1-methylxantine (IBMX)), 3T3-L1 cells are 
able to differentiate into adipocyte-like cells (Green and Kehinde, 1975; Green and 
Meuth, 1974; Rubin, et al., 1978; Russell and Ho, 1976). The induction of 
differentiation initiates deep phenotypic changes in 3T3-L1, including the adoption of 
a spherical shape and the presence of fully developed lipid droplets (Poulos, et al., 
2010). Mature adipocytes are characterised by an upregulation of the expression of 
pro-adipogenic genes (Gerhold, et al., 2002; Student, et al., 1980). 
 
Being derived by clonal expansion, 3T3-L1 cells proliferate as a homogenous 
cellular population and, therefore, exhibit a homogenous response to treatments up to 
20 cellular passages (Green and Kehinde, 1975; Green and Meuth, 1974). These 
characteristics support their choice as one of the most used cell lines to investigate the 
adipogenic potential of both endocrine and pharmacological compounds (Green and 
Meuth, 1974). A full description of the protocol used to maintain 3T3-L1, as well as 
to induce its differentiation into mature adipocytes, is shown in Chapter 5. 
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1.1.1. Cell viability 
 
The assessment of the cell viability is a key step in cell-culture based assays. 
For adherent cell lines, viable cells attach to the cell culture plates; cells that undergo 
cell death lose their adherence and are subsequently liberated to the medium. 
Therefore, many cell viability methods are based on the staining of adherent cells as 
an indirect measure for cell viability (Xu, et al., 2015). 
 
Crystal Violet staining is a simple and reliable method to stain adherent cells 
and thus quantify cell viability (Feoktistova, et al., 2016). Crystal Violet is a 
triarylmethane dye that binds to DNA and stains cell nuclei (Feoktistova, et al., 2016).  
Non-viable cells are removed by thoroughly washing the cell culture plates with water. 
Finally, the dye is eluted with methanol and quantified by measuring the optical 
density (absorbance) at 590 nm, providing a quantitative readout for cell viability 
(Feoktistova, et al., 2016). A full description of the method is shown in Chapter 5. 
 
1.1.2. Lipid staining (Oil Red O) 
 
The intracytoplasmic accumulation of lipids is one of the key phenotypic 
features of differentiated 3T3-L1 cells (Green and Meuth, 1974; Poulos, et al., 2010). 
This process mimics lipid accumulation (lipogenesis) observed in obesity in vivo and 
has, therefore, been extensively used as a model to validate putative pro- or anti-
adipogenic compounds.  
 
The staining of lipid droplets using Oil Red O has been used as a quantitative 
assay to measure lipogenesis in vitro (Cheung, et al., 2015; Janderova, et al., 2003; 
Kuri-Harcuch, et al., 1978; Rossmeislova, et al., 2013). Oil Red O is a fat-soluble diazo 
dye with a high affinity for lipids and cholesterol esters, but low affinity for biological 
membranes (Fowler and Greenspan, 1985). Also, Oil Red O has a higher affinity for 
lipids than for its own solvent (Fowler and Greenspan, 1985). These characteristics 
allow the entry of the dye to the cytoplasm, where it stains the lipid droplets. In order 
to allow quantitative measurements, the dye is eluted using 2-propanol and its 
absorbance photometrically determined at 518 nm (Kuri-Harcuch, et al., 1978).  
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1.2. Human Umbilical Vein Endothelial Cells (HUVEC) 
 
Human Umbilical Vein Endothelial Cells (HUVEC) are the most commonly 
used cell line to study vascular endothelial cell function and angiogenesis (Crampton, 
et al., 2007). Isolated from human umbilical veins upon collagenase digestion, HUVEC 
have fastidious growth factor requirements, including endothelial cell growth 
supplements, heparin and high concentrations of Foetal Bovine Serum (FBS) 
(Crampton, et al., 2007; Jaffe, et al., 1973). HUVEC can be obtained either as primary 
(e.g. ATCC PCS-100-010) or as established cell lines (e.g. ATCC CRL-2873 HUVEC-
CS or ATCC CRL-1730, HUV-EC-C), the latter of which was used in the present 
work. 
 
HUVEC constitutively express VEGFR-2 (the main receptor for normal cell 
function and angiogenesis) and produce a range of signalling molecules associated with 
vascular physiology, e.g. nitric oxide (NO) (Boerma, et al., 2006). During proliferation, 
HUVEC exhibit a cobblestone phenotype (Marin, et al., 2001). However, under specific 
conditions, they can be differentiated into tridimensional cultures (Heiss, et al., 2015). 
These features are exploited in specific assays to study specific steps of angiogenesis in 
vitro (i.e. cell migration and tube formation), as explained in detail in Sections 1.2.4. 
and 1.2.5. 
 
1.2.1. Cell viability 
 
See Section 1.1.1. 
 
1.2.2. Phosphorylation assays 
 
VEGFR-2 is the main receptor responsible for normal vascular endothelial cell 
function and angiogenesis (Huang, et al., 2012). In this work, VEGFR-2 
phosphorylation was quantified by ELISA (PathScan Phospho-VEGFR-2 (Tyr1175) 
Sandwich ELISA Kit #7335; PathScan Total VEGFR-2 Sandwich ELISA Kit #7340, 
Cell Signalling Technology). ELISA is a highly specific, flexible and sensitive method 
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that exploits the formation of antigen-antibody complexes for quantification purposes 
(Engvall and Perlmann, 1971). Sandwich ELISA consists of adding a sample (e.g. cell 
lysate) containing the antigen (e.g. Total or Phospho-VEGFR-2) to a monoclonal 
antibody-coated well, forming an antigen-antibody complex (Engvall and Perlmann, 
1971). After washing, a second enzyme-linked specific antibody for a different epitope 
of the antigen is added and allowed to react (Engvall and Perlmann, 1971). Finally, 
the substrate is added and converted by the enzyme into a coloured product (Engvall 
and Perlmann, 1971). The magnitude of the optical density of the developed colour is 
proportional to the amount of antigen.  
 
VEGFR-2 phosphorylation activates a range of downstream signalling 
pathways, including the Protein Kinase B (AKT). AKT phosphorylation was 
quantified by the (Phospho (Ser473) / Total AKT Assay Whole Cell Lysate Kit, Meso 
Scale Discovery (MSD)). Although also a Sandwich immunoassay, this assay uses a 
Multi-Array technology that requires a minimal amount of sample (10-25 L) 
compared to traditional ELISA and allows the detection of several biomarkers 
simultaneously (Figure 10a). The assay consists in adding the sample (e.g. cell lysate) 
to a plate pre-coated with capture antibodies for Phospho-AKT (Ser473) and total 
AKT (Figure 10b). Next, a solution containing the detection antibody (conjugated 
with an electro chemiluminescent compound, MSD SULFO-TAG label) is added. 
Analytes in the sample bind to the antibodies immobilized on the working electrode 
surface; and recruitment of the conjugated detection antibody by bound analytes 
completes the sandwich (Figure 10c). Finally, a MSD read buffer is added, providing 
the appropriate chemical environment for electrochemiluminescence. The plate is 
loaded into an MSD SECTOR Imager, inside which a voltage is applied to the plate 
electrodes, causing the labels bound to the electrode surface to emit light. The 
instrument measures the intensity of emitted light to provide a quantitative measure 
of phosphorylated and total AKT in the sample. 
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Figure 10. Principle of the MSD Phosphoprotein Assay. 
Spot diagram showing the MSD Phosphoprotein Multi-Array plate (a) and the placement of analyte 
capture antibody in each well (b). Analytes in the sample bind to the capture antibodies immobilized 
on the working electrode surface; recruitment of the conjugated detection antibody by bound analytes 
complete the sandwich (c). Adapted from (MSD, 2011). AKT: Protein Kinase B; p-AKT: Phospho-AKT 
 
 
1.2.3. NO quantification 
 
Amongst the range of signalling molecules produced by HUVEC, NO appears 
to be particularly relevant to vascular health (Tousoulis, et al., 2012). NO 
quantification was performed by the Griess Method (Tsikas, 2005), using the Total 
NO and Nitrate/Nitrite Parameter Assay (R&D Systems). NO is a gaseous free radical 
with a half-life of seconds; therefore, the levels of its more stable NO metabolites, 
nitrite (NO2-) and nitrate (NO3-), are usually used for its indirect measurement 
(Marletta, et al., 1988; Tsikas, 2005). This assay quantifies total NO following the 
enzymatic conversion of NO3- to NO2- by nitrate reductase. NO2- is detected by the 
Griess Reaction, a two-step diazotisation reaction in which acidified NO2- produces a 
nitrosating agent that reacts with sulfanilic acid to produce a diazonium ion (Figure 
11a). The latter is finally coupled to N-(1-naphtyl)ethylenediamine to form the 
chromophoric azo-derivative that absorbs light at 540-570 nm (Figure 11b) (Miles, et 
al., 1996). 
 
AKT 
p-AKT 
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Figure 11. Griess Reaction.  
The nitrosating agent generated from acidified nitrite reacts with sulfanilamide to yield a diazonium 
derivative (a). This reactive intermediate interacts with N-(1-naphtyl)ethylenediamine to yield a 
coloured diazo product (b) (Miles, et al., 1996). 
 
 
1.2.4. Cell migration assay 
 
Cell migration is a feature of vascular endothelial cells during angiogenesis 
(Gerhardt, et al., 2003; Lamalice, et al., 2007; Potente, et al., 2011). In this work, an 
exclusion zone assay was used to assess the migratory abilities of endothelial cells, by 
evaluating their ability to cover a defined cell-free zone (AlMalki, et al., 2014; Staton, 
et al., 2004).  
 
The RadiusTM Cell Migration Assay Kit comprises a patented plate, containing 
a biocompatible hydrogel spot in each well, to which cells cannot attach. Cells are 
seeded and, once firm cell attachment is achieved, the hydrogel spot is removed, 
exposing a cell-free region to study cell migration (Figure 12). The percentage of cell-
free area recovered by cells (Equation 1) provides a quantitative measure of their 
migrating ability (Yarrow, et al., 2004).  
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Figure 12. Cell migration assay: quantitative analysis. 
a) Microscopic aspect of HUVEC attached outside of the hydrogel spot immediately after hydrogel spot 
removal (t = 0h), defining a cell exclusion zone (1). b) Microscopic aspect of vehicle-treated HUVEC, 4 
hours after hydrogel spot removal (t=4h).  
 
% Area recovered = (1 −
cell − free area at t = x (where x =  2h, 4h or 6h)
cell − free area at t = 0h
 ) x 100 
 
Equation 1. Quantification of cell migrating activity. 
 
1.2.5. Tube formation assay  
 
The tube formation assay has been widely adopted to validate pro- and anti-
angiogenic compounds in vitro (Arnaoutova and Kleinman, 2010; Kubota, et al., 1988).  
Capillary-like tube formation is a complex phenotype that requires endothelial cells to 
synthesise proteases, to digest the matrix (e.g. Matrigel), to migrate towards each 
other and, finally, to align in order to form tubular structures; therefore, it 
complements the previous cell migration assay and provides a more comprehensive 
assessment of angiogenesis.  
 
Matrigel is a basal membrane extract usually obtained from Engelbreth-Holm-
Swarm (EHS) mouse sarcoma cells (Passaniti, et al., 1992). Its major components 
include collagens, heparan sulfate proteoglycans, laminins, fibronectin, matrix 
metalloproteinase (MMP) proenzymes and growth factors (FGF, TGF, VEGFA) 
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(Haralabopoulos, et al., 1994). In this assay, liquid Matrigel (4oC) is used to coat cell 
culture labware, followed by incubation at 37 oC to allow the proteins to polymerise; 
HUVEC are then cultured on the newly-formed gel (Malinda, 2001). Activated by the 
components of the basement membrane extract, HUVEC start exhibiting complex 
cellular behaviours and forming capillary-like structures (Haralabopoulos, et al., 1994; 
Malinda, 2001). The networks are usually fully developed after 16-24h and can be 
quantified either by manual or automatic methods. (Auerbach, et al., 2003; Carpentier, 
2012).  
 
2. In vivo mouse study: Matrigel subcutaneous plug 
 
The Matrigel subcutaneous plug assay is a fast and effective method to validate 
stimulators or inhibitors of angiogenesis in vivo (Fridman, et al., 2012; Tahergorabi 
and Khazaei, 2012). 
 
The principle of the assay is that, when subcutaneously injected in mice, Matrigel 
solidifies forming a “plug”. When angiogenic factors are present in the Matrigel, 
endothelial cells are chemotactically attracted into the plug, forming vessels (Baker, et 
al., 2006; Malinda, 2001).  After 7-10 days, the Matrigel plug is removed and the newly 
formed blood vessels are observed and quantified for assessment of angiogenesis (Baker, 
et al., 2006; Hasan, et al., 2004). 
 
3. 1H Nuclear Magnetic Resonance Spectroscopy 
 
1H Nuclear Magnetic Resonance (1H NMR) spectroscopy was used to 
characterise the contribution of indoles to the metabolic signature of obesity and 
cardiometabolic disorders. This reproducible research technique detects small 
molecular weight molecules present in complex biological matrices, allowing the 
characterisation of the metabolic profile of a given individual, at a particular time 
point and with minimal sample preparation effort (Holmes, et al., 2008; Nicholson, et 
al., 2002; Nicholson, et al., 1999). Over recent decades, considerable improvements in 
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spectral dispersion and the sensitivity of the technique enabled this method to detect 
metabolites in micromolar concentrations (Holmes, et al., 1997). 
 
3.1. Principles of 1H NMR Spectroscopy 
 
1H NMR spectroscopy exploits the magnetic properties of atomic nuclei to 
provide detailed information about the structure, chemical environment and 
abundance (quantification) of the molecules that contain them. 
 
Atomic nuclei are composed of protons and neutrons. All isotopes with an odd 
number of protons and/or neutrons exhibit an angular momentum – the “nuclear spin” 
– different than zero. The nuclear spin quantum number (I) depends on the atomic 
number (i.e. number of protons) and atomic mass (number of nucleons) present 
(Jardetzky and Roberts, 1981). Whilst all nuclei with I0 are detectable by 1H NMR 
spectroscopy, the most frequently used in biological approaches have I=1/2 (i.e. 1H, 
13C, 15N, 31P) (Jardetzky and Roberts, 1981). Amongst these, 1H is the most abundant 
element in biological molecules and therefore the most frequently used in NMR 
metabonomic studies (Jardetzky and Roberts, 1981).   
 
Upon application of a magnetic field (B0), the nuclear moments of the spins 
orient themselves in a set of possible orientations. The number of orientations is defined 
by the equation 2I+1 (Keeler, 2002). As an example, for I=1/2, there are two different 
orientations of the nuclear spin: a stable, “low-energy spin” (position ) and a high-
energy spin (position ) (Figure 13a). For each orientation, the spin is characterised 
by a frequency (, in Hz) and an angular speed ( , in Rad.s-1), as defined by the 
Larmor precession (Keeler, 2002).  
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Figure 13. Principles of 1H NMR Spectroscopy. 
As a consequence of the application of a magnetic field (B0), the nuclear moments of the spins 
orient themselves in several possible orientations. For I=1/2, there are two different orientations 
of the nuclear spin: a low-energy spin (position ) and a high-energy spin (position ) (a). Motion 
of the magnetised nuclei, upon action of this magnetisation vector M0.(b). Upon action of a specific 
pulse of radiofrequency (B1), some nuclear spins in the lower energy level are encouraged into high 
energy levels, promoting a new orientation of the magnetisation vector M0 (c). When the pulse 
(B1) stops, the excited spins return to their low energy status. Adapted from (Jardetzky and 
Roberts, 1981; Keeler, 2002). 
 
The population of the two energy levels is described by the Boltzmann 
distribution (Equation 2), where Nupper is the number of nuclei in the upper energy 
state, Nlower is the number of nuclei in the low energy stage, K is the Boltzmann 
constant and T is the absolute temperature (in Kelvin) and E is the energy difference 
between both levels.     
 
Nupper / Nlower = e -E/KT 
Equation 2. Boltzmann distribution. 
 
The difference on the populations of both energy levels originates a 
magnetisation vector (M0) following the same direction as B0. The energy difference 
between both energy levels (E) can be calculated by Equation 3, where  is the 
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gyromagnetic ratio (nuclear magnetic moment), h is the Plank’s constant and B0 the 
NMR magnetic field. 
 
E =  h B0 / 2 
Equation 3. Energy distribution between  
high- and low-energy statuses. 
 
 If a specific pulse of radiofrequency (B1) is applied at the resonant frequency , 
some nuclear spins in the lower energy level are encouraged into high energy levels, 
promoting a new orientation of the magnetisation vector M0 (Figure 13c). When the 
pulse (B1) stops, the excited spins return to their low energy status. This relaxation 
process comprises two aspects: a) the longitudinal (spin-lattice) relaxation time, that 
refers to the time constant for the return of M0 to the basal position in the z axis and 
b) the transverse (spin-spin) relaxation time that refers to time constant for the nuclear 
spins to return to the basal status in the X-Y plane. During this return to their basal 
status, the component of magnetisation releases a voltage, the Free Induction Decay 
(FID) that originates the 1H NMR signal. A Fourier transform is applied to convert 
the time domain signal of FID in a frequency domain and finally generate a 1H NMR 
spectrum (Jardetzky and Roberts, 1981; Keeler, 2002). 
 
 1H NMR spectroscopy provides not only information about the atomic nuclei, 
but also on the molecular structure and conformation. This is possible because each 
nucleus is directly affected by its surrounding chemical environment: for example, 
electronegativity, electron density and circulating electron ring currents generate a 
magnetic field around the nucleus that shields the nucleus from the external applied 
magnetic field. The difference between the applied field and the nuclear magnetic field 
(nuclear shielding) and the ratio between the nuclear shielding and the applied 
magnetic field (chemical shift) provide further information on the molecular structure 
(Jardetzky and Roberts, 1981; Keeler, 2002).  
 
 Finally, the splitting patterns of 1H NMR signals can provide additional spectral 
information about the connectivity of atoms within the molecule. Close magnetic nuclei 
can interact with each other spatially or via spin-spin coupling. In this case, spin-spin 
couplings from neighbouring groups belonging to the same molecule result in the 
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splitting of the NMR signals into two or more components. The complexity of the 
splitting pattern is a function of the number of neighbouring nuclei. According to the 
general rule of n+1, where n is the number of protons in adjacent atoms, a nucleus 
with two neighbouring protons will have its 1H NMR signals split in three peaks (i.e. 
a triplet) (Keeler, 2002). 
 
3.2. Monodimensional and multidimensional 1H NMR 
Spectroscopy 
 
1H NMR spectroscopy can be mono-dimensional (1D), bi-dimensional (2D) or 
multi-dimensional (nD). 1D NMR experiments start with the preparation time (or 
relaxation delay), during which the spins reach their equilibrium state. Next, a radio-
frequency pulse is used - the pulse width - to stimulate the nuclear spins into high-
energy statuses. When the spins return to their basal low energy state, generate a FID 
that is acquired during the acquisition time. A 1D NMR spectrum can be obtained in 
less than 5 minutes, however, in order to increase the signal-to-noise ratio, the radio-
frequency pulse is repeated multiple times, with a resulting increase on the time of the 
experiment (Van, et al., 2008). Although 1D NMR has successfully identified a range 
of metabolites abundant in human biofluids, less abundant metabolites are often 
hidden by overlap with other compounds (Van, et al., 2008). Several techniques were 
used to alleviate peak congestion, such as the use of isotopically enriched metabolites 
(Higashi, et al., 2014), sample fractionation (Borlak, et al., 2003) and spectral fitting 
of a set of known metabolites (Weljie, et al., 2006). Some 1D NMR pulse sequences, 
such as the spin-echo experiment, optimise the detection of low molecular weight 
compounds by reducing broad signals of macromolecules (Hahn, 1950).  
 
 Conversely, 2D NMR experiments add a second, modulated delay in the pulse 
sequence, and usually comprise four steps: 1) the preparation time, 2) the evolution 
time, where no pulses are applied and the nuclear spins freely rotate; 3) the mixing 
time, when a series of radio-frequency pulses are applied and finally the 4) acquisition 
time, during which the FID signal from the sample is detected (Jardetzky and Roberts, 
1981; Keeler, 2002). In 2D NMR, each frequency axis is associated with one of the two 
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time variables (evolution time and acquisition time), both of which are converted from 
a time series into a frequency series via a two-dimensional Fourier transformation 
(Keeler, 2002). Due to the deconvolution of the signal across a second dimension, 2D 
NMR provides more information that 1D NMR and is especially useful in the 
determination of the molecular structure (Van, et al., 2008). Types of 2D NMR 
methods include Correlation Spectroscopy (COSY), Heteronuclear Single Quantum 
Coherence Spectroscopy (HSQC) and the J-resolved experiment (J-Res) (Foxall, et al., 
1993; Keeler, 2002; Posma, et al., 2017; Rodriguez-Martinez, et al., 2017; Van, et al., 
2008).  
 
3.3. Unsupervised multivariate statistical analysis 
 
Metabolic profiling by NMR spectroscopy generates high-density data. 
Multivariate methods have been proposed as a useful approach to summarise the main 
sources of variation in these datasets, to perform discriminant analyses and to recognise 
patterns (Eriksson, et al., 2004). Multivariate analyses can be either unsupervised (no 
hypothesis required for model construction) or supervised (model constructed based in 
a previously established hypothesis). 
 
Amongst unsupervised methods, Principal Component Analysis (PCA) is one 
of the simplest and widest used methods (Nicholson, et al., 2007). In brief, PCA is a 
statistical procedure that transforms a set of observations (e.g. NMR spectra) into a 
new coordinate system of Principal Components (PC), which axes or directions 
describe the dominant pattern of the matrix (Hotelling, 1933; Jolliffe, 2002). The first 
PC (PC1), built from linear least squares analysis in order to maximise the variance 
of the data, accounts for the maximal variability observed (Hotelling, 1933; Pearson, 
1901). The second PC is orthogonal to the first one, and is added to improve the 
modelling of the data variance. Each succeeding PC has the highest possible variance, 
provided that it is orthogonal to the previous component (Hotelling, 1933; Jolliffe, 
2002; Pearson, 1901).  
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Geometrically, the principal components of the model (n=K) are used to 
construct a K-dimensions space into which the observations are projected, according 
to their respective variables. The coordinates of the observations in the K-dimensions 
space are represented by the scores (T), whilst the directions of the PC in the initial 
space are represented by the loadings (P). Both scores and loadings can be used to 
construct, respectively, the scores plot and the loadings plot. While the scores plot 
shows the relationship between observations and reveals patterns in the dataset, the 
loadings plot provides information on the contribution of the variables to the model  
(Keeler, 2002; Trygg, et al., 2007). The part of the matrix that is not explained by the 
PCA model (the “residuals” (E)) is visually represented as the distance between each 
observation and its projection on the principal components space. The PCA matrix is 
modelled by the equation: 
 
X = TPT + E 
Equation 4. Construction of the Principal Component Analysis matrix 
 
3.4. Supervised multivariate statistical analysis 
 
Contrarily to unsupervised methods, supervised statistical analysis models are 
based in previously established hypotheses. Therefore, these methods are particularly 
relevant when metabonomic profiling is used to find differences between groups (e.g. 
treated versus untreated) (Keeler, 2002). 
 
Partial Least Squares (PLS) is one of the most commonly used supervised 
methods in metabonomic analyses (Nicholson, et al., 2007). PLS regression calculates 
a linear regression model between two matrices (e.g. X = spectral data, Y = 
quantitative values such as time, concentration or clinical data) and identifies the 
maximal multidimensional variance between them (Bollard, et al., 2005). When Y is 
categorical, a variant of PLS is used (Partial Least Squares Discriminant Analyis (PLS-
DA) (Andersen, et al., 2012)).  
 
Spectral data from NMR often contain a certain level of variation that is not 
correlated with the Y matrix, and can therefore affect the interpretation of the PLS 
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model. Orthogonal Partial Least Squares (OPLS) was developed with the purpose of 
overcoming this limitation (Cloarec, et al., 2005; Fonville, et al., 2010). In this method, 
an integrated Orthogonal Signal Correlation (OSC) is incorporated in the model, 
partitioning the X variance into predictive and orthogonal (uncorrelated) components 
of the Y matrix (Cloarec, et al., 2005; Fonville, et al., 2010). As consequence, the 
variation of interest is optimised and the uncorrelated variation is minimised, leading 
to improved interpretability and easier visualisation (Cloarec, et al., 2005). However, 
the OSC filter does not improve predictability (Trygg and Wold, 2002). OPLS-DA 
(Discriminant Analysis) is an extension of OPLS for discrete variables, particularly 
useful in classification studies (Bylesjo, et al., 2006). 
 
 The robustness of the resulting models can be inferred from the R2Yhat and the 
Q2Yhat values, that estimate, respectively, the percentage of variation explained and 
the predictive ability of the model (Steel and Torrie, 1960). R2 values range between 
0 and 1 and, generally, the higher the value the better the model fits the data (Steel 
and Torrie, 1960).  
 
Cross-validation is usually performed by partitioning the data into 
complementary subsets, performing the analysis on one subset (the training set) and 
validating the analysis in the other data subset (validation set or testing set) (Seymour, 
1993). This operation is repeated until the whole dataset has been used as validation 
set, providing the value of Q2Y (i.e. the percentage of the predicted variance from the 
Y vector in the model). Q2Y values equal or above 0.5 are considered reliable for data 
interpretation (Eriksson, et al., 1999; Eriksson, et al., 2004). Another alternative for 
model validation consists of performing a permutation test; in this method, a number 
of parallel models based on the fit of randomly re-ordered Y data is generated, and the 
Q2Y is considered valid if significant different (p<0.05) from the distribution of Q2Y 
values generated in the random models (Eriksson, et al., 1999; Eriksson, et al., 2004). 
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3.5. Analytical and statistical strategies for biomarker 
identification 
 
Metabolite identification is performed by comparing the spectrum with existing 
databases that provide information on the shape and coupling of its signals (e.g. 
Human Metabolome Database) (Wishart, et al., 2007). Whenever their assignment is 
not obvious, both analytical and statistical strategies can be used. 
 
Regarding analytical strategies, 2D NMR experiments have proven extremely 
effective at identifying novel and known metabolites. J-resolved (J-Res) NMR remains 
one of the most popular among 2D experiments for metabolite assignment due to its 
simplicity and short acquisition time (Dona, et al., 2016). Through the J-Res 
experiment, a simplified projection of the proton spectrum in which all multiplet peaks 
appear as singlet can be extracted, with a resulting reduction in the complexity of the 
spectrum is achieved and clarification of most overlapping problems (Nagayama, et al., 
1977). Furthermore, in 2D J-Res NMR the coupling constant (J value) of each signal 
is represented in a second dimension (Nagayama, et al., 1977). In order to assign a 
given metabolite, both the chemical shifts and the coupling constants should be close 
to the values reported in existing databases (Dona, et al., 2016). 
  
Statistical techniques such as Statistical Total Correlation SpectroscopY 
(STOCSY), can provided further clarification (Cloarec, et al., 2005). STOCSY 
calculates the correlation matrix between a given point and the remainder of the 
spectrum, allowing the extraction all its correlated peaks. As the signals of each 
molecule correlate with its other peaks across the spectrum, STOCSY provides 
valuable information for metabolite assignment – but also for the identification of other 
metabolites correlated with the driving signal (Cloarec, et al., 2005). Another statistical 
approach, SubseT Optimisation by Reference Matching (STORM), selects subsets of 
spectra with specific signatures, providing fewer false positive correlations and a 
simpler interpretation of the correlation matrix, in comparison with STOCSY (Posma, 
et al., 2012).  
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Even when a given metabolite is confidently identified by NMR, it can be 
sometimes important to further confirm its assignment using analytical approaches, 
for example, when identifying novel or important biomarker (Dona, et al., 2016). 
Finally, the gold standard for metabolite experiment is the “spike-in experiment” 
(Bouatra, et al., 2013), in which a small volume of a solution of the compound of 
interest is added to the sample, with a resulting increase in the intensity of its  signal 
– and, consequently, the unequivocal identification of its NMR signature. 
 
4. Kinase screening 
 
Consisting on 518 kinases, the human kinome represents a broad repertoire of 
signal transduction triggers for human homeostasis and metabolism (Cohen, 2002; 
Manning, et al., 2002). Indoles’ targets in the human kinome targets were assessed 
using KdSELECT technology (DiscoverX Corporation), as described is previously 
published papers (Fabian, et al., 2005; Karaman, et al., 2008). This technique is based 
on a competition-binding assay that quantitatively measures the ability of a compound 
to compete with an immobilized, active site-directed ligand. The assay consists of an 
immobilized ligand, a DNA-tagged kinase and a test compound (Figure 14). 
 
Figure 14. Kinase screening by KINOMEscan technology. 
Compounds that bind the kinase active site prevent kinase binding to the immobilized ligand, 
reducing the amount of kinase captured on the solid support (Fabian, et al., 2005; Karaman, et al., 
2008).  
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The ability of the test compound (i.e. indolic compound) to compete with the 
immobilized ligand was measured by quantitative PCR of the DNA tag. Results for 
primary screen binding interactions are reported as % of control (%Ctrl), where lower 
numbers indicate stronger hits (Equation 5).   
 
%Ctrl = (
test compound signal − positive control signal 
negative control signal − positive control signal
)  x 100 
 
Equation 5. Quantification of primary screen binding interactions in the kinome screening. 
 
 
For positive hits, the binding constant (KD) was then calculated from an 11-
point dose-response curve. The TREEspot Software Tool was used to generate kinase 
interaction tree plots, which were reprinted with permission from KINOMEscan 
(DiscoverX Corporation). For compounds with inhibitory activity, the half-maximal 
inhibitory concentration (IC50) was determined using the Kinexus kinase-inhibitor 
activity profiling service (Kinexus). The technique is based on the direct quantification 
of radiolabelled phosphate from ATP onto a protein substrate of a target protein 
kinase. 
 
5. Molecular docking 
 
In this work, molecular docking analyses were used to investigate the complexes 
formed by a putative ligand (i.e. indolic compound) and a kinase target. Molecular 
docking is a modelling method that predicts the relative interaction of the two elements 
of the complex, providing information on the strength and type of signal generated by 
the interaction (Kitchen, et al., 2004).  Molecular docking focuses on computational 
simulations (e.g. GOLD software) to predict an optimised conformation such as the 
free energy of the overall complex is minimised. In order to achieve this, molecular 
docking involves three steps: 1) input of the kinase structure, 2) a search algorithm 
and 3) a scoring function (Kitchen, et al., 2004).  
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The structure of the kinase of interest was retrieved from The Protein Data Bank 
(PDB), the most comprehensive database for experimentally determined protein 
structures (Berman, et al., 2000). Next, the search algorithm provided by GOLD 
software (Cambridge Crystallographic Data Centre) provides a list of the possible 
orientations and conformations of the protein paired with the putative ligand. For this 
purpose, a genetic algorithm was used; in brief, genetic algorithms use the energy scores 
of each position (pose) as a fitness function to select input for the next iteration 
(Mitchell, 1996). The poses generated by the genetic algorithm are then evaluated 
using a scoring function (Ajay and Murcko, 1995). Most scoring functions incorporate 
molecular mechanics force fields estimates (i.e. solvent effects, conformational changes, 
internal rotations, association energy and free energy) to calculate the energy of each 
pose. Individual scores for each pose are finally ranked,  lower energies indicating a 
more stable system and thus more likely interactions (Ajay and Murcko, 1995). 
 
6. Basic Local Alignment Search Tool (BLAST)  
 
In this project, a BLAST-based strategy was used to predict gut microbial 
proteins involved in the metabolism of tryptophan into indoles. BLAST is the most 
widely used bioinformatics algorithm to compare primary biological sequence 
information (e.g. amino acid sequences of proteins, nucleotide sequences of DNA) 
(Altschul, et al., 1990).  
 
Specifically, BLAST allows the comparison between a query sequence (target 
sequence) with a previously compiled library or database. In this case, the tryptophan 
metabolism reactions pathway performed by human or prokaryotes was identified from 
the Kyoto Encyclopaedia of Genes and Genomes (KEGG) using the application 
programming interface (API) (http://www.kegg.jp/kegg/docs/keggapi.html). For 
each reaction, the KEGG protein target sequences (FASTA file) were searched against 
a compiled database of prokaryotic proteomes from RefSeq 
(https://www.ncbi.nlm.nih.gov/refseq/) and cultivation-based studies targeting the 
gut microbiota (Browne, et al., 2016; Lagier, et al., 2016) using BLAST. 
 
  
93 
 The BLAST algorithm identifies quickly and accurately high scoring sequence 
alignments between the target sequence and a database, using a heuristic approach 
(Altschul, et al., 1990). BLAST starts by removing low-complexity regions or sequence 
repeats in the query sequence and partitions the query protein sequence in smaller 
sequences, which are then listed as high-scoring or low-scoring matches. High-scoring 
matches are converted into an efficient search tree, allowing the program to rapidly 
compare database sequences (Altschul, et al., 1990).  
 
 BLAST is a bioinformatics approach that uses a family of tools, each one 
individually customised according to the query sequence, the database searched and 
the comparison intended. An overview of various BLAST approaches is shown in Table 
1 (adapted from (Johnson, et al., 2008)).  
 
 
Table 1. Overview of different types of Basic Local Alignment Search Tools 
BLAST type (acronym)  Target sequence Features 
Nucleotide-nucleotide (BLASTN) Nucleotide sequence Returns nucleotide sequence 
Protein-protein BLAST (BLASTP) Protein sequence Returns the most similar protein 
sequences from the protein 
database 
Position-Specific Iterative BLAST 
(PSI-BLAST) 
Protein sequence Returns protein sequences, 
particularly  sensitive for distant 
evolutionary relationships 
Nucleotide 6-frame translation 
protein (BLASTX) 
Translation product 
of a nucleotide 
query sequence 
Compares the translation 
products of a nucleotide query 
sequence (both strands) against 
a protein sequence database 
Protein-nucleotide 6-frame 
translation (TBLASTN) 
Protein sequence Compares a protein query 
against a nucleotide sequence 
database. 
Information adapted from (Johnson, et al., 2008)  
 
For protein sequence queries, the most commonly used approaches are BLASTP 
(for similar sequences) and PSI-BLAST (for distant evolutionary relationships) (Table 
1). 
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7. Networks and graph theory 
 
Graph theory is the study of mathematical structures used to model pairwise 
relationships between discrete objects (Biggs, et al., 1986). Although the first paper of 
the history of graph theory was first published in 1736, the actual term “graph” was 
coined by J. Sylvester, in 1878 (Sylvester, 1878). Graph theory has a wide range of 
applications in physics, computer science, engineering, finance, sociology and biology. 
With the advent of high-throughput technologies (‘omics’) and the exponential 
generation of publicly available data, the analysis of molecular networks has also 
gained a significant interest in biology and medicine (Bashan, et al., 2012; Habibi, et 
al., 2014). 
 
7.1. Graphs and networks 
 
Graphs are employed as models for systems of objects (i.e. nodes) and the 
relationships between them (i.e. edges) (Gentleman, et al., 2005). Edges are binary 
relationships that join two nodes; they can be directed or undirected. A directed edge 
is an edge where one extremity is designated the head (starting point) and the other 
the tail (endpoint) Directed graphs (or digraphs) can be used to model, for instance, 
transcription factor or signalling pathways, where the direction of the steps involved 
is well characterised. The “underlying graph” of a digraph is the graph resulting from 
converting all directed edges into undirected (Gentleman, et al., 2005). A network can 
be defined as a graph in which nodes and/or edges have specific attributes (e.g. names). 
Visually, nodes are represented by a dot and edges are represented by a line. In directed 
graphs, the direction of an edge is indicated by an arrow (Figure 15).  
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Figure 15. Example of a simple directed graph. 
 
7.2. Network optimisation and centrality measures 
 
Network analysis can be used as a tool to find optimal pathways within a given 
network. Furthermore, information in the relative relevance of individual nodes and 
edges in a graph can be identified by centrality measures (Freeman, 1977; Gentleman, 
et al., 2005). 
 
 Centrality measures are based on the assumption that nodes into which the 
highest number of paths converge are particularly relevant in the overall network 
(Bonacich, 1987). As an example, in biological pathways, a node with a higher 
centrality would have more relevance in the network, as more signalling pathways – 
and, therefore, more biological information – would converge or pass through it. 
 
Betweenness centrality is a widely used measure of centrality, first described by 
Linton Freeman in 1977 (Freeman, 1977). For every pair of nodes in a given directed 
network, there is at least one shortest path between them such that either the number 
of edges that the path passes through is minimised. The betweenness centrality for 
each node is the number of these shortest paths that pass through the vertex, 
calculated by the equation 
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𝒈(𝒗) =  ∑
𝒔𝒕(𝒗)
𝒔𝒕
𝒔≠𝒗≠𝒕
 
 
Equation 6. Betweenness centrality of a given node. 
 
where st is the total number of shortest paths from node s to node t, and st(v) is 
the number of shortest paths that pass through v (Equation 6)(Freeman, 1977).   
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Chapter 3 
Overview of microbial production of 
indoles and prediction of species involved 
 
1. Introduction 
 
The human gut microbiota communicates with its human host through a range 
of signalling metabolites that bind to human targets and impact their signalling 
pathways, thus modulating human health (Chilloux, et al., 2016; Russell, et al., 2013).  
Amongst these metabolites, indoles - heterocyclic compounds produced upon bacterial 
degradation of tryptophan - appear to be particularly relevant for human health.  
 
Indoles have been linked to deleterious cardiovascular phenotypes both in vitro 
and in vivo. In clinical studies, levels of indoxyl sulfate seem to be a powerful predictor 
of overall and cardiovascular mortality (Barreto, et al., 2009). Indoxyl sulfate induces 
oxidative stress in vitro (Faure, et al., 2006), a putative mechanism through which it 
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enhances cardiac fibrosis and cardiomyocyte hypertrophy. Indole-3-acetate is also a 
predictive marker of cardiovascular mortality; additionally, it induces endothelial 
inflammation (via AHR) and oxidative stress (Dou, et al., 2015). Recently, it was also 
suggested that indoles may be involved in obesity (Le Chatelier, et al., 2013; Zhang, 
et al., 2015). 
 
The production of indoles from substrates depends on the functionalities of the 
gut microbiota; consistently, their production is reduced by antibiotic treatment (Sun, 
et al., 2013) and affected by prebiotics (Xu, et al., 2002). Several bacterial strains have 
been reported to be involved in the production of indoles. Tryptophan can be directly 
converted to indole by tryptophanase, a bacterial lyase reported to be present in 
Bacteroides thetaiotaomicron, Proteus vulgaris and Escherichia coli (Jean and DeMoss, 
1968; Wesoly and Weiler, 2012); indole is further conjugated in the liver to form 
indoxyl sulfate. Alternatively, tryptophan can be deaminated by Clostridium spp. and 
Lactobacillus spp., producing indole-3-pyruvate, indole-3-lactate, indole-3-acetate and 
3-methylindole (Attwood, et al., 2006; Mohammed, et al., 2003; Russell, et al., 2013; 
Wesoly and Weiler, 2012; Whitehead, et al., 2008; Wikoff, et al., 2009). Studies 
performed in gnotobiotic mice demonstrated that the production of another indolic 
compound, indole-3-propionate, was completely dependent on gut microbial activity 
and colonisation with a single bacterial species, Clostridium sporogenes, was able to 
establish its production (Wikoff, et al., 2009). Whilst the aforementioned studies 
evaluated the impact of single species in the formation of individual indolic compounds, 
there is a need for a systematic approach investigating the contribution of the gut 
microbiota, as a complex ecosystem, to the formation of indoles. In order to fill this 
gap in knowledge, a computational framework was used to predict the contribution of 
the gut microbiota to the production of indoles.  
 
The specific aims of this chapter include: 
a) To identify the prokaryotic metabolic reactions involved to the production 
of indoles; 
b) To identify and predict gut prokaryotic species able to perform these 
metabolic reactions. 
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2. Materials and Methods 
2.1. Tryptophan reaction network 
 
A reaction network based on the tryptophan metabolism reference reaction 
pathway from KEGG (rn;R00380) (Kanehisa and Goto, 2000) was built in R (R Core 
Team, 2013). The reactions of the network were linked to their corresponding KEGG 
gene orthology identifiers using the KEGG API 
(http://www.kegg.jp/kegg/docs/keggapi.html, on 14 November 2016). Only reactions 
with gene orthologues corresponding to human, bacteria and/or archaea were retained 
in the network. Three additional reactions (rn:R00681, rn:R01971, rn:R01973) were 
included in the network despite not being linked to a orthology gene ID, because there 
is evidence that these reactions can occur in some species of bacteria (Du, et al., 2015; 
Hornemann, et al., 1971; Hornemann, et al., 1970; Jean and DeMoss, 1968; Roberts 
and Rosenfeld, 1977; Speedie, et al., 1975; Takai, et al., 1977). The filtered network 
was visualized in Cytoscape v.3.4.0 (Shannon, et al., 2003).  
 
2.2. Protein Basic Local Alignment Search Tool (BLASTP)  
 
Proteome sequences for 1313 prokaryotes were downloaded from the Human 
Microbiome Project (HMP) (http://hmpdacc.org/HMRGD/all/#data) on 14 
November 2016. A non-redundant set of proteomes (in terms of species coverage) 
representing 11,161 bacterial and 345 archaeal species was downloaded from RefSeq 
(https://www.ncbi.nlm.nih.gov/refseq/) on 14 November 2016. Proteomes for whole-
genome data described in recent cultivation-based studies targeting the gut microbiota 
(n=239; (Browne, et al., 2016) and n=175 (Lagier, et al., 2016)) were downloaded from 
GenBank and EBI. A fasta file of the concatenated proteomes was used to create a 
database against which the KEGG protein sequences associated with each reaction 
were searched using the Protein-Protein Basic Local Alignment Search Tool BLASTP 
(Johnson, et al., 2008). BLASTP is an local alignment search tool customised for 
protein searches; in brief, the algorithm compares amino-acid sequences of proteins 
from a query sequence with a library or database of sequences, identifying sequences 
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that resemble the query sequence above a certain threshold (Johnson, et al., 2008). In 
this case, data were filtered using an E value cut-off of 1x10-3 and 90% sequence 
coverage; only hits with > 95 % homology to database sequences were retained. 
 
2.3. Subnetwork analysis 
 
The results of the subnetwork analyses were visualized using different 
approaches. For indoxyl sulfate, relevant species of bacterial were clustered by phylum 
and visualised as a network in Cytoscape v.3.4.0. For indole-3-acetate, a reaction-
species heatmap colour-coded according to the ability of a given bacterium to perform 
each reaction was generated. In order to highlight the most relevant species, the 
reaction-species matrix was filtered as follows. Each path was assigned a value (path-
value) reflecting its contribution to the corresponding pathway (i.e., total number of 
reactions performed by the bacterial species /total number of reactions in a given 
pathway) (Equation 7).  
 
Path − value = ( 
Number of reactions performed (in a given pathway)
Total number of reactions (in a given pathway)
)   
 
Equation 7. Calculation of the path-values.  
Each path-value was calculated as the ratio between the number of reactions performed by a given 
bacterium and the total number of reactions of the metabolic pathway.  
 
 
Next, each individual bacterial score was calculated as the sum of all path-
values (i.e. bacterial contribution to each one of the paths involved in the production 
of a given compound) (Equation 8). According to these filtering criteria, the top 38 
ranked species were selected.  
 
score = ∑ (Path − value)
n
Path  = 1
 
 
Equation 8. Calculation of the individual bacterial score values. 
Individual scores were calculated as the sum of all the path-values (n = total number of paths 
involved in the production of a given compound). 
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3. Results 
3.1. Contribution of prokaryotic metabolism to the production of 
indoles 
 
In order to identify the contribution of the human gut microbiota to metabolic 
steps involved in the production of indoles from tryptophan, a network illustrating the 
metabolic reactions involved was computed, based on KEGG (Kanehisa and Goto, 
2000) (Figure 16). Only metabolic reactions performed by human, bacterial and 
archaeal species were included (reactions performed by other organisms were excluded 
and are described in Table 2). Based on this, 16 metabolites and 18 metabolic reactions 
(7 prokaryotic-specific, 4 human-specific and 7 present in both human and prokaryotes) 
were retained (Figure 16). In total, 39% of the reactions of the network are performed 
exclusively by bacteria and archaea species, reflecting the relevance of prokaryotes to 
the metabolism of indoles. 
 
 
 
Figure 16. Overview of the production of indoles from tryptophan. 
Network illustrating the metabolic reactions involved in tryptophan catabolism; all reactions 
linking L-Tryptophan to indole-3-acetate or to indoxyl are irreversible (unidirectional). 
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Table 2. List of the metabolic reactions involved in tryptophan metabolism. 
KEGG 
Reaction  ID* 
 KEGG 
Orthology 
  
 Gene   Definition   Organism 
R00673 K01667 tnaA Tryptophanase Prokaryotic 
R00677 K03334 IL4I1 L-amino-acid oxidase Human 
R00679 K00466 iaaM Tryptophan 2-monooxygenase Prokaryotic 
R00684 K14265 Tam1 Tryptophan aminotransferase Other 
R00685 K01593 DDC Aromatic-L-amino-acid decarboxylase Human and prokaryotic 
R01814 K00502 TPH1_2 Tryptophan 5-monooxygenase Human 
R01971**   n/a n/a n/a Prokaryotic  
R01973**   n/a n/a n/a Prokaryotic  
R01974 K04103 ipdC Indole-3-pyruvate decarboxylase Prokaryotic 
R02173 
K11182 AOC1, ABP1 Diamine oxidase Human 
K00274 MAO Monoamine oxidase Human and prokaryotic 
R02339 n/a n/a n/a Human 
R02678 
K14085 ALDH7A1 Aldehyde dehydrogenase family 7 member A1 Human 
K00149 ALDH9A1 Aldehyde dehydrogenase family 9 member A1 Human 
K00128 ALDH Aldehyde dehydrogenase (NAD+) Human and prokaryotic 
R02679   n/a n/a   n/a Other 
R02680   n/a n/a   n/a Other 
R02681 K11817 AAO1_2 Indole-3-acetaldehyde oxidase  Other 
R02700 K14265 Tam1 Tryptophan aminotransferase Other 
R02701 K01593 DDC Aromatic-L-amino-acid decarboxylase Human and prokaryotic 
R02908 K00274 MAO Monoamine oxidase Human and prokaryotic 
R03092   n/a n/a    n/a n/a 
R03096 K01426 amiE Amidase Prokaryotic 
R04093 K11868 CYP71A13 Indoleacetaldoxime dehydratase Other 
R04094 K01237 E3.2.1.147 Myrosinase Other 
R04903 
K00128 ALDH Aldehyde dehydrogenase (NAD+) Human and prokaryotic 
K00149 ALDH9A1 Aldehyde dehydrogenase family 9 member A1 Human 
K14085 ALDH7A1 Aldehyde dehydrogenase family 7 member A1 Human 
R04904 K00157 AOX Aldehyde oxidase Human 
R04905 K00543 ASMT Acetylserotonin N-methyltransferase Human and prokaryotic 
R04906   n/a n/a    n/a n/a 
R06804   n/a n/a    n/a Other 
R08160 K11813 CYP79B2 Tryptophan N-monooxygenase Other 
R08164 K11820 UGT74B1 N-hydroxythioamide S-beta-glucosyltransferase Other 
R08167 K11821 5T5A_B_C Desulfoglucosinolate sulfotransferase A/B/C Other 
R08168 K11818   CYP83B1   Cytochrome P450 family 83 subfamily B  Other 
R08170 K11819 SUR1, RTY S-alkyl-thiohydroximate lyase SUR1 Other 
R08605    n/a n/a    n/a n/a 
R08606    n/a n/a    n/a n/a 
R08609    n/a n/a    n/a n/a 
R10180 K16903 TAA1 L-tryptophan-pyruvate aminotransferase Other 
R10181 K11816 YUC2 Indole-3-pyruvate monooxygenase Prokaryotic 
 
*Metabolic reactions performed by performed by human, bacterial and archaeal species are shown in 
bold and were included in the metabolic network. Reactions performed by other organisms, or without 
assigned KEGG ID were excluded. **Reactions known to be carried out by bacteria, but without KEGG 
ID assigned. n/a, none assigned. 
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According to KEGG, indole-3-pyruvate is the sole indolic compound produced 
only by human metabolism. The production of all other indoles requires prokaryotic 
metabolism, either for all reactions (indole-3-acetate via indole-3-acetamide and indole) 
or at least for one reaction (indoxyl and indole-3-acetaldehyde). Bacterial metabolism 
is also required for the production of indole-3-lactate, indole-3-acetaldehyde and 3-
methylindolepyruvate, although these reactions have not been characterised yet. 
 
3.2. BLASTP as a tool to predict gut microbial species involved 
in tryptophan metabolism 
 
Next, it was explored which prokaryotic species may contribute to the metabolic 
network leading to the production of indoles. Although KEGG represents a popular 
reference database, its description of the prokaryotes involved in indole production is 
not comprehensive. In order to augment the coverage of prokaryotes involved in indole 
production reported in KEGG, BLASTP of KEGG proteins against databases of 
curated proteome sequences was used. In brief, the protein sequences associated with 
each reaction of the KEGG-based network were searched against compiled databases 
of prokaryotic protein sequences, including RefSeq (n = 11,506), HMP (n=1,313) and 
cultivation studies (Browne et al., 2016 (n=239); Lagier et al., 2016 (n=175)); only 
hits with > 90% sequence coverage and 95% homology were retained. Globally, 
BLASTP allowed the identification of 404 new prokaryotic gene homologues 
potentially implicated in indole metabolism (Figure 17a). At the single reaction level, 
increases were found in the number of prokaryotic species able to perform a given 
reaction, ranging from +7.8% (aldehyde dehydrogenase (NAD+)) to +57.1% 
(Acetylserotonin-N-methyltransferase) (Figure 17b). Furthermore, human-specific 
reactions reported in KEGG (see Table 2) were also searched using BLASTP, 
confirming they were not performed by prokaryotes. 
 
A filtering strategy to select prokaryotic species present in the human gut was 
applied. For this purpose, a database including microbial species present in the 
gastrointestinal tract from the Human Microbiome Project 
(http://hmpdacc.org/HMRGD/all/#data) and in the culture-based studies by (Lagier 
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et al., 2016) and (Browne et al., 2016) was compiled. In the gut-filtered dataset, 
BLASTP searches predicted a total of 49 new prokaryotic genes (Figure 17c). While 
some reactions are potentially performed by a reduced number of species 
(acetylserotonin-N-methyltransferase (n=2) and aromatic-L-amino-acid decarboxylase 
(n=6); corresponding respectively to 0.007 and 0.02% of the gut prokaryotic dataset), 
others are predicted to be performed by 48% gut prokaryotes (e.g. aldehyde 
dehydrogenase (NAD+), n=132) (Figure 17d). The conversion of L-tryptophan into 
indole by tryptophanase shows the highest percentage increase on the number of 
predicted species (+60%) (Figure 17d-e). 
 
 
Figure 17. Prediction of prokaryotic species involved in the production of indoles. 
a) Number of prokaryotic genes involved in the production of indoles, detected by KEGG, BLASTP or 
both. b) Number of prokaryotic species involved in each metabolic reaction. c) Venn diagram 
representing the number of gut prokaryotic genes involved in the production of indoles, detected by 
KEGG, BLASTP or both, after filtering. d) Number of gut prokaryotic species involved in each 
metabolic reaction, after filtering. e) List of reactions of the metabolic network, with the respective 
contribution of KEGG and BLASTP to the identification of associated prokaryotic species, before and 
after filtering. 
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3.3. Prokaryotic communities involved in the production of 
indole 
 
Having provided an overview of the prokaryotic metabolism of indoles, the next 
results focus on specific indolic compounds reported to be relevant for human health: 
indole and indole-3-acetate.  
 
Indole is synthesised in the gut by the action of a prokaryotic lyase, 
tryptophanase, on tryptophan and is then converted by hepatic enzymes into indoxyl 
and indoxyl sulfate (Figure 18a). By merging the KEGG + BLASTP gut dataset, 61 
prokaryotic species involved in this metabolic conversion were identified (Figure 18b). 
Data visualisation of these species, in the form of a phylum-clustered network, reveals 
a marked relative contribution of the phyla Bacteroidetes (n = 17) and Proteobacteria 
(n = 30) to this metabolic process (Figure 18b).  
 
BLASTP predicted 23 more species than recognised previously able to 
potentially perform this reaction, including, amongst others: Klebsiella oxytoca, 
Citrobacter farmeri, Shigella flexneri, Enterobacteriaceae bacterium, Aeromonas spp. 
e Escherichia spp. (Proteobacteria); Prevotella pallens, Prevotella nigriscens, 
Odoribacter laneus, Porphyromonas uenonis and Bacteroides spp. (Bacteroidetes); 
Propionibacterium spp. and Streptomyces spp. (Actinobacteria); Fusobacterium sp. 
(Fusobacteria) and Clostridium spp. (Firmicutes) (Figure 18b). No new species were 
identified in the phyla Spirochaetes and Verrucomicrobia.  
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Figure 18. Contribution of the gut microbiota to the production of indole. 
(a) Schematic representation of the production of indole via tryptophanase (“K01667”); (b) Network 
showing the prokaryotic species involved in the reaction, where species newly predicted by BLASTP are 
coloured in yellow. The size of the phylum nodes (green) reflects the number of species belonging to each 
phylum. 
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3.4. Prokaryotic communities involved in the production of 
indole-3-acetate 
 
The production of indole-3-acetate exhibits increased metabolic complexity, 
occurring through three metabolic paths: via indole-3-acetamide (Path 1), indole-3-
pyruvate (Path 2) or tryptamine (Path 3). Interestingly, while Path 1 is exclusively 
bacterial, both Path 2 and Path 3 exhibit microbial and mammalian co-metabolism 
(Figure 19a). An overview of the potential contribution of prokaryotic species to the 
individual reactions of the three paths is shown in Figure 19b.  In each path, the first 
step is consistently the one performed by a lower number of prokaryotic species, 
suggesting a critical role for a subset of species at the initiation of these metabolic 
pathways. 
 
A scoring system was created to highlight and rank the most relevant species, 
reflecting their overall contribution to the three metabolic paths. Score values assumed 
a bimodal distribution (Figure 19c), with higher scores corresponding to the ability of 
a microbe to perform a higher number of potential reactions (for further details on how 
the scores were calculated, see Section 2. Methods). After filtering the original heatmap 
using a score cut-off value of 1.66 (corresponding to the ability of a given species to 
perform 4 out of 7 reactions), 38 species were identified. As shown in Figure 19d, the 
species with highest scores belong almost exclusively to the phyla Proteobacteria 
(68.4%) and Firmicutes (28.9%). At the individual species level, Pseudomonas putida 
and Pseudomonas fluorescens exhibited the highest scores (score = 2.49), 
corresponding to their ability to potentially perform 6 out of the 7 metabolic reactions 
involved in the production of indole-3-acetate (Figure 19d). While most of these species 
were reported in KEGG, BLASTP searches allowed the identification of several 
additional species with high scores, such as Pseudomonas nitroreducens and Raoultella 
terrigena. Pseudomonas nitroreducens is potentially able to perform all the steps of 
Path 1 (exclusively bacterial) and complete the last steps of the other two paths. 
Conversely, Raoultella terrigena performs all the steps of Path 2 (initiated by human 
metabolism only, L-amino-acid oxidase (“K03334”)) and completes the last metabolic 
steps of the remaining paths. 
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Figure 19. Contribution of the gut microbiota to the production of indole-3-acetate. 
 (a) Schematic representation of the production of indole-3-acetate by three possible metabolic 
pathways, represented with orange (path 1), grey (path 2) or blue (path 3) arrows. (b) Heatmap showing 
the contribution of individual species to each the reactions involved in the production of indole-3-acetate. 
(c) Histogram showing the distribution of the score values. (d) Filtered heatmap selecting the 38 species 
with the highest contribution (score  1.66). *Exclusively bacterial reactions, **exclusively human 
reactions. 
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It should also be noted, however, that the scoring system proposed merely allows 
to identify the species worthy of further study in vitro and in vivo; however, it does 
not allow to make predictions as to which species make the greatest contribution to 
metabolism of indoles in the human gut. 
 
4. Discussion 
 
In this chapter, the contribution of the gut microbiota to the production of indoles 
was investigated. In particular, a systematic computational approach was used to 
identify the metabolic reactions and potential prokaryotic species involved in the 
production of indoles, as well as to predict members of the gut microbiota involved in 
these metabolic processes. 
 
4.1. Gut prokaryotic metabolism controls the majority of the 
reactions leading to the production of indoles 
 
First, the contribution of prokaryotes to the metabolic network leading to the 
production of indoles was investigated. Gut prokaryotic metabolism potentially 
contributes to 78% of the reactions of the metabolic network; however, the relevance 
of its contribution varies depending on the indolic compound considered. According to 
KEGG (and further validation by BLASTP-searches), indole-3-pyruvate is produced 
by human metabolism only, upon the action of the L-amino-acid oxidase; therefore, it 
should not be considered a microbiota-associated metabolite. L-amino-acid oxidase is 
a secreted enzyme encoded by the gene IL4I1 and is highly expressed in inflammatory 
cells, but also in the gastrointestinal tract, particularly in the colon and rectum 
(Ponten, et al., 2008). The enzyme is released into the intestinal lumen (Ponten, et al., 
2008), where it can convert tryptophan into indole-3-pyruvate, which can then be used 
as a substrate for gut prokaryotic metabolism. Therefore, although indole-3-pyruvate 
is not a gut microbial metabolite per se, it can be used as a substrate for the production 
of microbial metabolites, exemplifying an interesting case of mammalian-microbial 
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metabolic cooperation. In this study, it was not possible to conduct BLASTP searches 
on the reactions involved in the production of indole-3-lactate and 3-
methylindolepyruvate from indole-3-acetate, as these reactions are not linked with a 
KEGG ID orthology. However, according to the literature, these reactions have been 
identified, respectively, in Clostridium sporogenes (Jean and DeMoss, 1968) and 
Streptomyces griseus (Hornemann, et al., 1970). To our best knowledge, no genes have 
been assigned for these reactions. 
 
Apart from indole-3-pyruvate, our results suggest that all indolic compounds included 
in this network involve prokaryotic metabolism, at least partially. Further results focus 
on the production of a) indole (exclusively prokaryotic metabolism) and b) indole-3-
acetate (both shared by human and prokaryotic metabolism). 
 
4.2. Indole is exclusively produced by prokaryotic metabolism: 
Proteobacteria and Bacteroidetes are the main contributors 
 
Using a combined KEGG + BLASTP strategy on the gut-specific database, a 
total of 61 prokaryotes species were identified/predicted to be involved in the 
production of indole. Most species were from the phyla Proteobacteria (n = 30) and 
Bacteroidetes (n = 17). Amongst the species identified, many have been previously 
reported as tryptophanase-containing, thus validating the identification strategy 
adopted in this study (e.g. Bacteroides thetaiotaomicron, (Tannock, 1977) Escherichia 
coli (Smith, 1897), Escherichia fergusonii (Farmer, et al., 1985), Edwardsiella tarda 
(Amandi, et al., 1982), Haemophilus influenzae (Stull, et al., 1995)). The BLASTP 
strategy predicted, based on protein homology, 23 species previously unknown to be 
involved in indole production. Interestingly, some of them (Klebsiella oxytoca, 
Prevotella pallens and Prevotella nigriscens) were recently confirmed as indole-
producing species, encoding tryptophanase (TnaA) in their genomic DNA and/or 
producing detectable levels of indole (Alves, et al., 2006; Sasaki-Imamura, et al., 2011).  
 
As for the other predicted species, it is important to note that the detection of 
a protein sequence in a microbe’s genome is only an indicator that it may produce a 
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given metabolite from a substrate; it does not guarantee functionality and further in 
vitro studies are needed to confirm metabolic activity. Validation studies should 
include qualitative (e.g. Kovac’s reagent or Ehrlich’s reagent (Lombard and Dowell, 
1983)) or quantitative assessment (e.g. Liquid Chromatography - Mass Spectrometry 
(LC-MS) (Badenoch-Jones, et al., 1982)) of indole in pure cultures of bacteria, after 
growth in sterile tryptophan-containing medium.  
 
4.3. Proteobacteria and Firmicutes are the main contributors to 
the production of indole-3-acetate  
 
The contribution of gut prokaryotes to the production of indole-3-acetate was 
also evaluated. Three distinct prokaryotic biosynthetic pathways leading to the 
production of indole-3-acetate were identified, based on KEGG. Amongst these, two 
have already been described (via indole-3-acetamide and indole-3-pyruvate) (Patten, 
et al., 2013).   
 
The relative contributions of the microbiota and human metabolism varied 
between pathways. The production of indole-3-acetate via indole-3-acetamide is 
prokaryotic-specific (Path 1); Streptomyces spp. are amongst the species previously 
demonstrated to be involved in this conversion (Manulis, et al., 1994), but they are 
not commensals of the human gut. Conversely,, the production of indole-3-acetate via 
indole-3-pyruvate (Path 2) requires a host-specific enzyme, thus representing an 
example of host-microbiota co-metabolism, as suggested here and previously 
demonstrated by others (Sridharan, et al., 2014). Finally, all the reactions involved in 
the production of indole-3-acetate via tryptamine (Path 3) can be produced by both 
prokaryotic and human metabolism. 
 
Using a combined KEGG + BLASTP strategy on the gut microbiota database, 
a total of 205 prokaryotes involved in the production of indole-3-acetate were identified 
/ predicted; most species derived from the phyla Proteobacteria and Firmicutes. After 
implementing a scoring system to identify the species contributing to the highest 
number of steps of the overall metabolic network, the species with highest scores were 
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Pseudomonas putida and Pseudomonas fluorescens. Interestingly, both species were 
already proposed to be involved in the production of indole-3-acetate, in plant studies 
(Karnwal, 2009; Patten and Glick, 2002). Other high score species, such as Klebsiella 
oxytoca and Klebsiella pneumoniae, were also demonstrated to produce indole-3-
acetate in plant-based studies (Celloto, et al., 2012; Sachdev, et al., 2009). 
Furthermore, amongst the high-scoring species, two other gut microbial species were 
predicted (Pseudomonas nitroreducens and Raoultella terrigens). According to our best 
knowledge, these species have not been previously reported or predicted to produce 
indole-3-acetate. As mentioned above, these predictions require further in vitro 
validations (quantification of indole-3-acetate in pure cultures of bacteria by LC-MS, 
after growth of the organisms in sterile tryptophan-containing medium (Lin, et al., 
2015)).  
 
It is not surprising that many studies targeting indole-3-acetate-producing bacteria 
are performed in plants; for more than 70 years, indole-3-acetate has been recognised 
as the main auxin plant hormone, playing a critical role in cell division, vascular 
development and tropic response to light and gravity (Zhao, 2012). However, a recent 
study pointed out several commonalities between plant and the human gut microbial 
ecosystems (Ramirez-Puebla, et al., 2013). In particular, as indole-3-acetate-producing 
species present in plants are also found in the human gut, they can produce indole-3-
acetate to be putatively incorporated into human metabolic and signalling pathways.  
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5. Conclusion 
 
Altogether, the results shown in this chapter highlight the contribution of the 
human gut-associated prokaryotes to the production of indoles, potentially performing 
78% of the reactions included in this metabolic network. The metabolic pathways 
identified converged in the production of one of two indolic compounds: indoxyl sulfate 
(via indole) or indole-3-acetate (via indole-3-acetamine, indole-3-pyruvate or 
tryptamine). The results suggest that the contribution of the gut prokaryotes varies 
depending on the indolic compound considered: while indole-3-pyruvate is produced 
only via human metabolism, indole requires prokaryotic metabolism. For others, such 
as indole-3-acetate, both mammalian and microbial metabolism are involved.  
 
In this chapter, a phylum-level overview of the species involved in the 
production of indoxyl sulfate (via indole that undergoes further sulfation in human 
liver) and indole-3-acetate was provided.  While indole is potentially mostly produced 
by Proteobacteria and Bacteroidetes, the species showing higher scores for the 
production of indole-3-acetate belong to the phyla Proteobacteria and Firmicutes. 
Although the computational-based strategy used herein allowed the prediction of a 
wider range of species able to perform these metabolic reactions, the functional activity 
of these species needs to be confirmed by in vitro studies.  
 
As a natural expansion of this work, this computational strategy could represent 
a useful approach for those interrogating the metabolism of other gut-derived microbial 
metabolites relevant to human health. 
 
 
 
  
116 
 
  
  
117 
  
  
118 
  
  
119 
 
 
 
 
Chapter 4 
Contribution of indoles to the metabolic 
signature of human obesity  
 
1. Introduction 
 
A growing body of evidence suggests that gut microbiota have a critical role in 
human obesity and metabolism. This effect results from a complex interaction that 
incorporates not only differences in prokaryotic species, but also in their metabolic 
functions and, consequently, in the levels of resulting gut microbial metabolites (Cani, 
2014; Chilloux, et al., 2016). Various microbial metabolites have been demonstrated to 
play a role in obesity (Chilloux, et al., 2016), and SCFA have been a particularly 
studied group. While acetate exhibits anorexigenic properties by altering the 
hypothalamic expression of neuropeptides involved in appetite suppression (Frost, et 
al., 2014), propionate upregulates the release of appetite-suppressing gut hormones, 
such as glucagon-like peptide-1 and peptide YY (Psichas, et al., 2015). TMAO, a 
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choline-derived gut microbial metabolite, also limits impaired glucose tolerance in mice 
and in isolated pancreatic islets (Dumas, et al., 2017). 
 
Indoles have also emerged as metabolites with a putative role in obesity. As 
explored in the last chapter, bacterial degradation of tryptophan converges into the 
production of two indolic compounds: indoxyl sulfate (via indole) or indole-3-acetate 
(via indole-3-acetamine, indole-3-pyruvate or tryptamine). Indoles are then absorbed 
in the colon, thus entering systemic circulation (Sender, et al., 2016). Metabonomic 
studies have consistently identified indoles in human biofluids (Bouatra, et al., 2013; 
Danaceau, et al., 2003; Duranton, et al., 2012; Elliott, et al., 2015).  
 
In 2013, Chatelier et al. found that obese subjects have a lower bacterial gene 
count and exhibit significantly higher modules for the degradation of aromatic amino 
acids (e.g. tryptophan) (Le Chatelier, et al., 2013), therefore having a higher genomic 
potential for the production of tryptophan-derived metabolites. Recently, Zhang et al. 
reported for the first time an association between indoxyl sulfate and obesity, in a 
paediatric cohort (Zhang, et al., 2015). Obesity in children with Prader-Willi syndrome 
was associated not only with a higher production of indoxyl sulfate, but also with a 
higher abundance of the genes involved in the production of this metabolite (Zhang, 
et al., 2015). It is important to note, however, that these findings were reported in a 
context of genetic obesity, and cannot be directly extrapolated to non-syndromic 
obesity. 
  
In this chapter, a 1H NMR-based metabolic profiling approach was used to 
explore the contribution of indoles to the metabolic signature of obesity. The specific 
aims of this chapter include: 
 
a) To investigate the association between obesity and indoles, in a non-
syndromic adult cohort; 
b) To investigate the impact of putative confounders and/or mediators. 
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2. Materials and Methods 
2.1. Study participants 
The MetaHit study participants were randomly selected from the Inter99 study, 
a randomized intervention study conducted at the Research Centre for Prevention and 
Health in Glostrup, Denmark, between 1999 and 2006. Inclusion criteria included: 
BMI<25 kg.m-2 or BMI>30 kg.m-2, no known gastrointestinal disease, no previously 
bariatric surgery, no medications known to affect the immune system, and no 
antibiotics 2 months before fecal sample collection. A detailed description of the study 
is provided in (clinicalTrials.gov: NCT00289237). The study was approved by the local 
Ethical Committees of the Capital Region of Denmark (HC-2008-017) and was in 
accordance with the principles of the Declaration of Helsinki. All individuals gave 
written informed consent before participating in the study. 
 
2.2. Phenotyping, biochemical and dietary assessment 
Sample collection, phenotypical, biochemical and dietary assessments performed 
in Chapter 4 (MetaHit Study) were performed by collaborators from the MetaHIT 
consortium, as described in (Le Chatelier, et al., 2013). Participants were examined in 
the morning after an overnight fast. Height and weight were measured in participants 
without shoes and wearing light clothes. Waist circumference was recorded using a 
non-expandable measuring tape, and measured between the lower rib margin and the 
iliac crest. Percentage of whole body fat (%Fat) was assessed by DEXA and data 
analyses were conducted with the integrated software (Hologic Discovery A, Santax).   
Blood samples were collected after an overnight fast. Plasma glucose was 
analysed by glucose oxidase method (Granutest, Merck) and HbA1c was measured 
using a TOSOH G7 by ion-exchange high performance liquid chromatography. Plasma 
total cholesterol, plasma HDL-cholesterol and triglycerides were measured using Vitros 
5600 using reflect-spectrophotometrics. Plasma total free fatty acids were analysed 
using standard biochemical methods (Modular Evo). Homeostatic Model Assessment 
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for Insulin Resistance (HOMA-IR) was calculated as: (fasting plasma glucose 
(mmol.L−1) x fasting serum insulin (mU.L−1))/22.5. Serum insulin was measured using 
the AutoDELFIA insulin kit (Perkin-Elmer, Wallac). Serum adiponectin was analysed 
using a two-site-sandwich ELISA kit for measuring total human adiponectin (TECO). 
Serum leptin was measured using the Bio-Plex Pro diabetes assay. Plasma high-
sensitivity CRP was analysed by a particle-enhanced immunoturbidmetric assay on 
Modular Evo using the CRPL3 kit (Roche). Serum IL-6 and serum TNF- were 
analysed by Luminex using the Bio-Plex Pro cytokine assay (Bio-Rad). A detailed 
description of the biochemical measurements was published elsewhere (Le Chatelier, 
et al., 2013). Participants completed a self-administered 198-item Food Frequency 
Questionnaire, where they were asked to report their dietary intake during the previous 
month. A detailed description of the questionnaire and estimation of the dietary intake 
in the population was previously published (Lau C. et al, 2004). 
 
2.3. Sample preparation for metabolic profiling 
 
Urine samples were stored at -80oC and prepared by using 540 L of urine mixed 
with 60 L of urine buffer solution (0.1 M phosphate buffer solution (10% 2H20/H2O 
vol/vol for 100 mL), 18 g NaH2PO4 in 80 mL D2O, 100 mg trimethylsilylpropanoic 
acid (TSP), 13 mg NaN3; pH 7.4 with KOH). 
 
2.4. Spectra acquisition and pre-processing 
 
Standard 1H NMR spectra were acquired using a Bruker Advance III 
spectrometer (Bruker, Rheinstetten, Germany), operating at 600 MHz 1H frequency. 
The 1H NMR spectra were phased and baseline corrected by using in-house software 
and imported into Matlab (Mathwork, Inc) at high resolution. Each NMR spectrum 
was calibrated to the TSP signal at -0.00, using the RSPA algorithm and normalised 
(probabilistic quotient normalisation) (Dieterle, et al., 2006). The water signal was 
removed at -4.68-5.00. 
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2.5. Metabolite assignment 
 
Metabolite assignment was performed using a combination of resources, 
including NMR Chenomx NMR suite 7.0 software, Human Metabolome Database 
(HMDB), Matlab and in-house databases (Nicholson, et al., 1995), STOCSY (Cloarec, 
et al., 2005) and spike-in experiment. The spike-in experiment for indoxyl sulfate was 
performed on the urine sample with the highest quantity of the metabolite, by 
successively adding increasing volumes of indoxyl sulfate (5 L of a stock solution, 3 
M). Spectra were acquired using a Bruker Advance III spectrometer (Bruker, 
Rheinstetten, Germany), operating at 600 MHz 1H and processed as described in 
Section 2.4. Spectra acquisition and pre-processing. 
 
2.6. Statistical analysis 
 
For statistical comparisons between variables, total and partial correlations 
were performed, followed by correction for multiple testing using the Benjamini-
Hochberg (BH) method. Spearman or Pearson correlations were used, respectively, for 
non-parametric and parametric analyses. Adjustment for co-variables was performed 
using partial correlations (further details are provided in individual figure captions). 
Linear regression models were performed using the least squares approach. Significance 
was established on a p-FDR0.05 threshold of 0.05. 
 
 For metabonomic studies, common multivariate statistical approaches were 
used: PCA (Cloarec, et al., 2005; Gartland, et al., 1990; Gartland, et al., 1991; Holmes, 
et al., 1994) and OPLS-DA (Blaise, et al., 2009; Bylesjo, et al., 2006; Davidovic, et al., 
2011). The intensity of the signal of indoxyl sulfate, expressed as the peak integral 
(7.5040-7.5090 ppm), was log10-transformed and used for quantification and 
investigation of putative associations with clinical variables. A statistical threshold of 
p-FDR0.10 was adopted. 
 
  Statistical analysis was performed in R v.3.3.0 using the MWASTools package 
(Rodriguez-Martinez, et al., 2017), Matlab v.r2016a and GraphPad Prism v.5. 
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3. Results 
 
3.1. MetaHit cohort characterisation 
 
 
 The MetaHit cohort (Le Chatelier, et al., 2013) comprises 279 subjects (53.8% 
female), with an average age of 38.80  7.38 years. The cardiometabolic risk of the 
participants was assessed throughout an extensive characterisation of a) obesity-related 
parameters, b) metabolic homeostasis and c) inflammatory markers. A summary of 
these characteristics is shown in Table 3.  
 
 
Table 3. Metabolic summary description of the MetaHit study population. 
 Reference 
values 
MetaHit 
 Mean SD 95% CI 
Obesity parameters  
Whole body fat (%Fat) [12.00 – 28.00]  32.40 9.10 [31.33 - 33.47] 
BMI (kg m-2) [18.50 – 25.00] 29.60 6.03 [28.89 - 30.31] 
Weight (kg) n/a 87.77 19.77 [85.44 - 90.10] 
Waist (cm) n/a 99.97 16.39 [98.04 - 101.90] 
Metabolic Profile 
Plasmatic glucose (mmol L-1) [4.0 – 6.0] 5.74 0.53 [5.68-5.80] 
HbA1c (%) < 6.5 5.56 0.33 [5.52-5.60] 
Insulin (pmol L-1) < 174 53.01 33.79 [49.02-57.01] 
Total cholesterol (mmol L-1) [3.00 – 5.50] 5.52 0.95 [5.41-5.63] 
HDL-cholesterol (mmol L-1) [1.04 – 2.07] 1.55 0.53 [1.49-1.61] 
Triglycerides (mmol L-1)  [0.56 – 1.69] 1.34 0.70 [1.26-1.42] 
Leptin (g L-1) n/a 21.64 29.06 [18.20-25.07] 
Adiponectin (mg L-1) n/a 11.10 7.17 [10.26-11.95] 
Inflammatory Profile 
hsCRPf (mg L-1) < 5.0 2.65 2.82 [2.317-2.986] 
Interleukin-6 (pg mL-1) n/a 19.97 21.63 [17.41-22.53] 
TNF-  n/a 26.23 49.43 [20.36-32.10] 
 
BMI: Body Mass Index: defined as body mass (kg) divided by the square of the height (m2); HbA1c: 
Haemoglobin A1c, also referred as glycated haemoglobin; HDL-cholesterol: High-Density Lipoprotein 
cholesterol; TNF-: Tumour Necrosis Factor-.  Reference values: %Fat (Hewitt, et al., 1993); BMI 
(WHO, 2016); fasting plasmatic glucose and HbA1c (IDF, 2005); total cholesterol, HDL-cholesterol, 
triglycerides and hsCRP (Medscape, 2014);  for weight, waist, leptin, adiponectin, interleukin-6 and 
TNF-, no consensual reference ranges are available up to the date (n/a). 
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A more detailed description on the relationship between obesity parameters and 
other clinical and analytical measures is shown as a correlation matrix (Figure 20). 
The correlation matrix revealed a strong hierarchical clustering between several 
measures of obesity (Figure 20). Amongst these measures, the percentage of whole 
body fat (%Fat) was the parameter showing the strongest correlation with plasma 
leptin (r = 0.852, p-FDR0.001), a direct marker of adipocyte size (hypertrophy) and 
number (hyperplasia) (Figure 20), thus emerging as the ideal parameter to measure 
obesity. 
 
 
 
 
Figure 20. Correlation matrix between obesity parameter and other metabolic variables in the 
MetaHit study. Associations were computed using Spearman correlations. The p-values of the 
correlations were adjusted for multiple-testing using the BH criterion. Only significant correlations (p-
FDR < 0.05) are shown with colour matching the direction and the strength of the correlation. ALAT: 
Alanine transaminase; ASAT: Alanine aminotransferase; BMI Body Mass Index; HbA1c: Haemoglobin 
A1c, also referred as glycated haemoglobin; HDL-cholesterol: High-Density Lipoprotein cholesterol; 
HOMA-IR: Homeostatic model assessment for insulin resistance; TNF-: Tumour Necrosis Factor-; 
LPS: Lipopolysaccharide; FIAF: Fasting-Induced Adipose Factor. 
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Furthermore, %Fat was also the obesity measure exhibiting the highest 
correlation with HbA1c (r = 0.223, p-FDR 0.001), the current gold-standard for 
management of type 2 diabetes mellitus (Figure 20, Table 4). In a non-adjusted model, 
%Fat also positively correlated with other markers of metabolic dysfunction, including 
HOMA-IR, triglycerides, free fatty acids, interleukin-6 and C-reactive protein. All 
correlations remained significant after adjustment for age and gender, except for 
circulating free fatty acids (Table 4). 
 
Table 4. Spearman correlations between the percentage of body fat (%Fat) and other 
metabolic parameters 
  Unadjusted Age- and gender-adjusted 
 r  p-value p-FDR r p-value p-
FDR 
Demographic    
Age 0.009 8.90 x10-01* 9.06x10-01 - - - 
Gender -0.637 2.27 x10-30* 2.02x10-29* - - - 
Metabolic Profile        
Plasma glucose 0.173 5.65 x10-03* 1.07x10-02 0.348 1.29x10-08* 2.40x10-08* 
HbA1c (%) 0.223 3.33 x10-04* 7.67x10-04* 0.140 2.57x10-02* 3.34x10-02* 
Insulin (pmol l-1) 0.443 1.11 x10-13* 4.93x10-13* 0.623 1.51x10-28* 4.38x10-28* 
C-peptide  0.425 1.32 x10-12* 5.70x10-12* 0.607 7.41x10-27* 1.93x10-26* 
HOMA-IR 0.438 2.20 x10-13* 9.66x10-13* 0.635 5.25x10-30* 1.71x10-01* 
Total cholesterol 0.055 3.83 x10-01 4.65x10-01 0.034 5.93x10-01 5.93x10-01 
HDL-cholesterol -0.123 4.93 x10-02* 7.72x10-02 -0.412 8.45x10-12* 1.83x10-11* 
Triglycerides(mmol l-1)  0.256 2.67 x10-05* 7.33x10-05* 0.369 1.43x10-09* 2.85x10-09* 
FFA(mmol l-1) 0.246 7.40 x10-05* 1.87x10-04* 0.083 1.86x10-01 2.10x10-01 
Leptin(g l-1) 0.852 3.89 x10-73* 6.26 x10-72* 0.812 1.23x10-60* 7.97x10-60* 
Adiponectin (mg l-1) 0.018 7.75 x10-01 8.14 x10-01 -0.327 9.91x10-08* 1.72x10-07* 
Inflammatory Profile 
CRPf (mg l-1) 0.524 2.10x10-19* 1.48x10-18* 0.554 8.76 x10-22* 2.07x10-21* 
Interleukin-6 0.257 3.33x10-05* 9.09x10-05* 0.227 2.71 x10-04* 4.14x10-04* 
TNF- 0.045 4.78x10-01 5.63x10-01 0.045 4.78 x10-01 4.97x10-01 
FIAF(g l-1) 0.077 2.19x10-01 2.92x10-01 0.220 4.24 x10-04* 6.12x10-04* 
 
Associations were computed using Spearman correlations. The p-values of the correlations were adjusted 
for multiple-testing using the BH criterion. Only significant correlations (pFDR < 0.05) are shown with 
colour matching the direction and the strength of the correlation. ALAT: Alanine transaminase; ASAT: 
Alanine aminotransferase; BMI: Body Mass Index; FFA: Free Fatty Acids; HbA1c: Haemoglobin A1c, 
also referred as glycated haemoglobin; HDL-cholesterol: High-Density Lipoprotein cholesterol; HOMA-
IR: Homeostatic model assessment for insulin resistance; TNF-: Tumour Necrosis Factor-
Lipopolysaccharide; FIAF: Fasting-Induced Adipose Factor. 
 
 
3.2. Identifying the clinical phenotype to investigate the 
association between obesity and gut microbial changes 
 
Le Chatelier et al. have previously found that obesity, insulin resistance and 
dyslipidaemia are associated with lower bacterial richness (i.e. lower number of 
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bacterial genes) (Le Chatelier, et al., 2013). In this chapter, the relationship between 
bacterial gene count and various measures of obesity was explored. Bacterial gene 
count was significantly anti-correlated with all anthropometric measures of obesity, 
except with body weight (Figure 21). Importantly, %Fat exhibited the most significant 
correlation with gene count in both unadjusted (r = -0.242, p-FDR < 2.36x10-04) and 
age- and gender- adjusted models (r = -0.213, p-FDR < 1.28x10-03) (Figure 21 and 
Table 5). 
 
 
Figure 21. %Fat exhibits the strongest anti-correlation with bacterial gene count. a-e) 
Associations were computed using Spearman correlations. p values were corrected for multiple testing 
using the Benjamini-Hochberg (BH) criterion. Trend lines were calculated by linear regression using 
the least squares approach. A statistical threshold of 0.05 was adopted. BMI: Body Mass Index. 
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Table 5. Spearman correlations between obesity measures and gene count 
Total (unadjusted) and partial (age- and gender-adjusted) Spearman correlations were calculated, 
followed by correction for multiple testing using the BH method. A statistical threshold of 0.05 was 
adopted. %Fat: whole body fat (%); BMI: Body Mass Index. 
 
 
 As expected, %Fat exhibits the strongest correlation with leptin (a direct 
marker of increased adipocyte number and size) and the strongest anti-correlation with 
gut microbial dysfunction, and therefore was chosen to further investigate the 
contribution of microbial metabolites in subjects with increased adiposity. 
 
3.3. Investigating the metabolic profiles of patients with 
increased adiposity (%Fat) by 1H NMR  
 
A 1H NMR metabonomic approach was used to investigate the metabolic 
signature of patients with increased adiposity and, specifically, to assess the 
contribution of indoles. Urinary metabolic profiles were acquired using a standard 1D 
experiment with water pre-saturation; the chemical shifts of the most abundant 
metabolites assigned are presented in Table 6. 1H NMR profiling allowed the 
identification of urinary metabolites related to a wide range of both human and 
microbial-derived products. Concerning human metabolism, it was possible to identify 
metabolites involved in branched-chain amino acid and energy metabolism (e.g. valine 
(M1); citrate (M9) and lactate (M4)) and creatinine biosynthesis and skeletal muscle 
metabolism (e.g. creatinine (M11), glycine (M14), taurine (M13), creatine (M15), 
histidine (M21), alanine (M5)) (Table 6). 
Regarding gut bacterial metabolites, 1H NMR profiling identified products of 
three different host-microbial co-pathways. The first includes the bacterial conversion 
 Gene Count 
 Unadjusted 
Age- and gender- 
adjusted 
 r p-FDR r p-FDR 
%Fat (%) -0.242 2.36x10-04* -0.213 1.28x10-03* 
Weight (kg) -0.122 8.11x10-02 -0.140 1.13x10-02* 
Waist (cm) -0.147 3.23x10-02* -0.191 4.12x10-03* 
BMI (kg m-2) -0.200 2.93x10-03* -0.220 2.81x10-03* 
Hip (cm) -0.168 1.30x10-02* -0.155 2.20x10-02* 
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of dietary choline into methylamines (e.g. trimethylamine (TMA, M10), 
trimethylamine-N-oxide (TMAO, M12) and dimethylamine (DMA, M9)). The second 
co-metabolic pathway involves the production of hippurate (M20) - produced from 
dietary phenolics, aromatic amino acids and other related compounds upon bacterial 
action and further conjugated with glycine in the liver (Lees, et al., 2013). Metabolites 
from the third pathway, involved in the distal colonic protein putrefaction and 
metabolism of aromatic amino acids, include N-PAG (M7, produced from 
phenylalanine) (Holmes, et al., 2011; Russell, et al., 2013)) and indoxyl sulfate 
(produced from tryptophan, as previously described in Chapters 1 and 3). Apart from 
indoxyl sulfate (M19); no other potential indolic compounds were unambiguously 
assigned. 
 
Table 6. List of most abundant urinary metabolites assigned and respective chemical shift 
Metabolite key Metabolite name Chemical shift ( 1H ppm) 
M1 Valine 0.98 (d), 1.03 (d) 
M2 3-Hydroxybutyrate 1.19 (d), 2.30 (m) 
M3 Lactate 1.32 (d), 4.11 (q) 
M4 3-Hydroxy-3-methylglutarate 1.30 (s), 2.40 (m) 
M5 Alanine 1.47 (d) 
M6 Acetate 1.92 (s) 
M7 N-phenylacetylglutamine 7.36 (m), 7.40 (m) 
M8 Citrate 2.53 (d), 2.67 (d) 
M9 Dimethylamine 2.71 (s) 
M10 Trimethylamine 2.87 (s) 
M11 Creatinine 3.05 (s), 4.07 (s) 
M12 Trimethylamine-N-Oxide 3.26 (s) 
M13 Taurine 3.27 (t), 3.43 (t) 
M14 Glycine 3.57 (s) 
M15 Creatine 3.93 (s) 
M16 Trigonelline 4.43 (s), 8.07 (t), 8.83 (t) 
M17 Urea 5.8 (s) 
M18 Tyrosine 6.89 (d), 7.18 (d) 
M19 Indoxyl sulfate 7.51 (d), 7.71 (d) 
M20 Hippurate 7.56 (t), 7.65 (t), 7.84 (t) 
M21 Histidine 7.08 (s), 7.90 (s) 
M22 Formate 8.44 (s) 
(s) singlet; d (doublet); (t) triplet; (m) multiplicities 
 
A representative spectrum of a urine sample with the most abundant 
metabolites assigned is shown in Figure 22. 
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Figure 22. A typical urine 1H NMR spectrum (standard 1D spectrum with water pre-saturation). 
Most abundant metabolites are numbered as follows: M1: valine; M2: 3-hydroxybutyrate; M3: lactate; M4: 
3-hydroxy-3-methylglutarate; M5: alanine; M6: acetate; M7: N-phenylacetylglutamine; M8: citrate; M9: 
dimethylamine; M10: trimethylamine; M11: creatinine; M12: trimethylamine-N-oxide; M13: taurine; M14: 
glycine; M15: creatine; M16: trigonelline; M17: urea; M18: tyrosine; M19: indoxyl sulfate; M20: hippurate; 
M21: histidine; M22: formate. a.u.: arbitrary units; ppm: parts per million. 
  
131 
In order to explore the overall differences on the metabolic signature of patients 
with increased adiposity (%Fat), both unsupervised and supervised methods were used. 
Although no clear discrimination was observed in a PCA model including the metabolic 
profiles of individual on extreme quartiles of %Fat (5 Principal Components, mean-
centred model, (Figure 23a-b), a relatively good separation between groups was 
observed in an OPLS-DA model (5 Orthogonal Components, R2=0.9335, Q2=0.067, 
Figure 23c-d). Even though the Q2/R2 ratio is low (and, therefore, overfitting cannot 
be excluded), the separation between groups observed in this model suggests that 
individuals with increased adiposity exhibit a specific metabolic signature. 
In order to better explore the metabolic signature of individuals with increased 
adiposity, the total correlations between %Fat and 1H NMR metabolites were 
computed and visualised as a skyline plot (Figure 23e). In the spectral region between 
δ7.00–8.00, there were observed several signals positively associated with %Fat, which 
were putatively identified as indoxyl sulfate (Figure 23e). 
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Figure 23. Metabonomic signature of increased adiposity: Principal Component Analysis 
(PCA), Orthogonal Partial Less Squares-Discriminant Analysis (OPLS-DA) and skyline plot. 
a) Optimisation of the Principal Component Analysis model. b) PCA scores plot (5 PC, mean-centred 
model). Optimisation (c) and scores plot (d) of the OPLS-DA model. e) Visualization of the associations 
of %Fat with urine 1 H NMR metabolites. The associations were computed using total Spearman 
correlations. Total and partial (δ 7.00–8.00) skyline plots show the −log10 (p-val) × sign of beta 
coefficient of each NMR signal. Statistically significant signals positively associated with %Fat were 
coloured in red, and significant signals negatively associated with %Fat were coloured in blue. The 
arrows indicate signals putatively assigned as indoxyl sulfate. 
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3.4. Exploring the relationship between obesity and indoxyl 
sulfate 
The assignment of indoxyl sulfate was confirmed by acquiring a standard 1D 
spectrum and by performing a spike-in experiment (Figure 24). 
 
 
Figure 24. Confirmation of the assignment of indoxyl sulfate by a spike-in experiment. a) 
Standard spectrum of indoxyl sulfate. b) Detailed view (aromatic region) of a urine sample, highlighting 
the assignment of indoxyl sulfate and potential overlap with other metabolites. c-f) Three cumulative 
additions of 5 L of a stock solution of indoxyl sulfate (baseline: yellow; 5 L: red; 10 L: green; 5 L: 
purple) resulted in a progressive increase of the intensity of the metabolite’s signal. a.u.: arbitrary units; 
3-IS: indoxyl sulfate; a.u.: arbitrary units; ppm: parts per million.  
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Comparing the standard spectrum with a urine sample, it was possible to 
identify the optimal signals for quantification, for which no overlap which other 
compounds was observed (doublets at 7.70 and 7.50 ppm) (Figure 24a-b). The spike-
in experiment resulted in a progressive increase of the intensity of the metabolite’s 
signal (Figure 24c-f), thus unambiguously confirming its assignment. 
 
In order to further investigate the association between indoxyl sulfate and 
adiposity (%Fat), correlations with both anthropometric and analytical markers of 
obesity (e.g. leptin and adiponectin) were performed. For this targeted analysis, the 
signal of indoxyl sulfate at 7.50 (doublet) was integrated as the area under the curve 
(AUC) and log10-transformed (Figure 25a). Indoxyl sulfate positively correlated with 
%Fat (r = 0.1402, p-adaptiveSTS =0.06). No other significant correlations were 
observed between indoxyl sulfate and other obesity-related anthropometric parameters 
(Figure 25b). Correlations with other obesity-related analytical markers were also 
addressed; interestingly, indoxyl sulfate also correlated with increased plasmatic levels 
of leptin (r = 0.1576, p-adaptiveSTS =0.06), a marker for adipocyte number and size 
(Figure 25b). An overview of distribution of individual data points (and respective 
logistic regression models) for the associations between indoxyl sulfate and adiposity 
(%Fat), and indoxyl sulfate and leptin concentration, are shown in Figure 25c-d. The 
stability of the significant associations was confirmed by bootstrapping (resampling 
with replacement) with 10,000 iterations. The 95% confidence intervals (95%CI) for 
the correlations between indoxyl sulfate and %Fat and leptin were, respectively, 
[0.0322, 0.2419] and [0.0341, 0.3155].  
 
3.5. Assessing the effect of potential confounders, mediators and 
co-variables 
 
In order to identify potential confounders, mediators and co-variables implicated 
in the associations of indoxyl sulfate with obesity-related parameters, Pearson 
correlations were performed between indoxyl sulfate intensities and several 
demographic, metabolic and inflammatory variables; however, no significant 
associations were found (Figure 25e). 
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Figure 25. Correlations between indoxyl sulfate and other obesity-related parameters. 
a) The intensity of indoxyl sulfate intensity, expressed as the area under the curve (7.5040-7.5090 ppm), 
was log10-transformed; histograms represent the frequency distribution before and after normalisation; 
b) Pearson correlations were performed; Benjamini-Hochberg (FDR) and adaptive Storey-Taylor-
Sigmund (adaptiveSTS) corrections for multiple testing were applied as mentioned. Estimates (r) are 
colour-coded and plotted in red (if positive) or blue (if negative); p-values are shown. c-d) Distribution 
of individual data points and linear regression models for indoxyl sulfate and %Fat (c) and leptin (d). 
e) Potential confounders were assessed by performing Pearson correlations, BH-adjusted for multiple 
testing. Statistical analysis was performed in R v.3.3.0 using the MWASTools package. a.u.: arbitrary 
units; AUC: Area Under the Curve; BMI: Body Mass Index; CRP: C-Reactive Protein; HbA1C: 
Haemoglobin A1c; IS: Indoxyl Sulphate; TNF: Tumour Necrosis Factor-. 
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Although indoxyl sulfate is positively associated with increased adiposity 
(%Fat), these findings do not exclude, per se, the possibility of a direct dietary effect. 
Being a product of the bacterial degradation of tryptophan, increased levels of indoxyl 
sulfate in obese subjects could be explained by an increased consumption of this amino 
acid in these subjects. However, no significant associations were observed between 
indoxyl sulfate and tryptophan, nor with any other dietary compounds (Figure 26a-
b). 
 
 
 
 
Figure 26. Total correlations between indoxyl sulfate and dietary compounds. 
The intensity of indoxyl sulfate, expressed as the area under the curve (7.5040-7.5090 ppm), was log10-
transformed; Pearson correlations, both uncorrected (a) and BH-corrected (b) were performed. p values 
are plotted as sign*log(p), where positive bars represent positive estimates (r) and negative bars 
represent negative estimates. Bars (r) are colour-coded and plotted in grey (not-significant), red 
(significant, positive estimates) or blue (significant, negative estimates).  
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4. Discussion 
 
In this chapter, the contribution of indoles to the metabolic signature of obesity 
was investigated. First, the cohort was characterised and relationships between obesity 
and other variables were assessed, in order to identify the best obesity measurement 
to use for further correlative analyses. Next, a 1H NMR-based strategy was used to 
profile indoles in urine samples, and the association between 3-indoxysulfate and 
adiposity was investigated. Finally, the impact of putative co-variables, confounders 
or mediators was explored. 
 
4.1. Whole body fat (%Fat) exhibits the most significant 
correlation with leptin and bacterial gene count 
 
 Amongst all obesity measures these measures, %Fat was the parameter showing 
the strongest correlation with plasmatic leptin (r = 0.852, p-FDR0.001). Leptin is a 
product of the obese (ob) gene and is produced primarily in the adipocytes of white 
adipose (Green, et al., 1995). Although the primary function of leptin is to regulate 
energy balance by inducing satiety, its levels are increased in obesity, probably due to 
decreased sensitivity (leptin resistance) (Pan, et al., 2014). Leptin levels are known to 
be increased in obesity and to vary exponentially with the amount the fat mass; 
therefore, leptin levels have been proposed as direct marker of adipocyte size and 
number (Caro, et al., 1996). 
 
The strongest correlation between %Fat and leptin, can be explained by the 
higher accuracy of this measure to quantify obesity. Whilst the quantification of 
obesity by DEXA provides a direct quantification, other anthropometric models, such 
as BMI, are surrogate markers based on mathematical predictive models (Shah and 
Braverman, 2012; Wells and Fewtrell, 2006). Furthermore, the accuracy of BMI and 
weight measurements can be compromised by the contribution of other body 
components as muscle mass or bone mass (Donini, et al., 2013).  
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As described by Le Chatelier et al, gene count is anti-correlated with obesity 
(Le Chatelier, et al., 2013). Importantly, amongst all obesity measures, %Fat also 
exhibits the most significant statistical association with gene count. Again, this 
stronger association might be explained by the higher accuracy of this measure and, 
therefore, the higher statistical power regarding the detection of associations with 
markers of gut microbial dysfunction. Altogether, these results support the use of 
%Fat, whenever available, as the optimal measure to perform correlative analyses 
aiming to investigate the impact of the gut microbiota in obesity. 
 
4.2. %Fat is positively correlated with indoxyl sulfate 
 
According to Le Chatelier et al., obese subjects exhibit not only a significantly 
lower gene count, but also a higher genomic potential for the production of tryptophan-
derived metabolites (Le Chatelier, et al., 2013). In this chapter, metabonomic profiling 
was used to investigate the putative association obesity (expressed as %Fat) and 
indoles. 
 
1H NMR has been extensively used for metabolic profiling due to its high 
reproducibility and easy sample preparation; in particular, it is a widely validated 
approach for the study of the microbial-mammalian interaction in the development of 
obesity (Dumas and Davidovic, 2013). Consistent with previous studies (Calvani, et 
al., 2010; Elliott, et al., 2015), we were able to identify a range of mammalian products 
in urine metabolic profiles, including metabolites involved in branched-chain amino 
acid and energy metabolism (e.g. valine, citrate, lactate) (Giskeodegard, et al., 2015) 
and in biosynthesis and skeletal muscle metabolism (e.g. creatinine, glycine, taurine, 
alanine) (Elliott, et al., 2015). As in previous studies, a range of gut microbial 
metabolites were also identified, including methylamines, hippurate and products of 
aromatic amino acids degradation (e.g. N-PAG) (Dumas, et al., 2006; Elliott, et al., 
2015; Giskeodegard, et al., 2015). 
 
In this study, the only indolic compound identified in urine metabolic profiles 
was indoxyl sulfate. Indoxyl sulfate has been repeatedly identified in 1H NMR 
  
139 
metabonomic studies, mostly in human urine (Bouatra, et al., 2013; Danaceau, et al., 
2003; Duranton, et al., 2012; Elliott, et al., 2015; Giskeodegard, et al., 2015). However 
it is the first time that a positive association is reported between this metabolite and 
obesity (expressed as %Fat), in the context of non-genomic obesity. These results are 
consistent with a recently published study by Zhang et al., reporting a positive 
association between indoxyl sulfate and obesity, in the context of genetic obesity (i.e. 
Prader-Willi syndrome). Children diagnosed with Prader-Willi exhibited higher levels 
of indoxyl sulfate and increased abundance of genes involved on its production (Zhang, 
et al., 2015). Nonetheless, Prader-Willi syndrome is a very specific context 
characterised by an epigenetic phenomenon of imprinting (i.e., the deletion of paternal 
copies of the SNRPN and necdin genes along with clusters of small nucleolar RNAs) 
and therefore could not be generalised. By replicating the same findings in the MetaHit 
cohort, we demonstrate that the association between indoxyl sulfate and obesity is also 
present in non-genetic obesity.  
 
Indoxyl sulfate was previously identified by 1H NMR in the Intercontinental 
Study in Macronutrients in Arterial Pressure (Elliott, et al., 2015); however, no 
significant association was observed between its levels and BMI. As previously 
discussed, BMI is a surrogate marker, and its low accuracy might compromised the 
detection of associations with gut microbial metabolites. 
 
4.3. Levels of indoxyl sulfate are not correlated with tryptophan 
dietary intake 
 
The identification of confounding factors is vital to identify robust disease 
markers in clinical association studies (Vandeputte, et al., 2016). Amongst those, 
history of antibiotic treatment (Cho, et al., 2012), inflammation status (Le Chatelier, 
et al., 2013) (Hildebrand, et al., 2013) and diet (David, et al., 2014; Rezzi, et al., 2007; 
Stella, et al., 2006) are thought to be particularly relevant. For this study, only 
participants without previous antibiotic treatment 2 months before faecal sample 
collection were included, thus excluding the need to explore previous antibiotic intake 
as a potential confounder.  
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No associations were found between indoxyl sulfate and inflammatory markers. 
Previous studies found that indoxyl sulfate increases the inflammatory response to LPS 
in vitro, by increasing TNF- and IL-6 (Adesso, et al., 2013). However, it is important 
to note that these studies used very high concentrations, similar to the ones detected 
in uremic patients. Another study from (Brito, et al., 2016) also found a positive 
correlation between IL-6 levels and indoxyl sulfate, but again, participants included 
only patients with severe chronic renal disease. No studies validated similar findings 
in non-uremic patients. In this cohort, the absence of significant associations between 
the level of indoxyl sulfate and inflammatory cytokines suggests that the compound 
does not impact the pro-inflammatory status in the context of non-uremic patients. 
Therefore, it is not likely that the association between this gut microbial metabolite is 
obesity is mediated by a pro-inflammatory effect. 
 
Similarly, no significant correlations were found between tryptophan intake and 
indoxyl sulfate urinary levels. One of the main concerns regarding novel associations 
between obesity and gut microbial markers is whether the variations on these 
compounds reflect changes in the gut microbial metabolism, or simply reflect an 
increased consumption of the respective substrate (in this case, tryptophan). In line 
with the findings of Brito et al (Brito, et al., 2016), no significant correlation were 
found between indoxyl sulfate and tryptophan consumption (or any other nutrients), 
thus excluding a potential dietary confounding effect. 
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5. Conclusion 
 
In this chapter, indoxyl sulfate was identified as part of the metabolic signature 
of individuals with increased adiposity. Indoxyl sulfate correlated not only with whole 
body fat, but also with the plasmatic levels of leptin, which are a proxy for adipocyte 
size and number. Being physiologically plausible, the co-identification of both 
correlations strengthens a putative role of this metabolite in the context of obesity. 
These results are consistent with previous findings in the context of paediatric genetic 
obesity, thus suggesting that the association between indoxyl sulfate and obesity is not 
specific of a specific syndromic effect. 
 
Of note, as in other studies, no significant association was observed between 
indoxyl sulfate metabolite and BMI, a common but less accurate proxy for human 
obesity. The strength of the association between body fat (%Fat) and gut microbial 
changes (i.e. gene count or the production of this specific metabolite), supports its use 
as an optimal variable for studies aiming to investigate the impact of the microbial-
mammalian axis in human obesity. 
 
It is important to note that this significant association, is not, however, 
sufficient to generate causal inferences. In the next chapter, the effect of indoxyl sulfate 
will be tested in vitro and its targets and signalling pathways explored by a combined 
strategy including a kinase screening and network analysis. 
 
 
 
. 
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Chapter 5 
Validation of the pro-adipogenic effect of 
indoxyl sulfate in vitro 
 
1. Introduction 
 
In the previous chapter, a 1H NMR-based metabolic profiling strategy showed 
that indoxyl sulfate is positively correlated with adiposity (%Fat) and plasma levels of 
leptin (Margetic, et al., 2002). Although indoxyl sulfate has been previously associated 
with several cardiovascular effects (Adesso, et al., 2013; Barreto, et al., 2009; Dou, et 
al., 2007; Faure, et al., 2006; Muteliefu, et al., 2009; Yisireyili, et al., 2013), its 
association with increased adiposity only recently started being explored. In particular, 
the cellular responses, mechanism and targets involved in the potential pro-adipogenic 
effect of indoxyl sulfate remain unclear. 
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In order to understand the effect of a given pro-adipogenic compound, it is 
important to revisit the biomolecular basis of obesity. Two major mechanisms 
contribute to the expansion of the adipose tissue: a) increased adipocyte cell number 
(hypertrophy) and b) increased adipocyte cell size (hyperplasia) (Jo, et al., 2009) 
(Figure 27). Adipocyte hyperplasia results of increased lipid intracellular accumulation 
of lipids, a consequence if the unbalance between lipid accumulation (lipogenesis) and 
lipid breakdown (lipolysis) (Jo, et al., 2009). Lipogenesis is induced when nutritional 
abundance or lipogenic stimuli promote the entry of FFA into the adipocyte, both 
through passive and active mechanisms (Hajri and Abumrad, 2002). Intracellular FFA 
are converted into acyl-CoA by the acyl-CoA synthase, which is then then used as a 
substrate in the endoplasmic reticulum (ER) to produce triacylglycerol (TAG) (Shi 
and Burn, 2004). Nascent lipid droplets are released from the ER and are ulteriorly 
coated with perilipin, thus becoming mature lipid droplets (Tansey, et al., 2003).  
 
 
Figure 27. Schematic representation of the several cell types involved in obesity development 
in vivo. During adipose tissue expansion, both adipocyte number (hyperplasia) and size (hypertrophy) 
increase. The increase on adipocyte size results of increased intracellular lipid accumulation, a 
consequence of the unbalance between lipogenesis and lipolysis. During the development of obesity in 
vivo, the infiltration of macrophages also occurs, with subsequent release of pro-inflammatory cytokines. 
Activated adipocytes also produce multiple angiogenic factors that stimulate the development of a 
vascular network, in order to supply the energetic needs of the growing fat mass.  
Designed using Servier Medical Art designed medical elements. 
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Conversely, lipolysis occurs when fasting or lipolytic stimuli (e.g. 
catecholamines, glucagon) induce the phosphorylation of perilipin or of the hormone-
sensitive lipase (HSL) (Tansey, et al., 2003). The phosphorylation of perlipin exposes 
the lipid droplets to the action of HSL, resulting in the hydrolysis of TAG and 
subsequent release of FFA (Holm, 2003). FFA finally enter the bloodstream and are 
used as energy sources in the muscle and the liver, where they undergo mitochondrial 
-oxidation (Duncan, et al., 2007). 
 
The regulation of the relative rates of lipogenesis and lipolysis are determined 
by the nutritional status (e.g. glucose, FFA) and influenced by a wide range of 
endocrine factors (Rosen and MacDougald, 2006) (further details in Figure 28). Insulin 
is the best characterised pro-lipogenic extracellular factor; produced in the pancreatic 
Langherhans islets, it is  secreted in response to the elevation of glucose levels in plasma 
(Rorsman and Braun, 2013). Other pro-lipogenic factors include the Bone Morphogenic 
Protein (BMP) and Fibroblast Growth Factor (Rosen and MacDougald, 2006) (Figure 
28). Lipogenesis supressors have also been identified (e.g. Wnt-family proteins, 
Transforming Growth Factor ). Recently, the Platelet Derived Growth Factor  
(PDGFR) was also proposed as a novel lipogenesis inhibitor (Fitter, et al., 2012). 
Protein kinase-phosphoproteins interactions also play an inportant role in the 
regulation of lipogenesis and lipolysis. Kinases involved in the regulation of glucose 
metabolism (but also lipid metabolism, proliferation and inflammation) include: c-Jun 
N-terminal Kinase (JNK), Mitogen-Activated Protein Kinases (MAPK), Inhibitor of 
Kappa B-Kinase (IKK), Adenosine Monophosphate-activated Protein Kinase 
(AMPK), Protein Kinase B (AKT) and Extracellular Signal-Regulated Protein Kinase 
(ERK), amongst others (Engin, 2017). 
Signals from activators and repressors of lipogenesis are integrated in the 
nucleus by transcription factors that directly or indirectly regulate the expression of 
peroxisome proliferator-activated receptor  (PPAR) and CCAAT-enhancer-binding 
protein  (C/EBP) (Rosen and MacDougald, 2006). 
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Figure 28. Regulation of lipogenesis by extracellular factors. 
Insulin binds to the insulin receptor (IR), inducing the phosphorylation of the insulin receptor substrate 
(IRS). Bone morphogenetic protein (BMP) promotes lipogenesis by stimulating nuclear localization of 
Schnurri-2 (SHN2) and SMAD1; the Fibroblast Growth Factor (FGF) also enhances the expression of 
pro-lipogenic genes, subsequently to the activation of C/EBP and PPAR. Conversely, activation of 
-catenin signalling by Wnt-family proteins (e.g. Wnt10b) represses lipogenesis. Platelet Derived 
Growth Factor  (PDGFR) also inhibits lipogenesis (Artemenko, et al., 2005). Activator and repressor 
signals converge into C/EBP (CCAAT-enhancer-binding protein ) and PPAR (peroxisome 
proliferator-activated receptor ). BMP: Bone morphogenetic protein; CERB: cAMP response element-
binding protein; FGFR: Fibroblast Growth Factor Receptor; LEF/TCF: T-Cell Factor/Lymphoid 
Enhancer-Binding Factor; PDGFR: Platelet Derived Growth Factor Receptor; PI3K: phosphoinositide-
3-kinase; LRP: lipoprotein receptor-related protein receptor. Adapted from (Rosen and MacDougald, 
2006) and designed using Servier Medical Art designed medical elements. 
 
The phenotypic changes observed in adipocytes during intracellular lipid 
accumulation are mirrored by metabolic changes. The increase in adipocyte size is 
positively correlated with an increase in the expression of leptin, an hormone involved 
in the regulation of energy regulation and body fat storage (Caro, et al., 1996; Maffei, 
et al., 1995). Adipocytes also produce adiponectin, a hormone that regulates glucose 
homeostasis and fatty acid oxidation (Diez and Iglesias, 2003). Adiponectin levels are 
reduced in obese patients, while weight loss significantly enhances its circulating 
concentrations (Coppola, et al., 2009). Activated adipocytes also produce multiple 
angiogenic factors to stimulate the recruitment of macrophages and the development 
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of a vascular network to supply the growing fat mass (e.g. angiopoietin, insulin-like 
growth factor) (Samad, et al., 1998) (Figure 27).  
 
A growing body of evidence suggests that indoles may play a role in obesity and 
energy homeostasis. Le Chatelier et al. showed that obese patients show higher 
numbers of genes associated with the degradation of tryptophan, suggesting that 
circulating indoles may also be increased in obesity (Le Chatelier, et al., 2013). A 
recent study in a paediatric cohort reported that obese children, in the context of the 
Prader-Willi syndrome, exhibit higher abundance of genes involved in the production 
of indoxyl sulfate and a higher production of this metabolite (Zhang, et al., 2015). In 
the previous chapter, it was demonstrated that indoxyl sulfate positively correlates 
with adiposity and leptin levels in adults. However, although high-throughput methods 
identified associations between increased adiposity and specific aspects of the human 
gut microbiome, it remains unclear whether these associations have a causal nature, 
and which are the cellular mechanisms and targets involved (Yassour, et al., 2016).  
 
Although indoxyl sulfate binds AHR, this agonistic activity is not likely to 
mediate its putative pro-adipogenic effect. First, AHR is depleted during adipose 
differentiation (Shimba, et al., 1998). Also, in knock-in experiments, enhanced 
expression of AHR promoted  inhibition, not stimulation of lipogenesis (Shimba, et al., 
2003). Therefore, the identification of its pharmacological targets is critical to 
understand the molecular crosstalk underlying the effect of indoxyl sulfate in human 
metabolism (Dumas, 2011).  Despite being the second most targeted gene class in all 
therapeutic areas – in this context, the human kinome remains mostly unexplored 
(Cohen, 2002; Manning, et al., 2002). 
 
In this chapter, a combined strategy was implemented to clarify the cellular 
effects of indoxyl sulfate in adipocyte metabolism. Specific aims included: 
a) To validate the effect of indoxyl sulfate on cell viability, lipogenesis and 
adipocytokine production (in vitro model); 
b) To explore novel targets of indoxyl sulfate in the human kinome, and to 
predict the signalling pathways involved in the microbiome-kinome crosstalk 
(high-throughput kinome screening combined with network analysis). 
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2. Materials and Methods 
2.1. Cell culture 
 
3T3-L1 preadipocytes were obtained from Sigma Aldrich (Sigma Aldrich Co, 
LCC) and cultured in Dulbecco’s Minimal Eagle Medium with glucose (4500 mg/L) 
(DMEM, Gibco), supplemented with foetal bovine serum (FBS, 10%), penicillin-
streptomycin (1%) and of glutamine (1%) at 37ºC, with an atmosphere of 5% CO2. 
When the cell monolayer reached 80% confluency, cells were split and seeded in new 
T75 flasks at a density of 2-5x104 cells/cm2. Cells between passage 3 and 10 were used 
for these experiments. 
 
2.2. 3T3-L1 differentiation 
 
Cells were plated in 24-well plates at a seeding density of 2000 cells/cm2. Two 
days after reaching confluence, 3T3-L1 preadipocytes were induced with DMEM 
containing 0.4 M insulin, 500 M isobutylmethylxanthine (IBMX), 10% FBS, 1% 
penicillin-streptomycin and 1% glutamine (day 0). Cells were treated in differentiating 
medium (0.4 M insulin in DMEM containing 10% FBS, 1% penicillin-streptomycin 
and 1% glutamine) at day 2, day 4 and day 7, supplemented with either vehicle or 
indoxyl sulfate (Sigma Aldrich Co, LCC) at several concentrations (0, 0.01, 1 and 100 
M). Ten days after the induction (day 10), 3T3-L1 cells reached full differentiation 
into adipocytes. 
 
2.3. Cell viability assay  
 
At day 10, 3T3-L1 cells were carefully rinsed with phosphate-buffered saline (PBS, 
Sigma Aldrich Co, LCC), fixed with paraformaldehyde (3.7%, Sigma Aldrich Co, LCC) 
for 20 min and finally stained with Crystal Violet (0.05% (w/v), Sigma Aldrich Co, 
LCC) for 30 minutes. Cells were washed twice with tap water and allowed to dry at 
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room temperature. Methanol (1 mL) was then added to eluate the dye. Cell viability 
was measured by reading the absorbance of the eluates (200 L) at 540 nm, using a 
spectrophotometer plate reader (Synergy H1 Hybrid Reader, BioTek). 
 
2.4. Lipogenesis assay 
 
At day 10, lipogenesis was assessed by lipid staining with freshly prepared Oil 
Red O (Sigma Aldrich Co, LCC). After fixation with paraformaldehyde (further details 
in Section 2.3), 3T3-L1 cells were stained with previously filtered Oil Red-O solution 
(0.5% (w/v) in isopropanol) and incubated for 1 hour at room temperature. Cells were 
carefully washed for four times with distilled water, and the stained lipid droplets were 
observed and photographed (Olympus CK2 Inverted Microscope). The Oil Red-O dye 
retained in the cell was quantified by elution into straight 2-isopropanol and the 
absorbance of the eluates (200 L) was measured at 500 nm, using a spectrophotometer 
plate reader (Synergy H1 Hybrid Reader, BioTek). 
 
2.5. Adipocytokine quantification 
 
Cells were treated during differentiation with either vehicle or indoxyl sulfate, 
as previously described. At day 10, the supernatant medium of each replicate was 
collected, transferred into a clean Eppendorf tube and centrifuged at 8000 rpm for 5 
minutes. Leptin and adiponectin were quantified in the supernatants using, 
respectively, the Leptin Mouse Enzyme-Linked Immunosorbent Assay (ELISA) kit 
(ThermoFisher Scientific) and the Quantikine Mouse Adiponectin / Acrp30 ELISA 
Kit (R&D Systems), accordingly to the instructions of the manufacturer. Each sample 
was quantified in duplicate; the average of the readings was then calculated and the 
average zero standard O.D. was subtracted. For both assays, a four-parameter logistic 
(4-PL) standard curve was generated in GraphPad Prism; sample concentrations were 
interpolated from their respective standard curve. 
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2.6. Kinome screening 
 
Indoxyl sulfate kinome targets were assessed using the KdSELECT screening 
service (DiscoverX®), as previously described (Fabian, et al., 2005; Karaman, et al., 
2008). This technique is based on a competition-binding assay that quantitatively 
measures the ability of a compound to compete with an immobilized, active site-
directed ligand. The ability of indoxyl sulfate to compete with the immobilized ligand 
was measured by quantitative PCR of the DNA tag. Results for primary screen binding 
interactions are reported as % of control (%Ctrl), where lower numbers indicate 
stronger hits (for further details, see Chapter 2. General Methodology). 
 
The binding constant (KD) was calculated from an 11-point dose-response curve 
for the strongest hits identified in the kinome screening. The TREEspot Software Tool 
was used to generate kinase interaction tree plots, which were reprinted with 
permission from KINOMEscan (DiscoverX Corporation). The IC50 of the ten strongest 
hits was determined using the Kinexus kinase-inhibitor activity profiling service 
(Kinexus, Vancouver, Canada). The technique is based on the direct quantification of 
radiolabelled phosphate from ATP onto a protein substrate of a target protein kinases. 
For further methodological details on the kinome screening, see Chapter 2. General 
Methodology). 
 
2.7. Network analysis 
 
The genes of the strongest kinases identified (%Ctrl < 1%) were linked to their 
corresponding signaling pathways using KEGG API 
(http://www.kegg.jp/kegg/docs/keggapi.html) (Kanehisa and Goto, 2000) and the 
MetaboSignal package (Rodriguez-Martinez A, 2016). A directed network table (i.e. 
two column matrix) was generated where each row represents an edge connecting two 
nodes (from node in column 1 to node in column 2). The betweenness-ranked shortest 
paths (n < 8) were retained. In order to identify critical signalling nodes, the 
standardised betweenness ranks were calculated for each one of the subnetwork 
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comprising the shortest paths for each one of the kinases. The network was created 
and visualized in Cytoscape (Shannon, et al., 2003).  
 
2.8. Statistical analysis 
 
Normality was tested using the D’Agostino-Pearson Omnibus normality test, 
and parametric or non-parametric testing chosen accordingly. Comparisons between 
groups were performed by one-way analysis of variance (ANOVA) combined with 
Dunnett’s post-hoc test. The individual number of experiments performed is described 
in the individual figures. Data are displayed as % of control (vehicle), mean  s.e.m in 
all figures. A p-value of 0.05 was used as threshold for statistical significance. 
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3. Results 
3.1. Effect of indoxyl sulfate on 3T3-L1 viability 
 
Briefly, 3T3-L1 cells were treated during induction and differentiation with 
either vehicle or various concentrations of indoxyl sulfate (0.01, 1 and 100M), 
according to the differentiation protocol previously described (see Section 2.2). At day 
10 post-induction, 3T3-L1 cells were fixed and stained with Crystal Violet in order to 
quantitatively assess their viability (Figure 29a-b). 3T3-L1 cell viability was not 
significantly affected by treatment with indoxyl sulfate at any of the doses tested (one-
way ANOVA, p-=0.1770) (Figure 29c). 
 
 
Figure 29. Effect of indoxyl sulfate on cell viability. 
3T3-L1 adipocytes were treated with indoxyl sulfate (as indicated) or vehicle (PBS) during 
differentiation. At day 10, cell number was assessed by Crystal Violet. a) Microscopic cell 
morphology of 3T3-L1 preadipocytes at day 10 post differentiation (treated with vehicle, 40x 
magnification). b) Macroscopic and microscopic (10x) representative photographs of the various 
conditions tested. c) Viability was quantified as the optical density (O.D.) at 540nm. Results are 
expressed as % of control (vehicle), mean  s.e.m. of two independent experiments with six replicates 
each. One-way analysis of variance was performed (p=0.1770). No significant differences between 
groups were found using Dunnett’s multiple comparisons test. ns: non-significant, IS: indoxyl 
sulfate. 
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3.2. Effect of indoxyl sulfate on lipid accumulation  
The effect of indoxyl sulfate on intracellular lipid accumulation was 
subsequently tested.  3T3-L1 cells were treated with either vehicle or different doses 
of the compound (0.01, 1 and 100 M), during induction and differentiation. At day 
10, intracellular lipid content was quantified by Oil Red O staining (Figure 30).  
 
 
 
Figure 30. Indoxyl sulfate promotes lipogenesis in vitro in 3T3-L1. 
3T3-L1 adipocytes were treated with indoxyl sulfate (as indicated) or vehicle during differentiation. 
a) Microscopic cell morphology of 3T3-L1 preadipocytes at day 10 post differentiation, after 
staining with Oil Red O (40x magnification), when multiple lipid droplets were observed (1). b) 
Macroscopic and microscopic (40x) representative photographs of the conditions tested. c-d) 
Indoxyl sulfate increases lipid accumulation in both non-normalised and normalised data. Results 
are expressed as % of control, mean  s.e.m. of two independent experiments with six replicates 
each. One-way analysis of variance was performed for non-normalised and normalised lipid staining 
(p=0.0002 and p=0.0007, respectively) and comparisons between groups were performed by 
Dunnett’s post-hoc testing. IS: Indoxyl sulfate. *p < 0.05, ***p < 0.001.   
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Treatment with 0.01, 1 and 100 M resulted, respectively, in increases of 55.6% 
(p < 0.05), 52.3% (p < 0.05) and 51.2% (p < 0.001) in lipid content (normalised to cell 
number), when compared to vehicle-treated cells (Figure 30d). Interestingly, the pro-
adipogenic effect of indoxyl sulfate does not seem to be dose-dependent; instead, it 
reaches a plateau somewhere below the concentration of 0.01 M (Figure 30d). 
 
3.3. Effect of indoxyl sulfate on adipocytokines secretion 
 
Apart from accumulating triglycerides in the form of lipid droplets, 
differentiated adipocytes also synthesize and secrete several adipocytokines, involved 
in energy homeostasis (Gregoire, et al., 1998). In this experiment, the effect of indoxyl 
sulfate on the production of leptin and adiponectin was assessed (Figure 31). 
 
 
Figure 31. Effect of indoxyl sulfate on adipocytokine secretion in 3T3-L1. 
a-b) For both assays, a four-logistic parameter standard curve was generated, as recommended by the 
manufacturer. c-d) Results were normalised to cell ratio, per replicate, and are expressed as the mean  
s.e.m. of two independent experiments with four replicates each. One-way analysis of variance was 
performed for leptin and adiponectin quantification (p=0.006 and p=0.099, respectively). Comparisons 
between groups were performed by Dunnett’s post-hoc testing. IS: Indoxyl sulfate. *p < 0.05, **p < 0.01.   
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Consistently with its pro-adipogenic effect, indoxyl sulfate significantly increased leptin 
production at both 0.01 M (+50.6%, p < 0.01) and 1 M (+30.5%, p < 0.05) (Figure 
31c). Of note, at the highest concentration tested (100 M), indoxyl sulfate still 
increased leptin production by 17.5% compared to vehicle-treated cells, but in this case 
the effect was not statistically significant (p < 0.05) (Figure 31c). However, treatment 
with indoxyl sulfate did not show any significant effect on adiponectin production at 
any of the concentrations tested (one-way ANOVA, p = 0.099) (Figure 31d).  
 
3.4. Investigating the putative targets of indoxyl sulfate in the 
human kinome 
 
In order to explore novel putative targets mediating the pro-adipogenic effect 
of indoxyl sulfate in the human kinome, a high-throughput assay including a panel of 
456 clinically-relevant kinases was used. Kinases screened were grouped in seven 
families: Tyrosine Kinases (TK), Tyrosine Kinase-like (TKL), STE kinase group 
(STE); Cell Kinase 1 (CK1), Protein kinase A, G and C families (AGC), Calcium and 
Calmodulin-regulated kinases (CAMK) and CMGC kinase group (CMGC). As 
observed in Figure 32, indoxyl sulfate was able to inhibit 46.3% (n=183) of the kinases 
tested (%Ctrl < 35%).  
 
 Eight kinases exhibited extremely high binding affinity in the single-dose kinome 
screening, expressed as %Ctrl values<1%. These kinases include Platelet Derived 
Growth Factor Receptor  (PDGFRB), Serine/Threonine Kinase 32C (STK32C), KIT 
Proto-Oncogene Receptor Tyrosine Kinase (c-KIT), CDC42 Binding Protein Kinase  
(MRCKA), Myosin Light Chain Kinase 3 (MYLK3), CDC42 Binding Protein Kinase 
 (MRCKB), GLK (Germinal Center Kinase-like kinase), CLK3 (CDC Like Kinase 3) 
and ZAK (Sterile alpha motif and leucine zipper-containing kinase). The kinases 
exhibiting highest binding were selected for further confirmation of the physical 
interaction, by defining a multiple-dose binding curve, and thus calculating the 
respective dissociation constant (KD) values. KD values ranged from 9.9 to 730 M 
PDGFRB exhibited the lowest KD and, therefore, the highest affinity (Table 7). 
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Figure 32. Indoxyl sulfate exhibits kinome-wide effects in a single-dose screening. 
Indoxyl sulfate at a single dose (10 M) was screened against a panel of 456 clinically-relevant kinases. 
Preliminary screening identified 186 positive hits with potential binding <35 % vs control (DMSO), 
represented by a red dot whilst non-binding kinases are represented by a green dot. Kinase group names: 
TK, Tyrosine Kinases; TKL, Tyrosine Kinase-like; STE, STE kinase group; CK1, Cell Kinase 1; AGC, 
Protein kinase A, G and C families; CAMK, Calcium and Calmodulin-regulated kinases; CMGC, CMGC 
kinase group.  
 
 
Table 7. High binding affinity kinases for indoxyl sulfate, ranked by IC50  
Acronym Name KD IS Activity IC50/EC50 
PDGFRB Platelet Derived Growth Factor Receptor  9.9 M Inhibitor IC50 =11.7 nM 
STK32C Serine/Threonine Kinase 32C 17 M Activator EC50 =2.89 mM 
c-KIT KIT Proto-Oncogene RTK 20 M Inhibitor IC50 = 10.15 mM 
MRCKA CDC42 Binding Protein Kinase  26 M Inhibitor IC50 = 6.12 mM 
MYLK3 Myosin light chain kinase 3 45M Inhibitor IC50 = 7.00 mM 
MRCKB CDC42 Binding Protein Kinase  49 M Inhibitor IC50 = 33.25 mM 
GLK Germinal center kinase-like kinase 210 M Inhibitor IC50 = 4.61 mM 
ZAK Sterile  motif /leucine zipper-containing 
kinase 
730 M Inhibitor IC50 = 6.84 mM 
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Half maximal inhibitory concentration (IC50) or half maximal effective 
concentration (EC50) values for each kinase are shown in Table 7. STK32C is the only 
kinase activated by indoxyl sulfate, but only at a very high, non-physiological 
concentration (10 mM). All other kinases assessed are inhibited by indoxyl sulfate, 
with the strongest inhibitory effect observed for PDGFRB (IC50 = 11.7 nM). Other 
kinases inhibited by indoxyl sulfate (c-KIT, MRCKA, MYLK3, MRCKB, GLK, CLK3 
and ZAK) exhibit IC50 values in the micromolar range (Table 7). 
 
Amongst the 186 kinases screened, PDGFRB emerged as a strong candidate as 
a human target for indoxyl sulfate, with both the lowest KD and IC50 values. 
Interestingly, PDGFRB has previously been identified a negative regulator of 
lipogenesis (Artemenko, et al., 2005). Imatinib (a PDGFR-B inhibitor) promotes 
lipogenesis and increases the expression of key adipogenic transcription factors (e.g. 
C/EBP and PPAR) (Fitter, et al., 2012). Therefore, it was hypothesised that the pro-
adipogenic effect of indoxyl sulfate could be mediated via PDGFRB inhibition. 
 
As expected, PDGF-DD (a PDGFRB agonist) reduced lipogenesis in 52.7% 
compared to the vehicle (p<0.0001); this effect was reverted by imatinib 
 (p<0.0001). Consistently with previous results, indoxyl sulfate (100 M) increased lipid 
accumulation in 15.5% compared to vehicle (p<0.05). However, indoxyl sulfate is not 
able to counteract the anti-adipogenic effect of PDGFRB activation, thus suggesting 
that its effect is not mediated by PDGFRB inhibition (Figure 33).  
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Figure 33. Indoxyl sulfate does not counteract the anti-adipogenic effect of PDGF-DD. 
3T3-L1 adipocytes were treated vehicle, PDGF-DD (1 g/ml), imatinib (5 g/ml) or indoxyl sulfate 
(100 M). At day 10, lipogenesis was quantified by Oil Red O staining. PDGF-DD decreases lipid 
accumulation (p<0.0001) and this effect is lost in the presence of imatinib (p<0.0001). Results are 
expressed as mean ± s.e.m. of at two independent experiments with 4 replicates each. One-way 
analysis of variance was performed. Tukey’s post-hoc test was used for comparisons between groups 
*p<0.05; ***p<0.001. IS: indoxyl sulfate; PDGF-DD: Platelet Derived Growth Factor DD. 
 
3.5. Network prediction of targets of indoxyl sulfate involved in 
lipogenesis-related signalling pathways 
 
In order to identify critical signalling nodes between the identified kinome 
targets identified and lipogenesis, a network analysis approach was adopted. The 
KEGG API (Kanehisa and Goto, 2000) and the MetaboSignal package (Rodriguez-
Martinez A, 2016) were used to calculate the betweenness-ranked shortest paths 
between the eight validated high-affinity kinases and triacylglycerol were calculated. 
Six out of the eight kinases validated were retained in the network analysis (PDGFRB, 
ZAK, c-KIT, MRCKA, MYLK3 and MRCKB) (Figure 34). The shortest paths 
(shortest geodesic distance) were observed for PDGFRB and c-KIT (both via 1-
Phosphatidylinositol-4,5-bisphosphate phosphodiesterase -2 (PLCB2)-1,2 diacyl-sn-
glycerol).  
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Next, the betweenness rank was calculated for each node of the subnetwork 
comprising the shortest paths. The node with a highest standardized betweenness rank 
was PLCB2 (3.57 x 10-3) (Table 8), into which converge the signaling of 66.7% (n=4) 
of the shortest paths (PDGFRB, ZAK, c-KIT and MRCKA), including the two with 
the shortest geodesic distance. According to the network analysis, PLCB2 emerges as 
a critical signalling node into which converge the multi-kinase inhibition induced by 
indoxyl sulfate, and that can subsequently impact the adipogenic process itself. 
 
 
Figure 34. Prediction of relevant signalling pathways and metabolic nodes involved in the pro-
adipogenic effect of indoxyl sulfate.  
The signalling network was computed using the previously identified kinases as starting point and 
triacylglycerol as a final point. Betweenness-ranked shortest paths were computed using the Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) Application Programming Interface (Kanehisa and Goto, 
2000) and the MetaboSignal package (Rodriguez-Martinez A, 2016). The nodes comprised in the shortest 
paths for each kinase are highlighted in yellow. A full description of the acronyms of the nodes is 
provided in Table 8. 
 
Indoxyl sulfate 
Triacylglycerol 
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Table 8. Betweenness ranks for the nodes of the shortest-paths subnetwork. 
Node acronym Node name Betweenness rank 
PLCB2 
1-Phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase -2 
3.57 x 10-3 
MYLK Myosin light chain kinase 2.01 x 10-3 
CDC42 Cell division control protein 42 homolog 1.82 x 10-3 
SRC 
Proto-oncogene tyrosine-protein kinase 
Src 
1.57 x 10-3 
PRKCA Protein kinase C  1.22 x 10-3 
MAPK14 
Mitogen-activated protein kinase kinase 
14 
1.07 x 10-3 
MYLK12B Myosin light chain kinase 12B 5.07 x 10-4 
MAPK2K6 
Dual specificity mitogen-activated 
protein kinase kinase 6 
4.96 x 10-4 
LIMK1 LIM domain kinase 1 3.15 x 10-4 
 
4. Discussion 
 
In the previous chapter, a 1H NMR-based metabolic profiling strategy was used 
to demonstrate that indoxyl sulfate is positively correlated with adiposity in a human 
cohort.  Increased adiposity in human is a consequence of the increase on the number 
of adipocytes present in the adipose tissue (hyperplasia) and altered cellular 
metabolism (Jo, et al., 2009). In this chapter, a 3T3-L1 cell line model was used to 
validate in vitro the effect of indoxyl sulfate in both cell viability and metabolic 
functions (i.e. lipogenesis and leptin production). Furthermore, by combining a kinome 
screening high-throughput strategy with network analysis, relevant targets and 
signalling pathways putatively involved in the pro-adipogenic effect were identified. 
 
4.1. Indoxyl sulfate does not affect 3T3-L1 cell viability  
 
In healthy adults, the concentration of indoxyl sulfate in plasma is in the 
micromolar range (maximal plasmatic levels varying between 2.50 and 14.0 M 
(Duranton, et al., 2012)); higher concentrations can be observed in uremic patients 
(21.7 M, (Wu, et al., 2011)). Therefore, in this study, the doses used were in the 
micromolar range (0.01, 1 and 100 M). Indoxyl sulfate did not induce significant 
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changes on 3T3-L1 viability at any of the concentrations tested. These results are 
consistent with a recently published study showing that indoxyl sulfate does not exert 
significant deleterious effects on 3T3-L1 cell viability up to 1000 M (Stockler-Pinto, 
et al., 2016). Therefore, the pro-adipogenic effect of indoxyl sulfate is not exercised 
through a stimulating effect on adipocytes (hyperplasia). This concentrations, at which 
no toxic effects were observed, were used to perform the following experiments. 
 
4.2. Indoxyl sulfate promotes lipid accumulation in 3T3-L1  
 
3T3-L1 cells treated with indoxyl sulfate during induction and differentiation 
exhibited increased accumulation of intracellular lipids, at all doses tested (51.2 - 
55.6%, p<0.05), when compared to vehicle. This is the first time that a pro-adipogenic 
effect is reported for indoxyl sulfate in vitro. 
 
In order to confirm the pro-adipogenic effect of indoxyl sulfate, the levels of 
leptin and adiponectin were also evaluated. Previous kinetic studies demonstrated that 
leptin production increases during adipocyte differentiation, subsequently to the 
transcriptional activation of its gene obese (MacDougald, et al., 1995). In agreement 
with these results, it was found that treatment with indoxyl sulfate increased leptin 
production at both 0.01 M and 1 M, thus reinforcing the putative role pro-adipogenic 
role of indoxyl sulfate in vitro. Of note, at the highest concentration tested (100 M), 
indoxyl sulfate still increased leptin production by 17.5% compared to vehicle-treated 
cells, however, this increase was not significant. In striking contrast, in the present 
study, indoxyl sulfate did not affect adiponectin secretion. Although adiponectin and 
leptin both increase during adipocyte differentiation, they are secreted through distinct 
intracellular trafficking pathways; in particular, functional endosomes are required for 
adiponectin, but not for leptin secretion (Xie, et al., 2008). The lack of effect observed 
in adiponectin production might suggest that, concurrently with its pro-adipogenic 
effect, indoxyl sulfate may interfere with other specific aspects of the adiponectin-
secreting pathway.   
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As future work, these findings can be strengthened by increasing the number of 
experiments and by validating the pro-adipogenic effect using other molecular biology 
techniques. Adipocyte differentiation can be further assessed by quantifying the 
expression of adipocyte marker genes, including PPAR, a nuclear receptor from the 
ligand-activated transcription factors family and vital for adipocyte differentiation 
(Gregoire, et al., 1998). Other gene markers of adipocyte differentiation include 
C/EBP, FASN and ADIPOQ (Gregoire, et al., 1998; Sul, et al., 2000).  
 
4.3. Advantages and limitations of cell-based assays in the study 
of adipocyte metabolism and obesity 
 
In this study, 3T3-L1 were used as a model to study adipocyte cell metabolism 
in vitro. Originally isolated from Swiss 3T3 mouse embryos (Green and Kehinde, 1975), 
3T3-L1 offer an abundant source of homogenous cells responsive to metabolic stimuli 
and are therefore often used to investigate the effect of a given compound on lipogenesis 
(Ruiz-Ojeda, et al., 2016). However, one of its main disadvantages is that both the 
initial subculture and the adipogenic differentiation are time-consuming and that, 
being a mouse cell line, they may not fully reflect the effects on human metabolism 
(Student, et al., 1980). Also, as previously described, the increase of adipose tissue in 
vitro is the final result of an orchestrated effect that involves not only adipocytes, but 
also macrophages and vascular endothelial cells. Therefore - and since indoxyl sulfate 
has known effects in vascular endothelial cells (Dou, et al., 2007; Faure, et al., 2006) - 
in vitro studies using co-cultures of both cell types, as well as in vivo studies, are 
required to provide a more comprehensive overview on the effect of indoxyl sulfate on 
adipose tissue. 
 
4.4. Network analysis predicts that indoxyl sulfate has a multi-
kinase pro-adipogenic effect  
 
After validating the pro-adipogenic effect of indoxyl sulfate in vitro, putative 
targets mediating this effect were investigated. One of the best studied human targets 
of indoxyl sulfate is AHR; however, since this receptor is depleted during adipose 
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differentiation (Shimba, et al., 1998) and its overexpression inhibits lipogenesis 
(Shimba, et al., 2003), it does not seem to be involved in the pro-adipogenic effect of 
indoxyl sulfate. 
 
The high-throuput kinome screening, followed by confirmation of the binding 
and functional activity, identified eight high affinity targets for indoxyl sulfate in the 
human kinome (PDGFRB, c-KIT, MRCKA, MYLK3, MRCKB and ZAK). Amongst 
them, PDGFRB exhibited the lowest KD and IC50 values. PDGFRB was previously 
proposed as a negative regulator of lipogenesis (Artemenko, et al., 2005); its inhibition 
by imatinib promotes lipogenesis and increases the expression of key adipogenic 
transcription factors (e.g. C/EBP and PPAR) (Fitter, et al., 2012), Based on these 
results, it was hypothesised that the pro-adipogenic effect of indoxyl sulfate could be 
mediated via PDGFRB inhibition. However, in the concentrations tested, this 
hypothesis was not confirmed: indoxyl sulfate was not able to counteract the anti-
adipogenic effect of PDGFRB activation, thus suggesting that its pro-adipogenic effect 
is not mediated, at least solely, by PDGFRB inhibition. Additionally, given the 
kinome-wide impact of indoxyl sulfate, it is more likely that its impact on adipocyte 
metabolism is mediated by multiple kinases. 
 
The network analysis predicted six kinases (PDGFRB, c-KIT, MRCKA, 
MYLK3, MRCKB and ZAK) with shortest betweeness-ranked paths to triacylglycerol; 
shortest betweeness ranks, in this case, are a proxy measure to estimate their relevance 
in the signalling network leading to lipogenesis. Amongst these, PDGFRB, C-KIT, 
MRCKA, MRCKB are expressed in the adipose tissue (Ponten, et al., 2008). Similarly 
to PDGFRB, c-KIT has also been implicated in the development of obesity, as a loss-
of-function mutation of these gene results in increased obesity and decreased energy 
expenditure in mice (Huang, et al., 2014). Both PDGFRB and c-KIT signalling 
pathways converge into PLCB2, a critical node showing the highest standardized 
betweenness rank in the shortest-paths subnetwork. PLCB2 is expressed in adipose 
tissue (Ponten, et al., 2008) and codes for the enzyme 1-phosphatidylinositol-4,5-
bisphosphate phosphodiesterase 2, that converts phosphatidylinositol 4,5-biphosphate 
into inositol 1,4,5-triphosphate and diacylglycerol, which is further esterified into 
triacylglycerol by the diglyceride acyltransferase (Saponaro, et al., 2015).  
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Altogether, the network analysis presents a comprehensive map of the strongest 
candidate targets in the human kinome, revealing key targets and signalling key nodes 
for future functional investigations. As future work, phosphoproteomics approaches 
combined with network analysis may identify selected kinases and signalling pathways 
for individual validations. 
 
5. Conclusion 
 
In this chapter, it was demonstrated that indoxyl sulfate exhibits a pro-
adipogenic effect in vitro, characterised by increased intracellular lipid accumulation 
and enhanced leptin production. These results are consistent with the findings from 
the previous chapter, in which indoxyl sulfate significant correlated with adiposity and 
plasma levels of leptin. By proving a direct pro-adipogenic effect in adipocytes in vitro, 
the results shown in the chapter demonstrate that these associations do not rely on 
pure correlation: conversely, they might represent a causal effect of gut microbial 
metabolism on human adipose tissue function.  
 
Furthermore, a combined strategy comprising a high-throughput kinome 
screening and a network analysis approach was used to investigate the potential targets 
in the human kinome mediating this effect. This strategy revealed that indoxyl sulfate 
has kinome-wide effects, and network analysis shortlisted six kinases associated to 
shortest betweeness-ranked paths to triacylglycerol (PDGFRB, c-KIT, MRCKA, 
MYLK3, MRCKB and ZAK). Importantly, PLCB2 was identified as a critical node 
into which several of the shortest-path signalling pathways converge – however, further 
studies (i.e. phosphoproteomics combined with network analysis) are needed to further 
clarify the individual contribution of each pathway, followed by subsequent 
validations. 
 
By identifying and validating a role for indoxyl sulfate as a gut microbial 
metabolite with pro-adipogenic properties, these results propose a novel mechanism 
through which the gut microbiota can impact human obesity. 
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Chapter 6 
Exploring the effect of indole-3-acetate  
in the human kinome 
 
1. Introduction 
 
Indole-3-acetate is one of the most abundant indolic compounds in human 
plasma, with plasmatic concentrations raising up to 3 M and 19 M, respectively, in 
healthy and uremic patients (Calaf, et al., 2011; Duranton, et al., 2012). Once in 
bloodstream, indole-3-acetate can bind human pharmacological targets, therefore 
impacting signalling networks and metabolic pathways relevant for cardiometabolic 
diseases. The identification of these pharmacological targets can, therefore, improve 
our understanding of the microbial-mammalian molecular crosstalk, and in fine the 
impact of gut microbial metabolites in human health and disease (Dumas, 2011).  
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Previous studies attempted to identify putative targets for indoles, mostly 
GPCR and nuclear receptors (Chilloux, et al., 2016; Gondouin, et al., 2013; Jin, et al., 
2014; Venkatesh, et al., 2014). Indoles were shown to act as ligands for AHR; however, 
this effect is not class-specific, with different indolic compounds exhibiting either 
agonist or antagonist activities (Jin, et al., 2014). For indole-3-acetate, only a very 
weak AHR agonism was observed in vitro when dosing young adult mouse colonocytes 
(YMAC cells) at high, non-physiological, doses (250 M); a partial was also observed, 
but only at even higher concentrations (500 M) (Cheng, et al., 2015). 
 
In this chapter, it was hypothesised that indole-3-acetate can impact human 
metabolism by binding kinome targets. Whilst most of the studies to the date focused 
on defining agonisms/antagonisms of gut microbial metabolites for GPCR and nuclear 
receptors, screening the kinome opens a novel research front to understand the impact 
of gut microbial metabolites in human health. 
 
The primary aim of this chapter is a) to identify indole-3-acetate’s targets in 
the human kinome using a high-throughput kinase screening, followed by confirmation 
of the binding (dissociation constant, KD) and of the modulation of the phosphorylation 
activity (IC50). After confirming the inhibitory effect of indole-3-acetate in a single 
kinase (VEGFR-2), the secondary aims included: 
 
b) To model the physical interaction between indole-3-acetate and VEGFR-2, 
using molecular docking analysis; 
c) To validate the effect of indole-3-acetate on VEGFR-2 phosphorylation in vitro; 
d) To assess the impact of indole-3-acetate on signalling pathways downstream of 
VEGFR-2. 
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2. Materials and Methods 
 
2.1. Kinase screening 
Indole-3-acetate targets in the human kinome were explored using the 
KdSELECT screening service (DiscoverX®), as previously described (Fabian, et al., 
2005; Karaman, et al., 2008). The ability of indole-3-acetate to compete with the 
immobilized ligand was measured by quantitative Polymerase Chain Reaction (PCR) 
of the DNA tag. Results for primary screen binding interactions are reported as % of 
control (%Ctrl), where lower numbers indicate stronger hits (for further details, see 
Chapter 2. General Methodology).  
 
The binding constant (KD) was then calculated from an 11-point dose-response 
curve. The TREEspot Software Tool was used to generate kinase interaction tree plots, 
which were reprinted with permission from KINOMEscan® (DiscoverX Corporation®). 
The IC50 of indole-3-acetate on VEGFR-2 was determined using Kinexus kinase-
inhibitor activity profiling service (Kinexus, Vancouver, Canada). The technique is 
based on the direct quantification of radiolabelled phosphate from ATP onto a protein 
substrate of a target protein kinase - in this case, VEGFR-2.  
 
2.2. Molecular docking 
 
The macromolecular structure data of VEGFR-2 (id: 5EW3) was obtained from 
the Protein Database of the Research Collaboratory for Structural Bioinformatics 
(RCSB PDB) and pre-processed using the SYBYL© platform (Tripos, St. Louis, MO). 
Water molecules were removed and the protein was protonated at pH = 7 and 
minimised using 100 interactions. The structure of indole-3-acetate was obtained from 
PDBeChem (EMBL-EBI, Cambridge, UK). Structure data were loaded into GOLD 
software, and the docking parameters were optimised and validated by binding a 
known inhibitor (AAL993) to VEGFR-2 (Bold, et al., 2016). The validation results 
were used to define the binding site as a sphere with a radius of 8 Å around the centre 
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carbon atom in Val-848. Automatic detection of the receptor cavity was applied in 
order to limit atom binding events to solvent-accessible structures. Docking solutions 
were calculated by the ChemPLP function, a piecewise linear potential empirical 
scoring function, that models the steric interactions between two molecules as a 
function of heavy-atom clash potential, torsional potentional and hydrogen donors and 
acceptors (Korb, et al., 2009). Model visualisations were performed in PyMOL©. 
 
2.3. Cell culture 
 
Human umbilical vein endothelial cells (HUVEC) were obtained from BD 
Biosciences. In brief, cells were grown in collagen I-coated flasks and maintained in 
endothelial growth medium (EGM-2, Lonza), in an atmosphere of 5% CO2 at 37ºC. 
After reaching 80% confluence, cells were trypsinised and split at the ratio of 1:2 to 
1:6. Cells between passage number 3 and 10 were used for the experiments described. 
 
2.4. Total and phosphorylated VEGFR-2 quantification 
 
HUVEC cells were plated in 6-well collagen-coated plates (BD BioCoat. After 
reaching 80% confluence, cells were starved for 2 hours in EBM (Lonza). Cells were 
treated with vehicle (0.1% ethanol) or indole-3-acetate in maintenance medium without 
added VEGFA for 15 minutes. Stimulation with VEGFA (2 ng/mL, Sigma Aldrich) 
was then performed, and cell lysates were collected at 10 seconds, 10 minutes, 60 
minutes and 240 minutes post-stimulation; for further experiments, the 10 minutes 
post-stimulation time point was adopted.  
For preparation of the cell lysates, cells were first washed with ice-cold 
phosphate buffer saline, followed by lysis in RIPA buffer (Sigma Aldrich), 
supplemented with Protease Inhibitor Cocktail (Phosphatase Inhibitor Cocktail 2 and 
Phosphatase Inhibitor Cocktail 3, both at 1:100, Sigma Aldrich) and 
phenylmethylsulfonyl fluoride (PMSF) 1mM (Sigma Aldrich). After a 5-minute 
incubation at 4oC, cells were scraped and transferred to an Eppendorf tube and 
centrifuged for 10 minutes (14.000g, at 4oC). Cell lysates were finally transferred to a 
new tube and stored at -80 ºC. Total and phosphorylated VEGFR-2 were quantified 
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on cell lysates using the PathScan Phospho-VEGFR-2 (Tyr1175) Sandwich ELISA kit 
and PathScan Total VEGFR-2 Sandwich ELISA kit, both from Cell Signalling 
Technology, according to the manufacturer’s instructions. 
 
2.5. AKT phosphorylation assay 
 
HUVEC cells were cultured as described in 2.4. Cell lysates were prepared with 
Phosphatase Inhibitor I (1:100), Phosphatase Inhibitor II (1:100), and Protease 
Inhibitor Solution (1:100) diluted in Assay Diluent 39 (Meso Scale Discovery). Total 
and phosphorylated AKT were measured in undiluted samples using the MSD Multi-
Spot Assay System for Phospho-AKT (Ser473) Kit, a sandwich immunoassay 
performed, according to the manufacturer’s instructions. The plates were read using a 
MESO Sector Imager 2400 (Meso Scale Discovery).   
 
2.6. NO quantification assay 
HUVEC cells were plated in 6-well collagen-coated plates (BD BioCoat), in 
maintenance medium (EGM-2, Lonza ®). After reaching 80% confluence, cells were 
starved for 2 hours in basal medium (EBM, Lonza). Cells were treated with vehicle 
(0.1% ethanol) or indole-3-acetate in normal maintenance medium (without added 
VEGFA) for 15 minutes. Stimulation with VEGFA (2 ng/mL) was then performed, 
and cell supernatants were collected after 24h. Production of NO was measured using 
the Total NO and Nitrate/Nitrite assay (R&D systems). 
 
2.7. Statistical analysis 
For statistical comparisons between groups, normality was tested using 
D' Agostino & Pearson Omnibus normality test. Parametric or non-parametric one-
way analysis of variance (ANOVA) was used, followed by post hoc testing; for AKT 
and NO experiments, one-tail t-tests were performed. A threshold of p<0.05 was 
adopted for statistical significance. Data are displayed as mean  s.e.m in all figures. 
The number of cell culture experiments is indicated in individual figure legends.  
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3. Results 
 
3.1. Exploring the targets of indole-3-acetate in the human 
kinome 
 
In order to discover physical interactions between indole-3-acetate and human 
kinases, a high-throughput assay was used to screen this compound against a panel of 
456 clinically-relevant kinases. Indole-3-acetate showed a very specific physical 
interaction with a single kinase, the Vascular Endothelial Growth Factor Receptor-2 
(VEGFR-2) (Figure 35a).  
 
 
 
Figure 35. Indole-3-acetate binds VEGFR-2 and functionally inhibits its phosphorylation 
activity in a high-throughput kinase screening.  
a) VEGFR-2 was the only target identified for indole-3-acetate in the single dose-kinome screening 
(10000 nM). Preliminary positive hits with potential binding <35% are represented by a red dot, 
whilst non-binding kinases are represented by a green dot. Kinase group names: TK, Tyrosine 
Kinases; TKL, Tyrosine Kinase-like; STE, STE kinase group; CK1, Cell Kinase 1; AGC, Protein 
kinase A, G and C families; CAMK, Calcium and Calmodulin-regulated kinases; CMGC, CMGC 
kinase group. b) Confirmation of a physical interaction between indole-3-acetate and VEGFR-2 
(KD=930 M); c) Confirmation of the functional inhibition of VEGFR-2 phosphorylation activity 
by indole-3-acetate (IC50=333.7 M). a.u.: arbitrary units. 
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No other physical interactions between indole-3-acetate and other kinases were 
identified. The binding between indole-3-acetate and VEGFR-2 was confirmed by a 
multiple-dose binding curve, defining a dissociation constant (KD) of 890 M (Figure 
35b). As the KD only assesses the physical interaction (i.e. binding), the functional 
effect was tested by quantifying VEGFR-2 phosphorylation in the presence of ATP 
and multiple doses of indole-3-acetate. Increasing doses of indole-3-acetate 
progressively inhibited VEGFR-2 phosphorylation activity, defining a half-maximal 
inhibitory constant (IC50) of 333.7 M (Figure 35c), and therefore confirming a 
functional effect. 
 
3.2. Investigating the interaction between indole-3-acetate and 
VEGFR-2 by molecular docking analysis 
 
Next, the mechanism underlying the inhibitory effect of indole-3-acetate on 
VEGFR-2 was explored. First, the preferred binding sites of both ATP and indole-3-
acetate on VEGFR-2 molecule were predicted, determined as the 10 best docking 
solutions based on the respective ChemPLP scores (Table 9). The best docking solution 
for ATP (solution number 6, ChemPLP score = 52.00) was predicted to form hydrogen 
bonds with three different residues of the VEGFR-2 molecule (Cys-919, Glu-885 and 
Asp-1046) (Table 9). A spatial visualisation of this solution is shown in Figure 36a-b. 
 
For indole-3-acetate, the highest scoring docking solution (solution 8, ChemPLP 
= 49.89) predicted the formation of a bond between one of the oxygen atoms of indole-
3-acetate and the backbone nitrogen atom of the Asp-1046 residue of VEGFR-2 (Table 
9 and Figure 36c-d). As previously shown, ATP interacts with the same residue. The 
predicted length of the bond formed between indole-3-acetate and Asp-1046 (2.74 Å) 
is shorter than the sum of the van der Waals radii of both atoms, thus suggesting a 
hydrogen bond.  
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Table 9. Best docking solutions for ATP and indole-3-acetate, based on molecular docking 
predictions (ChemPLP scores) 
ATP  
Solution ChemPLP* Residues 
1 46.11 Cys-919, Glu-917, Glu-885, Asp-1046, Lys-868, Leu-840 
2 50.58 Cys-919, Glu-917, Glu-885,Asp-1046, Lys-868, Asn-923 
3 49.74 Cys-919, Glu-917, Glu-885, Asp-1046, Lys-868, Asn-923 
4 10.52 Asn-923, Cys-1045, Lys-868, Val-914, Glu-885 
5 44.94 Cys-919, Glu-917, Glu-885, Asp-1046, Lys-868, Asn-923 
6 52.00 Cys-919, Glu-885, Asp-1046 
7 51.84 Cys-919, Gly-885, Asp-1046, Asn-923 
8 44.46 Cys-919, Glu-885, Asp-1046 
9 47.94 Cys-919, Glu-917, Glu-885, Asp-1046, Lys-868, Leu-840 
10 49.10 Cys-919, Glu-917, Asp-1046, Lys-868, Leu-840 
 
Indole-3-acetate 
 
Solution  ChemPLP  Residues 
1 45.58 Cys-919 
2 46.40 Cys-919 
3 75.86 Asp-1046 
4 47.09 Cys-919 
5 45.96 Cys-919 
6 45.93 Asp-1046 
7 45.88 Asp-1046 
8 49.89 Asp-1046 
9 46.34 Cys-919 
10 49.82 Asp-1046 
 
*Highest ChemPLP scores represent higher binding affinity. Highest solution numbers and 
CHEMPLP scores are shown in bold. Residues from the best solutions for each case are also shown 
in bold whenever present in other solutions. 
 
 
 
Figure 36. Indole-3-acetate binds to the ATP-binding pocket in molecular docking analysis. 
a-b) Preferred binding position for ATP molecule (orange) on the VEGFR-2 molecule (grey). c-d) 
Preferred predicted binding site of indole-3-acetate (turquoise) is on the ATP-binding cavity of VEGFR-
2. e-f) Overlap of the two individual models reveals a close spatial relationship between the preferred 
docking positions of both molecules. In the detailed view of the ATP-binding pocket, VEGFR-2 residues 
are shown in dark grey and labelled; the hydrogen bonds established are represented as red dashed lines.   
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Of note, the ten best docking solutions for indole-3-acetate on VEGFR-2 
predicted the formation of the hydrogen bond with residues identified as part of the 
ATP-binding pocket (either Asp-1046 or Cys-919). The overlap of the preferred 
docking positions of ATP and indole-3-acetate highlights the existence of a close spatial 
relationship between both (Figure 36e-f).  
 
Next, it was assessed whether indole-3-acetate docking might be able to prevent 
subsequent ATP binding in the VEGFR-2 molecule. In order to test this hypothesis, 
the merged structure of VEGFR-2 and indole-3-acetate was used to model the best 
docking position for ATP. In this case, ATP was not predicted to form hydrogen bonds 
with any of the residues normally involved in the ATP-binding pocket (Table 10). As 
visualised in Figure 37, when modelling this complex (indole-3-acetate + VEGFR-2), 
ATP binding is displaced from the usual catalytic site. 
 
Table 10. Best docking solutions for ATP after previous docking of indole-3-acetate 
in the VEGFR-2 molecule 
 
 
 
 
 
Figure 37. Indole-3-acetate prevents ATP binding in the ATP-binding pocket of VEGFR-2. 
Superimposition of two ATP docking models: Preferred ATP position in the absence of indole-3-acetate, 
in the ATP-binding pocket of VEGFR-2 (ATP molecule in orange; VEGFR-2 molecule in grey); b)  
After docking indole-3-acetate in its highest scoring binding site, the optimal ATP binding site moves 
out of the ATP-binding cavity (ATP molecule in yellow). 
 
Solution 
number 
 
ChemPLP 
score 
 
Residues 
1 40.83 Gln-847, Lys-871, Gly-846, Gly-841 
2 37.37 Lys-838, Leu-840 
3 43.28 Lys-838, Leu-840 
4 44.37 Gln-847, Lys-871, Gly-841 
5 34.65 Lys-383, Leu-840 
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In summary, in silico docking simulations suggest that both ATP and indole-3-
acetate bind in the ATP-binding pocket of VEGFR-2, and both establish a hydrogen 
bond with the Asp-1046 residue. Furthermore, indole-3-acetate pre-docking on the 
VEGFR-2 molecule is predicted to prevent ATP to bind in its usual pocket, thus 
suggesting an ATP-competitive inhibitory mechanism. 
 
3.3. Optimisation of experimental conditions for phosphorylation 
assays  
 
Before validating the inhibitory effect of indole-3-acetate on VEGFR-2 in vitro, 
the experimental conditions were optimised. Human Umbilical Vascular Endothelial 
cells (HUVEC), a cell line that constitutively expresses this tyrosine kinase receptor 
(Arnaoutova and Kleinman, 2010), were used in this experiment The non-toxic range 
of indole-3-acetate was first tested by assessing the impact of the compound on cell 
viability. At the concentration of 1000 M, indole-3-acetate significantly reduced cell 
number (-47.1% vs control, p < 0.001) (Figure 38).  
 
Figure 38. Indole-3-acetate affects HUVEC viability at 1000 M. 
After 48 hours of treatment with indole-3-acetate, cells were fixed. Viability was assessed by Crystal 
Violet staining (Sigma Aldrich ®) and measured at 450 nm. a) Representative pictures of Crystal Violet-
stained HUVEC were taken with 40x magnification. b) Quantitative results are shown as means  s.e.m 
(n=3 independent experiments, 4 replicates each). One-way analysis of variance was performed 
(p=0.0073) and post-hoc comparisons between groups were performed with Dunnett’s multiple 
comparisons test. ***p=0.001 
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For subsequent assays, HUVEC cells were treated with concentrations ranging 
from 0.01 to 100 M, for which no toxic effect was observed. 
  
Next, the optimal time point to study VEGFR-2 phosphorylation was 
investigated. The main ligand of VEGFR-2 is the Vascular Endothelial Growth Factor 
A (VEGFA), which was used as agonist in the following experiments (Olsson, et al., 
2006). Total VEGFR-2 expression decreased in a time-dependent manner after 
stimulation with VEGFA; at 10 seconds post-stimulation a reduction of 9.3% was 
observed (p<0.01), followed by a progressive reduction of up to -51.7% at 240 minutes 
(p<0.0001) (Figure 39a). This effect was previously described and is reportedly linked 
to proteolytic phenomena and removal of endosome-associated cytoplasmic domains 
following VEGFR-2 activation and ubiquitination (Bruns, et al., 2010). As expected, 
VEGFA induced a rapid increase in the Phospho(Tyr1175)-VEGFR-2 fraction, with an 
increase of 45.0% after 10 seconds of stimulation (p<0.001); this increase was observed 
up to 60 minutes after stimulation (Figure 39b). Regarding the Phospho(Tyr1175)/total 
VEGFR-2 ratio, a rapid increase was also observed after 10 seconds of stimulation 
(+59.8%, p<0.01) which  remained significant up to 240 minutes (+117.1%, p<0.0001) 
(Figure 39c).  
 
 
 
 
Figure 39. Kinetics of total and Phospho(Tyr1175)-VEGFR-2 expression after stimulation. 
HUVEC cells were starved in basal medium for 2 hours and subsequently stimulated with VEGFA for 
15 minutes. Cell lysates were collected at 10 seconds and at 10, 60 and 240 minutes. Total VEGFR-2 
and Phospho(Tyr1175)VEGFR-2 were quantified by ELISA in the cell lysates. a) Total VEGFR-2 
expression; b) Phospho(Tyr1175) VEGFR-2 quantification; c) Phospho(Tyr1175)-VEGFR-2/total 
VEGFR-2 ratio quantification. Results are shown as mean  s.e.m. (% of control) of one experiment (3 
replicates). One-way analysis of variance was performed. Comparisons between groups were performed 
using Dunnett’s post-hoc testing. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 compared to non-
stimulated cells. 
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The earlier time points (10 seconds and 10 minutes) were therefore considered 
optimal for phosphorylation assays as they show a) a significant increase in 
phosphorylated/total VEGFR-2 ratio; b) maximal values for the phosphorylated 
fraction quantification (thus providing an optimal sensitivity for the assay) and c) 
minimal VEGFR-2 loss, therefore minimizing artefactual increases of the 
phosphorylated/total VEGFR-2 ratio. For technical feasibility reasons, the 10 minutes 
time point was chosen to test the effect of different doses of indole-3-acetate on 
VEGFR-2 phosphorylation.  
 
3.4. Effect of indole-3-acetate on VEGFR-2 phosphorylation  
After optimisation, the effect of indole-3-acetate on VEGFR-2 phosphorylation 
was assessed. The experimental design is shown in Figure 40a.  
 
 
Figure 40. Effect of indole-3-acetate on VEGFR-2 phosphorylation. 
a) Experimental design. HUVEC cells were starved in basal medium for 2 hours, treated with vehicle 
or indole-3-acetate at several doses for 15 minutes and stimulated with VEGFA for 10 minutes. Cell 
lysates were collected and total and phosphorylated (Tyr1145) VEGFR-2 were quantified by ELISA (Cell 
Signalling Technology). b) Phosphorylated VEGFR-2/total VEGFR-2 ratio quantification. Results are 
shown as mean  s.e.m (% of control) of four independent experiments. Parametric one-way analysis of 
variance was performed (p<0.0092). c) Comparisons between groups were performed using Dunnett’s 
post-hoc multiple comparisons test. *p<0.05; ***p<0.001. EBM: endothelial basal medium; I3A – indole-
3-acetate; VEGFA – Vascular Endothelial Growth FactorA. 
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As expected, stimulation with VEGFA resulted in a 51.0% increase of the 
phosphorylated (Tyr1154)/total VEGFR-2 ratio, when compared to non-stimulated 
cells. Pre-treatment with indole-3-acetate at 100 M significantly reduced VEGFR-2 
phosphorylation (-29.2% compared to VEGFA alone, p0.05) (Figure 40b-c).  
 
 
3.5. Effect of indole-3-acetate on VEGFR-2 downstream 
signalling: AKT phosphorylation and NO production 
 
Based on the previous results suggesting that indole-3-acetate inhibits VEGFR-
2, it was hypothesised that it would equally inhibit the kinase downstream signalling. 
Amongst the various signalling cascades activated by VEGFR-2 phosphorylation, the 
phosphoinositide-3-kinase Serine/AKT (PI3K-AKT) is particularly relevant for 
vascular health (Figure 41a). This signalling pathway regulates key physiological 
processes in vascular endothelial cells, including cell proliferation, differentiation and 
migration (Kang, et al., 2013). AKT also activates the endothelial Nitric Oxide 
Synthase (eNOS) and consequently the production of NO (Trouillon, et al., 2010), a 
compound that exhibits both vasodilator and pro-angiogenic properties.  
 
In these experiments, the effect of indole-3-acetate on AKT phosphorylation 
and NO production was evaluated. As expected, VEGFA induced a significant increase 
on AKT phosphorylation (+21.1%, p=0.033), when compared to non-stimulated cells 
(Figure 41b). Consistently with its effect as a VEGFR-2 inhibitor, indole-3-acetate was 
able to significantly counteract VEGFA-induced phosphorylation of AKT at the 
concentration of 100 M (p=0.026), using one-tail statistics (Figure 41b). The linear 
regression model shows that increasing concentrations of indole-3-acetate progressively 
reduce AKT phosphorylation (p = 0.025) (Figure 41c). 
 
The effect of indole-3-acetate on NO production was also evaluated. At 100 M, 
indole-3-acetate inhibited VEGFA-stimulated production of NO in 20.4%, when 
compared to the vehicle (p=0.037, one-tail t-test) (Figure 41d). In a linear regression 
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model, it is possible to observe that increasing concentrations of indole-3-acetate 
progressively reduce NO production (p=0.0157) (Figure 41e). 
 
 
 
 
 
Figure 41. Effect of indole-3-acetate on VEGFR-2 downstream signalling effectors: AKT 
phosphorylation and NO production. a) Overview of VEGFR-2 downstream signalling (adapted 
from (Olsson, et al., 2006)). Results for AKT phosphorylation (b) and NO production (d) are shown 
as mean  SEM (% control) of three independent experiments; normality was assessed by 
D’Agostino & Pearson Omnibus test and comparisons between groups were performed using one-
tail t-test. Linear regression models for AKT phosphorylation (c) and NO production (d); results 
are shown as mean  95% Confidence Intervals. *p <0.05; ***p<0.001. I3A – indole-3-acetate; 
VEGFA – Vascular Endothelial Growth FactorA 
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4. Discussion 
 
4.1. High-throughput kinase screening identified  
indole-3-acetate as an inhibitor of the VEGFR-2 
 
In this chapter, a high-throughput strategy was used to identify targets of 
indole-3-acetate in the human kinome. For the first time, indole-3-acetate was 
identified as an inhibitor for VEGFR-2. The physical interaction was confirmed by the 
calculation of the dissociation constant (KD) using an 11-point dose-response curve. As 
these methods only confirm compound-kinase binding (i.e. physical interaction), the 
functional effect was also confirmed by verification of the inhibition of the 
phosphorylation activity and calculation of the respective IC50.  
 
VEGFR-2 is a tyrosine kinase receptor crucial for endothelial vascular cell 
function and angiogenesis, which main ligand is the Vascular Endothelial Growth 
Factor A (VEGFA) (Olsson, et al., 2006) (A detailed description of the cellular effects of 
VEGFR-2 during the angiogenic process will be provided in Chapter 7, where these outcomes 
will be investigated).  
 
Of note, indole-3-acetate showed a very specific affinity for VEGFR-2. No other 
physical interactions were identified between indole-3-acetate and other receptors from 
the VEGF or Receptor Tyrosine Kinase (RTK) families, nor with any other kinases. 
This is a particularly important characteristic, as achieving a highly selective effect 
has proven to be a major challenge regarding the use of kinase inhibitors as a 
therapeutic tool (Fabian, et al., 2005; Fedorov, et al., 2007). VEGFR-2 inhibitors have 
been used as a therapeutic tool in medical conditions characterised by an upregulation 
of angiogenesis (Ellis and Hicklin, 2008); unfortunately, these molecules often exhibit 
undesired side-effects and cellular toxicity resulting from their lack of specificity. 
Geftinib, a VEGFR-2 inhibitor, has failed in clinical development due to intolerable 
side effects resulting from its lack of specificity (Huang, et al., 2012). Other VEGFR-
2 inhibitors show cross-reactivity towards targets involved in inflammatory responses 
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(DiMauro, et al., 2008; Weiss, et al., 2008). Contrarily to other VEGFR-2 inhibitors, 
indole-3-acetate seems to have a very selective effect and, presumably, less potential 
for side effects. 
 
4.2. Molecular docking suggests indole-3-acetate inhibits 
VEGFR-2 through an ATP-competitive mechanism 
 
Kinase inhibitors are known to exert their effects by four different mechanisms: 
a) competing with adenosine triphosphate (ATP), b) competing with the substrate, c) 
competing with both ATP and the substrate or d) binding outside the active site and 
inducing conformational changes that impact the active site activity (allosteric 
inhibition) (Posner, et al., 1994).  
 
In molecular docking analyses, indole-3-acetate was predicted to form a 
hydrogen bond with the backbone nitrogen atom of the Asp-1046 residue on the 
catalytic site of VEGFR-2. Asp-1046 is one of the elements of the hydrogen donor-
acceptor pair in the catalytic site of VEGFR-2 (Huang, et al., 2012) and facilitates the 
transfer of the -phosphate group (Kornev, et al., 2006). Therefore, by interacting with 
Asp-1046, indole-3-acetate inhibits VEGFR-2 activation by potentially impacting both 
mechanisms.  
 
Molecular docking simulations do not suggest the existence of a concomitant 
allosteric inhibitory component. The 10 best docking solutions predicted the formation 
of a hydrogen bond between indole-3-acetate and residues of the catalytic domain 
(either Asp-1046 or Cys-919, a cysteine residue located in the hinge). None of these 
models predicted a physical interaction with previously described allosteric sites (e.g. 
“HYD II” or “Phe pocket” (Weiss, et al., 2008)) or other residues outside of the catalytic 
site. Although these molecular docking results support an inhibitory effect of indole-3-
acetate on VEGFR-2, the main limitation of these findings is that they are based on 
in silico modelling and prediction. Therefore, these results provide incentive for further 
in vitro validations. 
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4.3. Indole-3-acetate inhibits VEGFR-2 phosphorylation in 
HUVEC 
 
In this chapter, it was shown that indole-3-acetate is able to impair the 
phosphorylation of VEGFR-2 in an in vitro model.  
 
The HUVEC cell line was selected for these validation studies, since it 
constitutively expresses VEGFR-2 and is a classic model for the study of this receptor 
(Arnaoutova and Kleinman, 2010). VEGFR-2 is a tyrosine kinase receptor crucial for 
endothelial vascular cell function and angiogenesis, whose main ligand is the Vascular 
Endothelial Growth Factor A (VEGFA) (Olsson, et al., 2006). Although there are 
multiple isoforms of VEGFA, the most common in humans, both quantitatively and 
qualitatively, is VEGF165 (Mac Gabhann and Popel, 2008) (Shibuya, 2011). Upon 
VEGFA binding, VEGFR-2 undergoes dimerisation, followed by autophosphorylation 
of the tyrosine residues on the receptors intracellular domain (Olsson, et al., 2006). 
VEGFR-2 has several tyrosine phosphorylation sites bound to VEGFA, either in the 
kinase-insert domain (Tyr951 and Tyr996), in the kinase domain (Tyr1054 and Tyr1059) 
and in the C-terminal tail (Tyr1214 and Tyr1175) (Takahashi and Shibuya, 2005). Each 
phosphotyrosine site recruits distinct sets of adaptor proteins, leading to distinct 
downstream signalling pathways (Olsson, et al., 2006; Tan, et al., 2013). Amongst 
these phosphosites, Tyr1175 in one of the major VEGFA-dependent autophosphorylation 
sites in humans (Takahashi, et al., 2001). Tyr1175 plays an essential role in vascular 
function and development; mice that express a mutated Tyr1173 (the homologous 
residue for Tyr1175 in murine) die at early embryonic stages due to vascular defects 
similar to the ones observed in VEGFR2-/- mice. 
  
  In line with previous literature (Shibuya, 2011), VEGFA induced VEGFR-2 
phosphorylation on the Tyr1175 residue. It is important to note that the increase on 
VEGFR-2 phosphorylation observed, although significant, was not consistently 
observed in other experiments performed using the same experimental conditions.  
 
Regarding indole-3-acetate, it was shown to impair VEGFA-induced 
phosphorylation of the same residue. These findings are consistent with previous results 
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from the kinome screen and molecular docking analysis, and validate in vitro the 
inhibitory effect of indole-3-acetate on VEGFR-2. As future work, these results could 
be potentially strengthened by testing higher concentrations of agonist (as well as 
different combinations of concentrations of both VEGFR-2 and indole-3-acetate) and 
by trying alternative normalisation techniques (i.e. normalisation to total protein 
content). 
 
4.4. Indole-3-acetate supresses VEGFA-induced AKT 
phosphorylation and NO production    
 
In this chapter, it was demonstrated that indole-3-acetate impacts signalling 
pathways downstream of (Tyr1145)VEGFR-2, including AKT phosphorylation and NO 
production. 
 
It has been previously documented that VEGFR-2 phosphorylation in the  
Tyr1145 residue activates several downstream signalling pathways (Shibuya, 2011). In 
particular, phosphorylated (Tyr1145) binds to two SH2-domain-containing adaptor 
molecules: 1) phospholipase C (PLC) and 2) shb (Takahashi, et al., 2001) (Holmqvist, 
et al., 2004). The PLC/PKC pathway activates several downstream signalling 
effectors, including the endothelial Nitric Oxide synthase (eNOs) and the MEK/MAPK 
and Raf/Ras pathways (Olsson, et al., 2006) (Figure 41a). The shb/PI3K pathway 
results in the downstream activation of AKT (Holmqvist, et al., 2004). The PI3K-AKT 
pathway is particularly relevant for vascular health; it is involved in a range of 
signalling pathways that regulate cell proliferation, differentiation and migration 
(Kang, et al., 2013). By activating the endothelial Nitric Oxide synthase (eNOs), AKT 
also induces the production of NO, a compound that exhibits both vasodilator and 
pro-angiogenic properties (Trouillon, et al., 2010). 
  
As previous results indicate that indole-3-acetate is a VEGFR-2 inhibitor, testing 
was performed for the possibility of a relationship in a single direction (one-tail t-test). 
Strategies to improve these results include a) to increase the number of experiments, 
b) to optimise the combination of the concentrations of VEGFR-2 and indole-3-acetate 
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used and c) to investigate the optimal time points to access AKT phosphorylation and 
NO production. Additionally, in order to have a more comprehensive overview of the 
impact of indole-3-acetate on (Tyr1145)VEGFR-2 downstream signalling, it would be 
important to clarify its putative inhibitory effect in other pathways (i.e. FAK/paxillin, 
Src and PKC/MEK/ERK). 
 
5. Conclusion 
 
In summary, indole-3-acetate was proposed, for the first time, to be an inhibitor 
of VEGFR-2 - a key receptor for vascular endothelial function and angiogenesis.  
 
A high-throughput kinase screening was used to identify the human targets of 
indole-3-acetate in the human kinome, and revealed a very specific effect of indole-3-
acetate as VEGFR-2 inhibitor. Using molecular docking analysis, it was showed that 
indole-3-acetate could preferentially dock in the ATP-binding site of VEGFR-2, thus 
exerting a potential competitive effect. The effect of indole-3-acetate was further 
validated in cell-based assays in HUVEC, which demonstrated that pre-incubation 
with indole-3-acetate impaired (Tyr1145)VEGFR-2 phosphorylation. Upon ligand 
binding, VEGFR-2 undergoes phosphorylation and activates signalling cascades 
involved in vascular function and key steps of the angiogenic process (i.e. AKT/NO 
production). Consistently with its role as a VEGFR-2 inhibitor, these preliminary 
results suggest indole-3-acetate inhibits VEGFA-induced phosphorylation of 
downstream signalling effectors (AKT), as well as the production of its respective 
vasoactive end-product (NO), in one-tail analyses.  
 
By showing that indole-3-acetate is able to physically bind to VEGFR-2 and 
inhibit its phosphorylation activity and its downstream signalling, a novel role as a 
microbial metabolite with anti-angiogenic properties emerges for this compound. In 
vitro and in vivo validation assays are required to validate this hypothesis.  
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Chapter 7  
Effect of indole-3-acetate on 
angiogenesis in vitro  
 
 
1. Introduction 
 
In the previous chapter (Chapter 6), a combined strategy including a high-
throughput kinome scan, molecular docking modelling and cell-based assays identified 
indole-3-acetate as a putative competitive inhibitor of VEGFR-2.  
 
VEGFR-2 is the main receptor involved in angiogenesis, the physiological 
process of growth of new blood vessels (Potente, et al., 2011; Shibuya, 2011). In the 
strictest sense, angiogenesis designates vessel sprouting from pre-existing vascular 
structures; this process is distinct from vasculogenesis, which refers to the formation 
of primitive blood vessels from angioblasts (mesoderm cell precursors) (Potente, et al., 
  
192 
2011; Risau and Flamme, 1995). Angiogenesis is a fundamental process in human 
development, where the growth of new blood vessels provides the growing organs with 
the necessary oxygen supply, as well as with trophic signals that modulate 
morphogenesis (Carmeliet, 2005). In adulthood, endothelial cells still preserve their 
ability of dividing in response to pro-angiogenic stimuli in physiological processes 
(ovarian cycle and placental development during pregnancy). Of note, abnormal 
angiogenesis has been reported in a range of human diseases, including cancer, 
inflammatory diseases and, importantly, in several cardiometabolic disorders (e.g. 
atherosclerosis (Van Belle, et al., 1997), ischemic heart disease (Jesmin, et al., 2005; 
Shiojima, et al., 2005), obesity (Fukumura, et al., 2003; Rupnick, et al., 2002) diabetes 
(Caldwell, et al., 2005; Rivard, et al., 1999; Waltenberger, 2001) and arterial 
hypertension (Kubis, et al., 2002; Sane, et al., 2004)).  
 
Angiogenesis is a multistep process, which includes specific hallmarks: 1) cell 
activation and matrix remodelling, 2) cell proliferation, 3) cell migration and 4) tube 
formation (Adams and Alitalo, 2007; Carmeliet and Jain, 2011) (Figure 42). 
 
 
Figure 42. Hallmarks of angiogenesis. 
The events leading to the formation of new vessels include a) endothelial cell activation and 
dissolution of the basement membrane; b) proliferation of endothelial cells; c) cell migration 
towards angiogenic cues, and d) tube elongation and formation of branches and loops by 
convergence of the newly-formed sprouts. Adapted from (Adams and Alitalo, 2007; Carmeliet and 
Jain, 2011) and designed using Servier Medical Art elements. 
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The VEGFA/VEGFR-2 system impacts most of the key steps of this process 
(Olsson, et al., 2006; Shibuya, 2011) (Figure 43). 
 
 
Figure 43. Role of VEGFA/VEGFR-2 in key steps of angiogenesis. 
 
Cell activation is the first step of the angiogenic process (Eble and Niland, 2009; 
Herbert and Stainier, 2011). In the absence of pro-angiogenic stimuli, endothelial cells 
remain in a quiescent status, regulated by a low-level autocrine VEGFA signalling 
(Herbert and Stainier, 2011). Increased levels of pro-angiogenic stimuli (amongst which 
VEGFA is one of the most important) activate endothelial cells to produce matrix 
metalloproteinases that degrade the basement membrane (Blasi and Carmeliet, 2002; 
Eble and Niland, 2009; Herbert and Stainier, 2011). The degradation of the basement 
matrix is crucial to overcome the spatial restriction and therefore allow endothelial cell 
migration (Potente, et al., 2011). Subsequently, VEGFA enhances the permeability of 
the endothelial layer and promotes the extravasation of plasmatic proteins, thus 
creating a scaffold into which endothelial cells can migrate (Eble and Niland, 2009; 
Herbert and Stainier, 2011) (Figure 43). 
 
VEGFA does not have a relevant effect as a mitogen in endothelial cells (Olsson, 
et al., 2006), but it does regulates endothelial cell migration (Figure 43). Via VEGFR-
  
194 
2 activation, VEGFA induces the formation of long and abundant filopodia in 
endothelial cells and consequently the adoption of a motile phenotype (Gerhardt, et 
al., 2003) (Potente, et al., 2011). VEGFR-2 receptors present in filopodia are able to 
sense VEGFA and other chemoattractant stimuli; hence, they guide cell migration and 
orientate the growth of the vessel sprout (Potente, et al., 2011). Finally, the formation 
of tubular structures occurs, supported by endothelial cells that elongate the vascular 
sprout and establish adherent and tight junctions, thus ensuring the stability of the 
newly-formed vessel  (Potente, et al., 2011). After defining its basal-apical polarity, 
endothelial cells contour their apical membrane with negatively charged glycoproteins; 
this creates an apical repulsive signal that results in the creation of the lumen (Strilic, 
et al., 2009). Initiation of blood flow, pericyte attachment and formation of a basement 
membrane provide further stabilisation of the structure (Potente, et al., 2011).  
 
During angiogenesis, endothelial cells experience profound phenotypical changes 
that require the remodelling of the actin cytoskeleton (i.e. formation of filopodia, cell 
migration, formation of the vascular lumen) (Gerhardt, et al., 2003; Lamalice, et al., 
2007). Downstream of VEGFR-2, the AKT/endothelial NO synthase pathway has been 
shown to be critically involved in these mechanisms. AKT inhibition impairs VEGFA-
stimulated remodelling of the actin cytoskeleton and cell migration (Morales-Ruiz, et 
al., 2000; Noiri, et al., 1997; Ziche, et al., 1994).  
 
Previous results suggest that indole-3-acetate is able to inhibit the 
phosphorylation of VEGFR-2 and its downstream signalling effector AKT; therefore, 
it was hypothesised that indole-3-acetate would exhibit anti-angiogenic properties. In 
this chapter, a cell-based approach was used to examine the putative inhibitory effect 
of indole-3-acetate in key steps of angiogenesis in vitro. Specific aims include: 
a) To assess the impact of indole-3-acetate on HUVEC cell migration; 
b) To assess the impact of indole-3-acetate on HUVEC tube formation. 
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2. Materials and Methods 
 
2.1. Cell culture 
HUVEC were obtained from BD Biosciences. In brief, cells were grown in 
collagen I-coated flasks and maintained in an atmosphere of 5% CO2 at 37ºC. After 
reaching 80% confluence, cells were trypsinised and split at the ratio of 1:2 to 1:6. Cells 
between passage number 3 and 10 were used for the experiments described. 
 
2.2. Cell migration assay 
 
HUVEC cells were trypsinised and seeded in a 24-well Radius Cell Migration 
Assay plate (Cell Biolabs). Each well of the plate contained a 0.68 mm biocompatible 
hydrogel spot (RadiusTM Gel) that prevents HUVEC cells attachment. Five hours 
after seeding, cells reached confluency and the hydrogel spot was removed. Cells were 
then pre-treated with either indole-3-acetate (0.01, 1 or 100 M) or vehicle for 15 
minutes, followed by stimulation with endothelial growth medium (EGM) (prepared 
with endothelial basal medium (EBM-2, Lonza) and endothelial cell growth 
supplements (EGM-2 Lonza Bulletkit), and supplemented with VEGFA at the 
concentration of 2ng/mL (Sigma Aldrich, LCC)). Photographs were taken hour for 6 
hours using a Zeiss Axiovert 200M Live Cell Imaging Microscope (Zeiss, Jena, 
Germany). Migration was quantified as the percentage of the area recovered by 
migrating cells after hydrogel spot removal (full details in Chapter 2. “General 
Methodology”). Image Processing and Analysis in Java (ImageJ) software was used to 
perform area measurements (Schneider, et al., 2012). 
 
2.3. Tube formation assay 
 
The Millicell Micro-Angiogenesis Inhibition Assay (EMD Millipore) was used to 
assess capillary tube formation. Matrigel was added to a Micro-Angiogenesis slide and 
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allowed to solidify at 37oC for 1 hour. HUVEC were seeded at a density of 2x105 
cells/well and treated either with a) vehicle, b) endothelial growth medium (EGM, 
prepared with EBM-2 and endothelial cell growth supplements (EGM-2 Lonza 
Bulletkit), and supplemented with VEGFA (Sigma Aldrich), at the concentration of 
2ng/mL or c) EGM (as previously described) plus various concentrations of indole-3-
acetate (0.01, 1 or 100 M)). After 16 hours of incubation, cells were labelled with 2 
μM of Calcein-AM for 15 minutes for 30 minutes at 37oC in 5% CO2. Photographs were 
taken using a 484 nm excitation and 520 nm emission filter on an Axiovert 200 
microscope equipped with a 10x objective. Confocal microscopy photographs were 
taken simultaneously. The quantification of the network parameters was evaluated by 
the Angiogenesis Analyser plug-in, ImageJ software (Carpentier, 2012). 
 
2.4. Statistical analysis 
 
Normality was tested using the D' Agostino-Pearson Omnibus normality test, 
and parametric or non-parametric testing chosen accordingly. For cell-based assays, 
parametric or non-parametric one-way ANOVA was used, followed by post hoc testing 
(p<0.05 considered to be statistically significant). The number of replicates for each 
experiment is indicated in the individual figure legends. Data are displayed as mean  
standard error of the mean (s.e.m) in all figures.  
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3. Results  
3.1. Effect of indole-3-acetate on cell migration  
 
In order to study the effect of indole-3-acetate on key steps of angiogenesis, we 
first investigated the effect of the compound on cell migration, one of the most critical 
hallmarks of the process. In brief, HUVEC cells were plated in a RadiusTM 24-well 
plate, using EGM (Figure 44a). Each well contained a biocompatible hydrogel spot 
that prevented cell attachment. For 5 hours, cells were allowed to reach confluence by 
firmly attaching outside of the spot. After hydrogel spot removal (Figure 44b), HUVEC 
cells were pre-treated with either indole-3-acetate (0.01, 1 or 100 M) or vehicle for 15 
minutes, followed by stimulation with EGM (Figure 44c-d).  EGM was prepared with 
endothelial basal medium (EBM-2) and endothelial cell growth supplements (EGM-2 
Lonza Bulletkit), and supplemented with VEGFA (Sigma Aldrich), at the 
concentration of 2ng/mL). 
 
Figure 44. Assessment of HUVEC migrating activity in vitro. 
An exclusion zone assay (RadiusTM, Cell Biolabs) was used. Experimental steps include a) HUVEC 
seeding; b) hydrogen spot removal; c-d) HUVEC pre-incubation with either indole-3-acetate or vehicle 
for 10 minutes, followed by stimulation with endothelial growth medium (EGM was prepared with basal 
medium (EBM-2) and endothelial growth factors, and supplemented with VEGFA, as described). Cells 
were allowed to migrate for 6h into the newly revealed area. e) After 6 hours, confocal microscopy 
images were taken using a FITC filter. Designed using Servier Medical Art elements. EBM-2: Endothelial 
Basal Medium; EGM: Endothelial Growth Medium; I3A: Indole-3-acetate; VEGFA: Vascular 
Endothelial Growth Factor A. 
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Cells were allowed to migrate for 6h and photographs were taken at 0h, 2h, 4h 
and 6h) (Figure 44e). The proportion of the area recovered was measured and used as 
a proxy for migration potential (For further details, see section 2.2 of this Chapter). 
As expected, stimulation with EGM increased cell migration, when compared to non-
stimulated cells, at both 4h (54.4% vs 41.6%, p=0.037) and 6h (55.6% vs 69.4%, 
p=0.038) (Figure 45a-b).  
 
Pre-treatment with indole-3-acetate at 100 M was able to counteract this 
effect. Cells pre-treated with indole-3-acetate (100 M) exhibited a significant 
reduction of their migrating activity at both 4h and 6h, when  compared to cells pre-
treated with vehicle prior to stimulation (27,4% vs 54,2%, p=0.008 and 40.1% vs 
69.4%, p=0.019, respectively). Pre-treatment with lower concentrations of indole-3-
acetate (0.01 and 1 M) however, did not have a significant effect on cell migration at 
any of the time points evaluated (p>0.05) (Figure 45a-b). 
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Figure 45. Indole-3-acetate inhibits cell migration in HUVEC. 
a) Representative microscopic images (10x magnification). The white dashed line delimits the exclusion 
zone area. b) Migrating activity, expressed as the percentage of the initial area (0h) recovered by 
migrating cells. Results are shown as mean  s.e.m. of two independent experiments. One-way ANOVA 
was performed and Fisher’s post-hoc testing was used for comparisons between groups. *p<0.05; 
**p<0.01; EGM: Endothelial Growth Medium; I3A - indole-3-acetate. 
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3.2. Effect of indole-3-acetate on tube formation 
 
In this experiment, the effect of indole-3-acetate on endothelial cell tube 
formation was evaluated. In brief, endothelial cells were seeded in a gelled basement 
membrane extract (Matrigel), which provides a structure for cells to attach, migrate 
towards each other and finally align in order to form tubular structures (Arnaoutova, 
et al., 2009). HUVEC cells were then stimulated with EGM (prepared with EBM-2 
and endothelial cell growth supplements (EGM-2 Lonza Bulletkit), and supplemented 
with VEGFA (Sigma Aldrich), at the concentration of 2ng/mL), with or without 
indole-3-acetate (Figure 46a). As recommended by the manufacturer, a known 
inhibitor of tube formation (sulforaphane) was used to confirm that the experimental 
system was responsive to inhibitory stimuli (Arnaoutova and Kleinman, 2010).  
 
 
 
 
 
Figure 46. Assessment of tube formation by HUVEC in vitro. 
a) Experimental design. b-e) HUVEC stimulated with EGM were used in this figure as an example 
to describe the constitutive elements of the network. Confocal microscopy (b) and fluorescence 
microscopy, after Calcein-AM staining (c). d) Confocal image processed by ImageJ Angiogenesis 
Analyser.  e) Detailed description of the main variables quantified by ImageJ Angiogenesis 
Analyser: nodes (1) are identified as pixels with at least 3 neighbours and give rise to branches 
(terminal portions of the tree) (2). A segment (3) is a non-terminal portion of the tree, delimited 
by two junctions (4). The definition of piece includes both terminal and non-terminal portions of 
the tree, i.e. branches (2) and segments (3). EGM: Endothelial Growth Medium (as previously 
described); I3A: Indole-3-acetate. 
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After 16h of incubation, HUVEC cells formed stable tubular structures. Calcein-
AM staining was then performed and microscopic images were taken and processed 
using ImageJ Angiogenesis Analyser software (Carpentier, 2012), automatically 
quantifying the constitutive elements of the tubular network (Figure 46d-e). The 
constitutive elements describe the network regarding a) the number of connecting 
structures (number of nodes, junctions, branches and pieces) and b) the length of the 
tubular network (total length, total branches length and, total branching length [sum 
of length of pieces]).  
 
3.2.1. Exploratory approach using unsupervised multivariate methods 
 
In order to understand the contribution of the individual variables to the model, 
all variables (i.e. constitutive elements of the network) were used to build a Principal 
Component Analysis (PCA) model, which explained 94.4% of the variability (2 
Principal Components, R2 = 0.944). In the scatter scores plot, it is possible to observe 
a clear separation between groups, as well as the effect of increasing doses of indole-3-
acetate (yellow arrow) in the tubular network (Figure 47a). The loadings score plot 
shows the global contribution of the variables to the model (Figure 47b).  
 
In order to identify which variables contribute most to the model, the 
cumulative R2 of the individual contributions to the PCA model were plotted (Figure 
47c). Five variables exhibited a R2>0.90, including number of nodes, number of 
junctions, number of branches, total length, total branching length and total branches 
length (Figure 47c). The impact of indole-3-acetate on these variables will be further 
explored in the next section using univariate statistics.  The effect of indole-3-acetate 
is also observed in an O2PLS-DA model (R2Yhat = 0.338, Q2Yhat = 0.139) (Figure 47d).  
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Figure 47. Unsupervised multivariate analysis by PCA and O2PLS-DA: an exploratory 
approach to study the effect of indole-3-acetate on tube formation in vitro. 
a) PCA 3D Scores plot; b) PCA loadings plot; c) Contribution of individual variables to the PCA. 
The yellow dashed represents the threshold for R2=0.90. d) O2PLS-DA model. 
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3.2.2. Univariate analysis of the constitutive elements of the network 
 
 In order to quantify the effect of indole-3-acetate on tube formation, the above-
mentioned variables were individually measured and univariate analysis was 
performed. HUVEC cells formed tubular networks in all tested conditions, except when 
treated with sulforaphane, a known angiogenesis inhibitor; in this case, HUVEC cells 
remained rounded as solitary cells, thus validating the responsiveness of this assay to 
inhibitory stimuli (Figure 48a).  
 
As expected, stimulation with EGM significantly increased the number of 
connecting structures of the tubular network; the number of nodes, junctions and 
pieces increased by 59.7%, 80.2% and +52.6%, respectively (p<0.05 for all) (Figure 
48b-d). Indole-3-acetate was able to counteract these effects, both at 1 and 100 M 
(p<0.05); cells with indole-3-acetate at 100 M exhibited a significant reduction on the 
number of nodes (-52.4%, p<0.01), number of junctions (-51.5%, p<0.01) and number 
of pieces (-49.2%, p<0.01), when compared to control (Figure 48b-d). For all these 
parameters, treatment with lowest doses of indole-3-acetate (0.01 M) did not show a 
significant effect (p<0.05) (Figure 48b-d). Indole-3-acetate was also able to reduce 
parameters regarding the length of the tubular network; but, in this case, a significant 
effect was only observed at the highest dose tested (100 M) (Figure 48e-g). Cells 
treated with indole-3-acetate (100 M) exhibited a reduction on the total length, total 
branching length and total branches length of the tubular network (-37.3%, -50.9% 
and -55.9%, respectively; all p<0.05).  Treatment with lower doses of indole-3-acetate 
(0.01 and 1 M), however, did not have a significant effect (Figure 48e-g).  
Altogether, these results demonstrate that indole-3-acetate is able to inhibit the 
ability of HUVEC cells to form tubular structures in vitro, as quantitatively 
demonstrated by its negative impact on the number of connections and on the length 
of the tubular network (Figure 48h). 
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Figure 48. Indole-3-acetate inhibits tube formation in HUVEC. 
a) HUVEC cells were seeded in Matrigel-coated wells and treated as previously described. b-g) Results 
are shown as mean  s.e.m. of 4 independent experiments. One-way ANOVA was performed and 
Dunnett’s post-hoc testing was used for comparisons between groups. h) Radar plot providing an 
overview of the mean values for each one of the variables and respective p values for one-way ANOVA 
*p<0.05; **p<0.01; ***p<0.001. I3A - indole-3-acetate; EGM – Endothelial Growth Medium; Sulf – 
Sulforaphane. 
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4. Discussion 
In the previous chapter, molecular docking analyses suggested that indole-3-
acetate is able to physically bind to VEGFR-2, and inhibit both its phosphorylating 
activity and its downstream signalling (AKT/NO). Altogether, these results suggested 
that indole-3-acetate could exhibit anti-angiogenic properties. In this chapter, this 
effect of indole-3-acetate was tested in vitro. 
 
In this chapter, well-established cell-based assays were used to demonstrate the 
inhibitory effect of indole-3-acetate on HUVEC cells on cell migration and tube 
formation. As previously shown, indole-3-acetate at 1000 M significantly reduces cell 
viability (see Chapter 6); also, the maximum concentration of indole-3-acetate detected 
in blood is in the micromolar range (Calaf, et al., 2011; Duranton, et al., 2012). 
Therefore, in order to best mimic physiological conditions, the concentrations used in 
these experiments ranged from 0.01 to 100 M.  
 
4.1. Indole-3-acetate inhibits cell migration in vitro 
 
As previously described, angiogenesis is a multistep process, that includes a) 
cell activation and basement membrane disruption, b) cell migration and proliferation 
and c) formation of tubular structures. The preferred initial strategy to investigate the 
putative anti-angiogenic propertied of a given compounds is to test its effects in one 
or several of these steps in vitro (Staton, et al., 2004) (Auerbach, et al., 2003).  
 
In the first study, the effect of indole-3-acetate on cell migration was assessed 
using a “cell exclusion zone assay”. Cell exclusion zone assays are a novel approach to 
overcome the disadvantages of the classic scratch assays or transmembrane assays 
(Kam, et al., 2008; Mastyugin, et al., 2005; Staton, et al., 2009; Staton, et al., 2004). 
Cell exclusion zone assays do not induce cell damage (Poujade, et al., 2007) and provide 
an accurate and precise area to study cell migration, thus offering robust and 
reproducible data (Hulkower and Herber, 2011). Other advantages of this novel method 
include the possibility to use a more physiological migrating surface (e.g. collagen I 
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coating) and the possibility to perform real-time measurements (Hulkower and Herber, 
2011).  
 
In this experiment, it was established for the first time that indole-3-acetate 
(100 M) significantly reduces the migrating activity of HUVEC; these results are 
consistent with its putative role as a VEGFR-2 inhibitor. Several in vitro studies have 
demonstrated that other known VEGFR-2/VEGFA inhibitors (e.g. bevacizumab) exert 
their anti-angiogenic properties, at least partially, by significantly impairing cell 
migration (Hein and Graver, 2013). Interestingly, other indolic compounds (indole-3-
carbinol and indoxyl sulfate) were also shown to reduce cell migration in endothelial 
cells (Wu, et al., 2005) (Dou, et al., 2004). However, there is no published evidence 
suggesting that these effects are mediated through VEGFR-2 inhibition. 
 
Although a critical event, cell migration is only one step amongst several 
required for the formation of new vascular sprouts. Therefore, in order to demonstrate 
the anti-angiogenic effect of a given compound in vitro it is recommended to assess its 
effect in more than one mechanistic step (Auerbach, et al., 2003).  
 
4.2. Indole-3-acetate inhibits tube formation in vitro 
 
In this study, the effect of indole-3-acetate on tube formation was assessed. 
Tube formation is a complex phenotype, that requires endothelial cells to synthesise 
proteases, to digest the matrix (e.g. Matrigel), to migrate towards each other and, 
finally, to align in order to form tubular structures - thus mimicking a pseudo-capillary 
network in vitro (Arnaoutova, et al., 2009; Arnaoutova and Kleinman, 2010; Grant, et 
al., 1991; Haralabopoulos, et al., 1994). Hence, the tube formation assay complements 
the previous cell migration assay and provides a more comprehensive assessment of 
angiogenesis in vitro (Arnaoutova, et al., 2009; Arnaoutova and Kleinman, 2010; 
Haralabopoulos, et al., 1994). Although being the most specific assay to test 
angiogenesis in vitro, some considerations shall be discussed regarding the tube 
formation assay. First, uneven surfaces affect the response of the tubular network to 
pro-angiogenic factors; therefore, the setting up of the assay shall be performed 
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carefully, ensuring an even coating in each well (Liu, et al., 2002). In this study, these 
potential biases were minimised by excluding all the wells in which coating was uneven 
and/or bubbles were present. Second, it is important to assure an unbiased 
quantitative evaluation of the vascular network, ensuring that tubular structures are 
adequately distinguished from the background and/or undifferentiated proliferating 
islands (Auerbach, et al., 2003). To overcome this pitfall, an automated tool 
(Angiogenesis Analyser for Image J) was used in this study to automatically extract 
unbiased characteristic information of the network (Carpentier, 2012).  
 
In this study, it was shown for the first time that indole-3-acetate (at 100 M) 
is able to significantly reduce several quantitative parameters of the pseudo-capillary 
network formed by HUVEC in vitro.  In particular, the compound significantly reduced 
the length of the network (total length, the total branching length and total branches 
length of the tubular network) and the number of connecting structures (nodes, 
junctions and pieces), when compared to vehicle-treated cells. Although the same 
decreasing effect on the number of connections was observed when treating HUVEC 
with a lower dose (1 M), no significant effects were observed on tubular length 
parameters. These results are consistent with the previously reported effects of indole-
3-acetate on cell migration, where a significant inhibitory effect was observed at 100 
M. By demonstrating that indole-3-acetate is able to significantly inhibit HUVEC 
tube formation in vitro, these results complement the previously described inhibitory 
effect on cell migration - and reinforce its putative role as a gut microbial metabolite 
with anti-angiogenic properties. 
 
Although previous pharmacological inhibition assays and molecular docking 
analyses suggest that I3A anti-angiogenic effect might be directly mediated through a 
competitive inhibition of VEGFR-2, further experiments are required to explore the 
contribution of this and other putative receptors. Small interfering RNA (siRNA) / 
short hairpin RNA (shRNA) experiments targeting other putative receptor involved 
(i.e. AHR) might be useful to clarify and/or exclude other underlying mechanisms 
involved. The impact of indole-3-acetate on VEGFR-2 would be unequivocally 
demonstrated by a cell-based model with mutagenesis on specific amino acid residues 
of the receptor that bind the metabolite. In this case, the absence of anti-angiogenic 
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effect in the presence of indole-3-acetate would validate that the compound exerts its 
effect through VEGFR-2 inhibition. 
 
Other indolic compounds (indole-3-carbinol and indoxyl sulfate) were previously 
shown to inhibit tube formation in vitro; however, as previously mentioned, no target 
was proposed for their inhibitory effects (Wu, et al., 2005). Due to the structural 
similarities between molecules, it would be relevant to also screen these molecules as 
potential VEGFR-2 inhibitors.  
 
4.3. Angiogenesis assays in vitro: advantages and pitfalls 
 
Angiogenesis assays in vitro present several advantages: they can be performed 
rapidly and generate data that allow the quantitative analysis of the angiogenic process 
in cell-based models (Auerbach, et al., 2003). An approach to maximize the information 
yielded by in vitro assays is performing several complementary assays in vitro, as 
described in this Chapter (Staton, et al., 2009; Staton, et al., 2004). Furthermore, the 
value of in vitro assays can be improved by safeguarding that the conditions used are 
as close as possible to the ones observed in vivo (Auerbach, et al., 2003). In order to 
accomplish this, in these studies, physiological concentrations of the compound and 
specific coatings were used (e.g. Collagen-I, Matrigel). 
 
Although in vitro assays provide critical information on the inhibitory effect of 
indole-3-acetate on angiogenesis, it is important to note that these assays represent 
but a first step to validate the anti-angiogenic properties of this compound. Regardless 
of the adjustments performed, in vitro assays are carried out in conditions that, 
globally, are very different from physiological. Consequently, irrespective of the 
amount of information generated by in vitro tests, in vivo tests are an absolute 
requirement for the accurate evaluation of regulators of angiogenesis. 
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5. Conclusion 
 
This chapter demonstrated that indole-3-acetate, at the concentration of 100 
M, is able to significantly reduce the migrating activity of HUVEC. Consistently, 
indole-3-acetate also reduced tube formation, by decreasing both the length of the 
network and the number of connections established observed. Altogether, these results 
demonstrate that indole-3- acetate at 100 M is able to impair the development of the 
pseudo-capillary network in vitro.  
 
These results are consistent with the previous chapter’s findings suggesting that 
indole-3-acetate is a VEGFR-2 inhibitor, inhibiting both the phosphorylation of the 
receptor and downstream signalling pathways relevant for the angiogenic process 
(Chapter 6). Altogether, these results support the role of indole-3-acetate as a gut 
microbial metabolite with anti-angiogenic properties. However, in vivo tests are 
necessary to validate these findings, as will be explored in the next chapter. 
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Chapter 8  
Effect of indole-3-acetate on 
angiogenesis in vivo 
 
1. Introduction 
 
 Angiogenesis is a key process for human development and health – and its 
dysregulation is associated with a range of cardiometabolic disorders (e.g. 
atherosclerosis, ischemic heart disease and post-ischemic revascularisation, obesity, 
diabetes and arterial hypertension) (Caldwell, et al., 2005; Fukumura, et al., 2003; 
Jesmin, et al., 2005; Kubis, et al., 2002; Rivard, et al., 1999; Rupnick, et al., 2002; 
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Sane, et al., 2004; Shiojima, et al., 2005; Van Belle, et al., 1997; Waltenberger, 2001) 
(Brill, et al., 2005)).  
 
In the previous chapter, it was demonstrated that indole-3-acetate is able to 
inhibit key steps of angiogenesis in vitro (i.e. cell migration and tube formation). 
Although in vitro assays are the first validating step when assessing the pro- or anti-
angiogenic effect of a given compound (Auerbach, et al., 2003), it is not clear to which 
extent they predict responses in vivo (Arnaoutova, et al., 2009; Staton, et al., 2009). 
In vivo, angiogenesis involves primarily endothelial cells but is further controlled by 
the surrounding microenvironment (Rahat, et al., 2014). The relationship and cross-
talk between endothelial cells and immune cells, fibroblasts, pericytes and the 
extracellular matrix, affects gene expression and phenotypic distinction - and, finally, 
determines whether endothelial cells survive and proliferate, or enter apoptosis (Jung, 
et al., 2002). In vivo tests are, therefore, an absolute requirement for the accurate 
evaluation of regulators of angiogenesis (Staton, et al., 2009; Tahergorabi and Khazaei, 
2012). 
 
In vivo angiogenesis models are based on the natural development of 
angiogenesis in different biological matrices, including the rat cornea (“corneal 
angiogenesis assay”), the chick extraembryonic membrane (”chick chorioallantoic 
membrane (CAM) assay”) or in subcutaneous plugs of mice sarcoma extract (“Matrigel 
plug assay”) (Tahergorabi and Khazaei, 2012). Amongst the in vivo assays to study 
angiogenesis, the Matrigel subcutaneous plug assay is a fast and effective approach to 
screen stimulators or inhibitors of angiogenesis (Fridman, et al., 2012; Tahergorabi and 
Khazaei, 2012). Furthermore, this assay allows a direct validation of the observed 
inhibitory effect of indole-3-acetate on tube formation in vitro, an experiment also 
performed in Matrigel. 
 
 Matrigel consists of a mixture of extracellular matrix and growth factors 
obtained from Engelbreth-Holm-Swarm mice sarcoma (Passaniti, et al., 1992). Pro- or 
anti-angiogenic compounds can be added to cold liquid Matrigel (<4oC), which is 
subsequently injected subcutaneously in the dorsal or ventral region of the mice 
(Passaniti, et al., 1992). At body temperature, Matrigel becomes a solid gel (the 
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“Matrigel plug”), into which endothelial cells migrate, thus forming vessel-like 
structures (Baker, et al., 2006; Malinda, 2001). Importantly, as the Matrigel plug is 
injected into the subcutaneous tissue (“hypodermis”), its close contact with fibroblasts, 
immune cells, adipose cells and macrophages mimics closely the microenvironment of 
physiological angiogenesis in vivo (Tahergorabi and Khazaei, 2012). 
 
In this chapter, we tested the effect of indole-3-acetate in vivo using the 
subcutaneous Matrigel plug. In particular, we investigated the impact of indole-3-
acetate on a) plug weight (as an indirect measure of vascularisation (Bhat, et al., 
2013)) and b) on the area of the endothelial vascular network developed within the 
plug. 
 
2. Materials and Methods 
2.1. Animal studies 
 
C57BL/6J mice (Charles River) were weaned at 3 weeks, housed in groups of 6 
animals, maintained under standard breeding conditions (12 h/12h light-dark cycle) 
and fed ad libitum a chow diet (B&K Universal, Hull, U.K.) At day 0, 8-week-old mice 
were anaesthetised with propofol to undergo Matrigel subcutaneous injection 
(ForeneH, Abbott). All procedures were carried out in accordance with the U.K. Home 
Office guidelines on animal welfare. 
 
2.2. Matrigel in vivo plug assay 
 
Matrigel was prepared with 20 U/mL of heparin, 150 ng/mL of mouse 
recombinant VEGFA (VEGFA165, Sigma Aldrich Co, LCC), with or without indole-3-
acetate (100 M). 300 L of liquid Matrigel with or without VEGFA (100 M) were 
subcutaneously injected into the right and left flanks of each mouse, respectively. 
Matrigel was allowed to polymerize into a solid gel by body temperature. After 7 days, 
the animals were sacrificed by cervical dislocation and the Matrigel plugs were 
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harvested, weighted and photographed. Following fixation in 10% buffered formalin, 
the plugs were embedded in paraffin. Sections from each sample were cut at a thickness 
of 5 m using a standard rotary microtome (Leica Biosystems). 
 
2.3. Immunohistochemistry 
 
Four of 5 m sections were transferred onto pre-cleaned glass slides (Mercedes 
Medical, Sarasota, FL, USA). Dried slides were incubated at 65oC for 1h and used for 
haematoxylin and eosin (H&E) staining or immunohistochemistry to observe the nuclei 
of infiltrating cells. For immunohistochemistry, sections were deparaffinised and 
blocked for 30min with 10% normal goat serum. Slides were incubated with primary 
anti-CD31 antibody (Abcam, UK) (dilution 1:50) overnight at 4oC. The secondary 
antibody (Alexa Fluor 488-AffiniPure Goat Anti-Armenian Hamster, Jackson 
Immnunoresearch, PA, USA) was incubated for 1h at room temperature. Cell nuclei 
were counterstained with 4′-6-Diamidino-2-phenylindole (DAPI). DAPI in mounting 
medium, before assembling the slide.  
 
2.4. Imaging protocol 
 
CD31 (or platelet endothelial cell adhesion molecule-1 (PECAM-1)), a marker 
for endothelial cells, was used to quantify angiogenesis (Muruganandham, et al., 2006; 
Ragel, et al., 2007). CD31+ area was quantified by considering three random sections 
of the peripheral region of each Matrigel plug, at 40x magnification. Fluorescent images 
were obtained using a Nikon Eclipse E600 fluorescent microscope coupled to a RGB-
MS-C micro colour camera. Image J software was used for image processing and 
quantification, according to the protocol described in Figure 49. 
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Figure 49. Microscopic imaging and analysis protocol for the quantification of the CD31+ area. 
a) Protocol for imaging analysis. b) Details of the staining for DAPI (blue) and CD31 (green). c) 
CD31 staining and d) percentage of CD31+ -stained area / total,, as assessed by ImageJ 
quantification (Angiogenesis Analyser plug-in) (Carpentier, 2012). All images were captured at 40x 
magnification. 
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2.5. Statistical analysis 
 
Normality was tested using D' Agostino & Pearson Omnibus normality test, 
and parametric or non-parametric testing chosen accordingly. This study included 
three independent experiments, with a total number of nine mice. Paired t-test was 
used to compare groups. Two-way ANOVA was used to quantify the percentage of 
variation explained by indole-3-acetate and individual effect. Data are displayed as 
mean  s.e.m in all figures. A p-value of 0.05 was used for statistical significance.  
 
3. Results 
 
In brief, 300 L of liquid Matrigel (150 ng/mL of mouse recombinant VEGFA, 20 
U/mL of heparin (Sigma Aldrich Co, LCC) with indole-3-acetate (100 M) or vehicle 
were subcutaneously injected, respectively, into the right and left flanks of each 
C57BL/6 mouse (Figure 50a). After 7 days, the animals were sacrificed and Matrigel 
plugs were harvested, weighted and fixed. Figure 50 describes the experimental design 
and the main histologic characteristics observed in a control plug. During this 7-day 
experiment, mouse endothelial cells migrated into the plug (Figure 50b) and formed 
new vascular structures, which can be observed in further detail in Figure 50c-d.  
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Figure 50. Matrigel subcutaneous plug assay (control plug). 
a) Experimental design using dual implantation for paired statistics. b-d) Microscopic details of 
the vascularization network at day 7 in the control plug (H+E staining, 20x magnification): 
endothelial cells infiltrate the Matrigel plug (1), forming new vascular structures, which are 
observed in both longitudinal (2) and cross sectional (3) perspectives. 
 
 
3.1. Effect of indole-3-acetate on plug weight  
 
Plug weight is an indirect measure of angiogenesis, subsequent to the increase 
on the number of vascular structures and intraluminal blood in the plug (Bhat, et al., 
2013). In this study, plugs with VEGFA alone and VEGFA + indole-3-acetate weighted 
0.185  0.042 g and 0.132  0.037 g, respectively. Indole-3-acetate plugs were on average 
26.5% lighter than their respective controls (p=0.022) (Figure 51).  
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Figure 51. Plug weight is lower in plugs treated with indole-3-acetate. 
Plug weight values are expressed as mean  s.e.m. of three independent experiments (n = 3). A 
paired two-tail t-test was performed for comparisons between groups. *p < 0.05. 
 
3.2. Effect of indole-3-acetate on the vascular area 
 
Macroscopically, the control plugs (containing VEGFA only) displayed a darker 
red colour, denoting increased blood content (Koo, et al., 2015)), when compared with 
plugs containing VEGFA and indole-3-acetate and implanted in the same mouse 
(Figure 52a). Regardless of inter-individual variability, for each mouse, the abundance 
of red colour was generally higher in the control plug (Figure 52a). Representative 
microscopy imaging after H+E staining of both conditions also suggests a higher 
development of the vascular network in the control plugs (VEGFA only) (Figure 52b-
e).  
 
In order to quantify the vascular area, immunohistochemistry for the Cluster of 
Differentiation 31 (CD31) was performed. CD31 (or platelet endothelial cell adhesion 
molecule-1 (PECAM-1)) is abundantly present in the surface of endothelial cells, and 
has been extensively used to quantify angiogenesis (Muruganandham, et al., 2006; 
Ragel, et al., 2007). Stitched images provide a global overview of the CD31+ area in 
the plugs (Figure 53a-b); within the control plug, it is possible to observe several 
convoluted CD31+ structures (Figure 53a); conversely, in the plug treated with indole-
3-acetate, these structures are less evident (Figure 53b).  
 
Summary 
Two-tailed paired t-test   
p value 0.022 
Number of pairs 8 
95% CI -0.095 to -0.010 
R squared 0.553 
0.0 0.1 0.2 0.3
AVEGF
 + I3AAVEGF
Plug weight (in grs)
*
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Figure 52. Macroscopic and microscopic overview of the Matrigel plugs. 
a) Macroscopic aspect of all the plugs included in the analysis. Individual mice are described as M1 to 
M8. b-d) Representative pictures for one mouse are shown (H+E staining). b) The control exhibits a 
well-developed network, with newly-formed vessels converging into vascular pools (b, right and left 
inferior corners). c) A poorly-developed vascular network is observed in the plug containing indole-3-
acetate, and no blood pools are detected. At a higher magnification (20x), the peripheral region of the 
control plug exhibits a higher density of migrating cells (d), when compared to the plug containing 
VEGFA + I3A (e). I3A: indole-3-acetate: VEGFA: Vascular Endothelial Growth Factor A. 
 
The CD31+ area was measured using the Image J software and expressed as the 
% of the total area of microscopic field (see representative images in Figure 53c). In 
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average, the CD31+ area in the plug with indole-3-acetate was 69.1% lower than in its 
paired control (p=0.005) (Figure 53d). 
 
The Matrigel subcutaneous plug assay has a high inter-individual variability 
(Fridman, et al., 2012). Consistently, in this study, a two-way analysis of variance 
revealed that the individual effect accounted for 18.8% of the total variation (p=0.045), 
whilst indole-3-acetate accounted for 31.8% of the total variance (p<0.0001). The 
interaction between the indole-3-acetate and inter-individual effect was not significant 
(p=0.1521). 
 
Figure 53. Indole-3-acetate inhibits angiogenesis in a subcutaneous Matrigel plug model. 
a-b) Matrigel plugs were harvested after 7-day post- implantation, sectioned and stained with CD31 for 
immunohistochemistry. c) Sections were co-stained with DAPI (blue) for nucleus. Angiogenesis was 
quantified by measuring the CD31+ -stained area for immunofluorescence with Image J software, in 
three random fields per plug. The average of the three measurements was calculated. d) Results are 
expressed as means  s.e.m. of three experiments). Two-tail paired t-test was used for comparisons 
between groups. *p<0.05; I3A: indole-3-acetate; VEGFA: Vascular Endothelial Growth Factor A. 
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4. Discussion 
 
It was previously demonstrated that indole-3-acetate is able to inhibit key steps 
of angiogenesis in vitro, using the HUVEC cell line (see Chapter 7). However, it is 
important to note that angiogenesis in vivo is a complex and highly regulated process 
that involves primarily endothelial cells but is further controlled by the cellular 
microenvironment and other cell types (e.g. macrophages, adipocytes) (Rahat, et al., 
2014). In this chapter, the effect of indole-3-acetate on angiogenesis was confirmed, by 
employing a subcutaneous Matrigel plug assay. Specifically, we investigated the effect 
of the compound on the plug weight and the extension of the developed vascular area. 
 
4.1. Indole-3-acetate reduces plug weight 
 
In this study, we showed that indole-3-acetate significantly reduces the plug 
weight (-26.5%, p<0.022), when compared to control. These findings are in line with 
its predicted anti-angiogenic role based on VEGFR-2 inhibition and in vitro validation 
assays. Potent anti-angiogenic compounds (e.g. acacetin) are known to reduce the plug 
weight by up to 80%, when compared to the control (VEGFA only) (Bhat, et al., 2013). 
The decrease on plug weight was suggested to be a direct consequence of the inhibition 
of angiogenesis, with a resulting decrease on the number of vascular endothelial cells, 
vascular structures and intraluminal blood in the plug (Bhat, et al., 2013). However, 
these results must be interpreted with caution, as plug weight is highly affected by the 
size of the vessels and by stagnant pools of blood (AlMalki, et al., 2014). The 
quantification of angiogenesis by immunohistochemistry techniques has proven to 
produce more reliable and reproducible quantitative data (Schoell, et al., 1997; 
Simpson, et al., 1996). 
 
4.2. Indole-3-acetate reduces the area of the vascular network  
 
In order to investigate the impact of indole-3-acetate on the extension of the 
vascular network, CD31 immunohistochemistry was performed (Vermeulen, et al., 
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1996). CD31, also named PECAM-1, is a member of the immunoglobulin superfamily 
and plays an important role in angiogenesis, leukocyte migration and integrin 
activation (Newman, et al., 1990). Various immunohistochemistry methods using anti-
CD31 antibodies have been developed to quantify angiogenesis (Vermeulen et al. 1996). 
Moreover, the measurement of the CD31+ area has been recognised as the most 
accurate index of vascularization (Schoell, et al., 1997; Simpson, et al., 1996) and was 
therefore the strategy adopted for quantification purposes in this experiment. 
 
In this study, Matrigel plugs supplemented with indole-3-acetate resulted in a 
significant decrease in the vascularised area. The percentage of CD31+ area was on 
average 69.1% lower in the plug treated with indole-3-acetate, when compared with its 
paired control (p=0.005). Consistently with previous studies (Fridman, et al., 2012), a 
significant inter-individual variability was observed, accounting for 18.8% of the total 
variation (p=0.045). The effect of individual variation on angiogenic response was 
minimised by implanting both a treated plug and a control in each mouse. This 
strategy allowed the use of paired statistical analyses, thus increasing statistical 
robustness. Regardless of inter-individual variability, all plugs treated with indole-3-
acetate exhibited a smaller CD31+ area, when compared with their respective controls. 
Altogether, these results suggest that indole-3-acetate is able to downregulate 
angiogenesis in vivo. These results are in line with the previous results in vitro, in 
which indole-3-acetate (at 100 M) was able to inhibit both cell migration and tube 
formation (see Chapter 7). This dual effect might account, at least partially, for lower 
in vivo vascularisation observed in the presence of indole-3-acetate. 
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5. Conclusion 
 
Previous pharmacological inhibition assays and molecular docking analyses 
(Chapter 6) suggested that the indole-3-acetate might inhibit angiogenesis, through a 
direct competitive inhibition of VEGFR-2. This hypothesis was validated in vitro in 
Chapter 7, and finally in vivo in the present chapter.  
 
 Anti-angiogenic compounds have been proposed as a therapeutic approach in a 
range of pathologies characterised by increased proliferation of blood vessels 
(Taraboletti and Margosio, 2001; Vuorio, et al., 2012). This growing list of pathologies 
includes, amongst others, several cardiometabolic disorders (e.g. atherosclerosis, 
hypertension, obesity, diabetic retinopathy) and cancer (Tahergorabi and Khazaei, 
2012). In order to validate a therapeutic role for indole-3-acetate in atherosclerosis, 
further work could include dosing ApoE-/- mice (a well-established mouse model for 
the study of atherosclerosis (Meir and Leitersdorf, 2004)) with indole-3-acetate, and 
assess its impact on the extension of the plaque, compared to non-treated controls. 
Xenograft studies could also clarify the role of indole-3-acetate in the development and 
progression of cancer, where sustained angiogenesis is a hallmark that allows the 
critical delivery of oxygen and energy to the neoplasia (Hanahan and Weinberg, 2011). 
 
By identifying, for the first time, a role for indole-3-acetate as a gut microbial 
metabolite with anti-angiogenic properties, we identify a novel mechanism through 
which the gut microbiota can closely modulate a range of diseases with public health 
impact. Furthermore, this metabolite emerges both as a potential biomarker and 
therapeutic tool for such conditions, as will be further explored in the final chapter 
(Chapter 9. General Discussion).  
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Chapter 9  
General Discussion 
 
 
Over the last decades, various studies have highlighted the critical role of the 
gut microbiota in the onset and development of obesity and CVD (Delzenne and Cani, 
2011; Jonsson and Backhed, 2017; Xu and Gordon, 2003).  
 
Although protein kinases are one of the pharmaceutical industry' s most 
important classes of drug targets - with almost 20 protein kinase inhibitors currently 
approved for clinical use and hundreds undergoing clinical trials (Cohen, 2002; 
Manning, et al., 2002) -, the human kinome remains an unexplored repertoire of 
microbial transduction triggers for human homeostasis and metabolism. Exploring the 
microbiome-kinome crosstalk opens, therefore, a novel research avenue to understand 
the impact of gut microbial metabolites in human health. 
 
Amongst gut microbial metabolites, indoles were suggested to play a role as 
signalling molecules in obesity, as obese patients show higher modules for the 
degradation of tryptophan (Le Chatelier, et al., 2013). Most pro-inflammatory and 
pro-oxidative effects of indoles in vascular endothelial cells are thought to be mediated 
by AHR (Ito, et al., 2016; Jin, et al., 2014); however, as the expression of this receptor 
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is lost during adipocyte differentiation, this receptor is not likely to mediate its effects 
on energy metabolism in adipocytes (Shimba, et al., 2003).  
 
The overall hypothesis of this work was that gut microbial metabolites - and in 
particular indoles - bind to human kinases, impact signalling pathways and interfere 
with cellular processes relevant to obesity and cardiometabolic disorders, thus acting 
as chemical messengers in the microbiome-kinome crosstalk. 
 
This work describes two examples of indoles acting as chemical messengers in 
the microbiome-kinome crosstalk: while indoxyl sulfate shows a potential kinome-wide 
effect and pro-adipogenic properties, indole-3-acetate selectively inhibits VEGFR-2 and 
consequently angiogenesis. Both examples demonstrate how gut microbial metabolites 
can impact mechanisms relevant for the onset and development of obesity and 
cardiometabolic disorders. Although belonging to the same chemical family, these 
microbial metabolites demonstrate different patterns of impact on the human kinome. 
Hence, the impact of indoles in the microbial-mammalian crosstalk should be 
investigated at individual level, rather than assuming that their potential effects are 
class-specific.  
 
In this Chapter, a summary of the key findings will be presented, followed by 
discussion of the strengths of the experiments, opportunities for future work and, 
finally, broader implications for human health. 
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1. Key findings 
 
1.1. Gut microbial degradation of tryptophan converges to the production 
of indoxyl sulfate and indole-3-acetate  
 
 Using a systematic computational approach, it was demonstrated that the 
production of indoles is highly dependent on gut microbial metabolism, with 78% of 
the metabolic reactions being predictively performed by gut prokaryotes (Chapter 3). 
The metabolic reactions involved in the degradation of tryptophan into indoles 
converge to two main metabolites: indoxyl sulfate (via indole) and indole-3-acetate.  
 
 Regarding the production of indole (which is later sulfated in the liver in indoxyl 
sulfate), most predicted species belonged to the phyla Proteobacteria and 
Bacteroidetes. This systematic computational strategy predicted 23 species previously 
not associated with indole metabolism; two of these species were recently confirmed as 
indole-producing species, encoding tryptophanase in their genomes and/or producing 
detectable levels of indole (Alves, et al., 2006; Sasaki-Imamura, et al., 2011).  
 
 A different pattern was observed for indole-3-acetate, for which bacterial 
production was mostly associated with Proteobacteria and Firmicutes. Pseudomonas 
putida, Pseudomonas fluorescens, Klebsiella oxytoca and Klebsiella pneumoniae are 
amongst the species predicted to carry out several metabolic steps involved in the 
production of indole-3-acetate; interestingly, these species were previously 
demonstrated to be involved in the production of indole-3-acetate in plant studies 
(Karnwal, 2009; Patten and Glick, 2002). This data mining strategy also allowed the 
prediction of species previously not associated with indole-3-acetate production (i.e. 
Pseudomonas nitroreducens and Raoultella terrigens). Altogether, these results 
highlight the contribution of the gut microbiota to the production of indoles and 
demonstrate that each indolic compound has its own specific production path, to which 
a specific group of prokaryotes is likely to contribute.  
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1.2. Indoxyl sulfate exhibits pro-adipogenic properties through a putative 
multiple-kinase effect 
 
Indoxyl sulfate, the only indolic compound unambiguously assigned by 1H NMR 
in the MetaHit study, is positively correlated with both adiposity (%Fat) and plasma 
levels of leptin (Chapter 4). No significant associations were found between indoxyl 
sulfate, inflammatory or metabolic parameters, or dietary tryptophan, thus excluding 
the effect of potential confounders. The pro-adipogenic effect of indoxyl sulfate was 
investigated in vitro (Chapter 5), where preliminary results suggest that it increases 
accumulation of intracellular lipids and production of leptin. 
 
 A high-throughput kinome screening demonstrated that indoxyl sulfate exhibits 
kinome-wide effects, binding to 46.3% of the kinases tested in a single-dose screening. 
Highest affinity bindings were found for PDGFRB, STK32C, c-KIT, MRCKA, 
MYLK3, MRCKB, GLK and CLK3, with PDGFRB emerging as the strongest 
candidate, with the lowest KD and IC50 values. As PDGFRB was previously identified 
as a negative regulator of adipogenesis (Artemenko, et al., 2005; Fitter, et al., 2012), 
it was hypothesised that the pro-adipogenic effect of indoxyl sulfate could be mediated 
by inhibition of this receptor. However, this metabolite was not able to counteract the 
anti-adipogenic effect of PDGFRB activation, thus leading to the rejection of the initial 
hypothesis. 
 
Given the kinome-wide impact of indoxyl sulfate, it is more plausible that its 
impact on adipocyte metabolism is mediated by a complex integration of effects of 
multiple kinases. Using a network-based analysis, the relevance of each kinase to the 
signalling pathways involved in adipogenesis was ranked. Kinases involved in the 
shortest betweenness-ranked paths leading to the production of triacylglycerol included 
PDGFRB, c-KIT, MRCKA, MYLK3, MRCKB and ZAK. The signalling of PDGFRB, 
ZAK, c-KIT and MRCKA converge to PLCB2, which therefore emerged as a 
potentially critical node for the pro-adipogenic effect of indoxyl sulfate. Altogether, 
these results identify indoxyl sulfate as a gut microbial metabolite with pro-adipogenic 
properties and provide seminal evidence on the putative targets and mechanisms 
mediating its effect. 
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1.3. Indole-3-acetate exhibits anti-angiogenic properties through a putative 
VEGFR-2 inhibition 
 
 Contrary to indoxyl sulfate, indole-3-acetate appears to have a very specific 
effect, with a single positive hit (VEGFR-2) in the kinome screening (Chapter 6). The 
single-dose kinome scan was complemented by the confirmation of the physical 
interaction (KD = 890 M) and by the verification of inhibition of the phosphorylation 
activity (IC50 = 333.7 M). The physical interaction between indole-3-acetate and 
VEGFR-2 was further explored by molecular docking analysis, which suggested an 
ATP-competitive inhibitory mechanism. The inhibition of VEGFR-2 
autophosphorylation by indole-3-acetate was subsequently confirmed in HUVEC; 
consistent with a putative role as VEGFR-2 inhibitor, indole-3-acetate significantly 
reduced the phosphorylation of AKT and the production of NO.  
 
 As VEGFR-2 is the main receptor involved in angiogenesis, it was hypothesised 
that indole-3-acetate would exhibit anti-angiogenic properties. Supporting this 
hypothesis, indole-3-acetate significant inhibited both HUVEC cell migration and tube 
formation in vitro (Chapter 7). The anti-angiogenic effect of indole-3-acetate was 
further demonstrated in vivo using a Matrigel subcutaneous plug assay, where the 
compound inhibited the area of the plug’s vascular network, expressed as the per cent 
of the CD31+ area (Chapter 8). 
 
Altogether, this combined strategy comprising a kinome screening and 
molecular docking analyses, combined with a panel of cell-based assays and, finally, in 
vivo validations provides a comprehensive body of evidence supporting an anti-
angiogenic role for indole-3-acetate. 
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2. Experimental strengths and future work 
  
 The data-mining strategy proposed in Chapter 3 is the first attempt to use a 
systematic computational approach to clarify the gut microbial metabolism of indoles. 
This strategy provides a systematic overview of the metabolic pathways and predicted 
species involved in the metabolism of these compounds, identifying a list of novel 
species. However, as mentioned before, these predictions require experimental 
validation, such as the quantification of indole-3-acetate in pure cultures of bacteria 
grown in tryptophan-containing media (e.g. by LC-MS/MS). As a broader application, 
this methodology can be a useful tool to interrogate the metabolism of other gut 
microbial products.  
 
In Chapter 4, a positive association between indoxyl sulfate and whole body fat 
(%Fat) was identified, in the context of non-genetic obesity. 1H NMR was used due to 
its high reproducibility and wide use in metabolic profiling in the context of obesity 
and cardiometabolic disorders, thus allowing comparisons with other studies (Calvani, 
et al., 2010; Dumas, et al., 2006; Elliott, et al., 2015). The assignment of indoxyl sulfate 
was confirmed by a spike-in experiment, as recommended when identifying a novel or 
putatively relevant biomarker (Dona, et al., 2016). The relationship between indoxyl 
sulfate and dietary intake was further explored, and potential metabolic and dietary 
confounders were excluded. In order to strengthen these findings, the statistical 
relationship between indoxyl sulfate and obesity should be further validated in other 
human cohorts. Of note, indoxyl sulfate was the only indolic compound unambiguously 
assigned by 1H NMR in this study. Indole-3-acetate was putatively assigned as a low-
intensity signal in a standard ID experiment with water pre-saturation, and confirmed 
by 2D experiments (COSY and HSQC); however, spectral overlap with other 
compounds prevented an adequate quantification of this metabolite. Future work 
should address the unambiguous assignment and quantification of other indoles, using 
targeted mass spectrometry methods (Markley, et al., 2017), in order to explore their 
association with obesity and/or other cardiometabolic disorders. 
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One of the strengths of this work relies on capitalising on the clues provided by 
1H NMR to investigate the role of indoles as pharmacological players, thus moving 
from correlation to causation. For the first time, it was demonstrated that indoxyl 
sulfate increases lipogenesis and leptin production in 3T3-L1, one of the most used cell 
lines to investigate the adipogenic potential of both endocrine and pharmacological 
compounds (Green and Kehinde, 1975; Green and Meuth, 1974) (Chapter 5). These 
findings can be strengthened by increasing the number of experiments and by 
validating the pro-adipogenic effect using other molecular biology techniques, such as 
quantification of the expression of adipocyte marker genes by qPCR. In particular, 
PPAR, a nuclear receptor from the ligand-activated transcription factors family and 
vital for adipocyte differentiation (Gregoire, et al., 1998), and other markers of 
adipocyte differentiation (i.e. C/EBP, FASN and ADIPOQ (Gregoire, et al., 1998; 
Sul, et al., 2000)) should be further investigated.  
 
 By identifying key examples of how indoles act as chemical messengers in the 
microbiome-kinome crosstalk (Chapters 5 and 6), this work opens a new research 
avenue to understand the impact of gut microbial metabolites, and in particular 
indoles, in obesity and cardiometabolic disorders. Although being one of the 
pharmaceutical industry’s most important classes of drug targets (Cohen, 2002; 
Manning, et al., 2002), the human kinome remained an unexplored repertoire of 
microbial transduction triggers for human homeostasis and metabolism. Importantly, 
this work highlights the within-class heterogeneity of indoles, with individual 
compounds exhibiting different targets and different kinome specificity. In the first 
example, indoxyl sulfate shows kinome-wide effects, representing an increased 
challenge regarding the clarification of targets and signalling pathways. Although a 
preliminary map of the strongest candidate targets is provided in this thesis, further 
work using phosphoproteomics coupled with network integration is needed to provide 
system-level information, to characterise the pathways involved and to identify 
potential inter-pathway cooperation.  
 
Conversely, indole-3-acetate was identified as a specific inhibitor of VEGFR-2. 
VEGFR-2 is the main regulator of angiogenesis. Thus, the anti-angiogenic effect of 
indole-3-acetate was validated in vitro. As recommended, the effect of the compound 
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was evaluated in more than one mechanistic step (Auerbach, et al., 2003), using a 
panel of well-established cell-based assays and mimicking as close as possible 
physiological conditions (e.g. concentration, surface coating with Collagen-I and 
Matrigel), and finally validated in vitro using a Matrigel subcutaneous plug. Overall, 
one of the major strengths of this work is the consistency between in silico, in vitro 
and in vivo results that, combined in a comprehensive research strategy, support an 
anti-angiogenic effect of indole-3-acetate. 
 
However, some experimental limitations should be noted. Although indole-3-
acetate significantly impaired the phosphorylation of Tyr1175, one of the major 
autophosphorylation sites of VEGFR-2 in humans in vitro (Takahashi, et al., 2001), 
the magnitude of VEGFR-2 activation was not consistent between experiments 
performed under the same experimental conditions. As future work, these results could 
be potentially strengthened by testing higher concentrations of the compounds and the 
agonist, and by trying alternative normalisation techniques (i.e. normalisation to total 
protein content). Using molecular docking analysis, indole-3-acetate was predicted to 
inhibit VEGFR-2 through an ATP-competitive effect. Also, although indole-3-acetate 
was also shown to inhibit VEGFR-2 downstream signalling (AKT phosphorylation and 
NO production) (Chapter 6), it is important to note that one-tail testing was performed 
(i.e. testing for inhibition, as predicted by the IC50). These results can be strengthened 
in the future by increasing the number of experiments, optimising the concentrations 
used and investigating of the optimal time points to assess both outcomes. 
Additionally, in order to have a more comprehensive overview of the impact of indole-
3-acetate on (Tyr1145)VEGFR-2 downstream signalling, it would be important to 
clarify its effect in other pathways (i.e. PKC/MEK/ERK, Src and FAK/paxillin). 
Finally, although in silico molecular docking is one of the most frequently used methods 
to predict the binding-conformation of small molecule ligands to a given target 
(Kitchen, et al., 2004), it requiring further in vitro validations (i.e. mutagenesis of the 
amino acids predicted to be involved in the binding). 
 
Finally, it is important to consider that the effect of indole-3-acetate might be 
a multiparametric pharmacological response with a primary target (VEGFR-2) and 
multiple secondary targets. AHR, a nuclear receptor suggested to have a negative 
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impact in angiogenesis (Eckers, et al., 2016), was previously proposed as a target of 
indole-3-acetate; however, only a very weak AHR agonism was observed in vitro using 
high, non-physiological doses (250 M). These findings do not support that the effect 
of indole-3-acetate, at physiological concentrations, is mediated by AHR, however, 
small interfering RNA (siRNA) / short hairpin RNA (shRNA) experiments targeting 
other putative receptor involved should provide further insights in order to include, 
exclude or assess the magnitude of the contribution of the targets involved. In this 
case, a direct VEGFR-2 inhibition arises as a simpler, more logical and testable 
putative explanation, thus emerging as preferable according to the law of parsimony 
(lex parsimoniae, a problem-solving principle used as an heuristic guide in the 
development of theoretical models in science) (Gauch, 2003).  
 
3. Consequences of kinome inhibition for obesity and 
cardiometabolic diseases 
 
3.1. A novel contribution of the gut microbiota to human obesity 
 
Several microbial metabolites have been previously shown to play a role in 
obesity. As an example, SCFA (i.e. butyrate, propionate and acetate) exert a beneficial 
effect in diet-induced obesity (Chilloux, et al., 2016). While acetate alters the 
hypothalamic expression of neuropeptides involved in appetite suppression (Frost, et 
al., 2014), propionate upregulates the release of glucagon-like peptide-1 and peptide 
YY (Psichas, et al., 2015).  
 
 In this work, indoxyl sulfate is proposed as a novel gut microbial metabolite 
involved in human obesity. By demonstrating that the levels of indoxyl sulfate are 
positively correlated with adiposity, these results are in line with the findings of Zhang 
et al, who reported higher levels of this metabolite in a context of paediatric genetic 
obesity (Zhang, et al., 2015). Altogether, these results support that the association 
between indoxyl sulfate and obesity is not specific of a genetic context. The underlying 
conceptual model proposes that, in obese patients, gut dysbiosis and increased genomic 
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ability to degrade tryptophan (Le Chatelier, et al., 2013) result in an increased 
production of indoxyl sulfate, which exhibits pro-adipogenic properties and thus 
contributes to increased adiposity. 
 
An exploratory target screening provided new knowledge on the impact of 
indoles on the human kinome, reinforcing the relevance of this repertoire of proteins 
as a critical object of study to better understand the microbial-mammalian crosstalk. 
By shortlisting putative human targets of indoxyl sulfate, this work provides a first 
attempt to clarify the targets and mechanisms by which indoxyl sulfate affects the 
onset and progression of obesity. PLCB2 emerged as a potentially critical node for the 
pro-adipogenic effect of indoxyl sulfate; it codes for the enzyme 1-phosphatidylinositol-
4,5-bisphosphate phosphodiesterase 2, which hydrolyses PIP2 to IP3 and DAG. DAG 
is further esterified into TAG by the diglyceride acyltransferase (Saponaro, et al., 
2015). Both IP3 and DAG are involved in processes relevant to obesity. DAG 
stimulates PKC, which in turn phosphorylates myristoylated alanine-rich protein 
kinase C substrate (MARCKS); MARCKS then binds actin and calcium-calmodulin, 
finally inducing insulin exocytosis (Lustig, 2003). Insulin secretion is also promoted via 
IP3, which induces calcium release from intracellular stores (Lustig, 2003). 
 
3.2. Impact of inhibition of angiogenesis by gut microbial metabolites in 
human health and disease 
 
 The identification of indole-3-acetate as a gut microbial metabolite with anti-
angiogenic properties has wide-ranging implications for human health. Angiogenesis is 
a tightly controlled process and, when dysregulated, contributes to a variety of human 
diseases. Insufficient angiogenesis has been associated with other cardiometabolic 
outcomes, such as hypertension (where impaired vasodilation leads to microvessel 
rarefaction) (Battegay, et al., 2007) or diabetes (characterised by impaired angiogenesis 
in ischemic limbs, but increased neovascularisation in the retina) (Tamarat, et al., 
2004). Angiogenesis also seems to play a relevant role in atherosclerosis. Adventitial 
angiogenesis allows atherosclerotic plaques to develop beyond a critical thickness point 
(Barger and Beeuwkes, 1990). It was demonstrated that angiogenesis inhibitors (i.e. 
endostatin and TNP-470) are able to reduce the size of atherosclerotic plaques by 85% 
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and 70%, respectively (Moulton, et al., 1999). Furthermore, the neo-vascular network 
renders plaques more fragile and prone to rupture and is, therefore, a cause of luminal 
occlusion and acute coronary syndromes (Barger and Beeuwkes, 1990; Moreno, et al., 
2004). As a gut microbial metabolite with anti-angiogenic properties, indole-3-acetate 
could exhibit a similar protective effect in patients with atherosclerosis.  
 
 The findings from this work provide new knowledge on the role of the gut 
microbiota in angiogenesis (a key process in the onset and development of 
atherosclerosis) and naturally complement the conceptual model proposed by Jonsson 
and Backhed that suggests the gut microbiota can impact atherosclerosis via 
infections/inflammatory responses that aggravate plaque development or rupture, or 
upon the action of gut microbial metabolites (Jonsson and Backhed, 2017). 
 
Indole-3-acetate naturally emerges as a particularly interesting therapeutic tool 
in the context of angiogenesis-related health outcomes, as will be further explored in 
Section 3.4. The gut microbial pharmacopeia as a potential therapeutic tool. 
 
3.3. The gut microbial pharmacopeia as a potential therapeutic tool 
 
Indoles are a heterogeneous class: each one of the studied metabolites exhibits 
a particular metabolic production pathway, different human targets and specificity 
pattern – and, therefore, different potential as therapeutic tools.  
 
 Indole-3-acetate is as a particularly interesting therapeutic tool in the context 
of angiogenesis-related health outcomes, particularly in atherosclerosis and cancer. As 
angiogenesis inhibitors are able to reduce the size of the atherosclerotic plaque 
(Moulton, et al., 1999), indole-3-acetate may have a similar beneficial effect, which 
remains to be validated in vivo (e.g. using an ApoE-/- mouse model). Sustained 
angiogenesis is also a hallmark of cancer (Hanahan and Weinberg, 2011), several anti-
angiogenic drugs are currently used for its treatment (Oehler and Bicknell, 2000; 
Taraboletti and Margosio, 2001; Vasudev and Reynolds, 2014). VEGFA is 
overexpressed in most solid cancers, and its inhibition can supress tumour growth in 
animal models (Oehler and Bicknell, 2000). Based on these findings, numerous anti-
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cancer therapies targeting angiogenesis have been developed, many of which are 
approved by the Food and Drugs Administration (Carmeliet and Jain, 2011; Potente, 
et al., 2011). Contrary to most VEGFR-2 inhibitors that inhibit multiple kinases and, 
therefore, have a wide range of side effects, indole-3-acetate has shown a very specific 
inhibition for VEGFR-2 in our kinome screening – and, therefore, a lower potential for 
side effects. Therefore, indole-3-acetate could represent both a protective factor and a 
therapeutic tool in the context of cancer, especially in colon (where its absorption 
occurs and the area of contact is maximal) and in the liver and portal circulatory 
system (where its concentrations are particularly high). 
 
Finally, putative microbial interventions aiming to modulate indoles should 
integrate the impact of indoles-producing species as part of a broader body of 
knowledge, as these species might also contribute to the production of other 
metabolites with either beneficial or deleterious effects for health outcomes. Due to the 
complexity of the gut microbial ecosystem, significant impact is unlikely to be achieved 
unless several species are simultaneously targeted.  
 
3.4. Gut microbial metabolites in risk stratification and personalised 
medicine 
 
Currently, the clinical management of obesity and cardiometabolic disorders 
consists of a comprehensive, non-personalised lifestyle management, associated or not 
to pharmacological therapies. However, there is an obvious inter-individual 
heterogeneity. Rather than ignoring the existence of multiple phenotypes, the 
personalised medicine movement has embraced the belief that individual-level risk 
stratification can be used to inform treatment, but also to empower patients to adopt 
healthier choices and promote meaningful behaviour changes. 
 
The potential of metabonomics in personalised health care has been extensively 
explored (Nicholson, et al., 2011); as an example, basal metabolite levels were able to 
predict future weight gain in patients undergoing chemotherapy for early stage breast 
cancer (Keun, et al., 2009). Similar to indoxyl sulfate, other gut microbial metabolites 
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(e.g. SCFA, bile acids, TMAO) have been suggested to play a role on the onset of 
obesity and other cardiometabolic disorders (Chilloux, et al., 2016; Dumas, et al., 
2017). Altogether, the contributions of individual metabolites could be incorporated in 
the development of stratification tools in the context of obesity and cardiometabolic 
disorders, moving into a more personalised delivery of care. Similarly, if the protective 
effect of indole-3-acetate on atherosclerosis and cancer is confirmed, the endogenous 
levels of indole-3-acetate can be investigated as putative risk markers for the occurrence 
of acute coronary syndromes or cancer, respectively, in high-risk patients.   
 
4. Conclusion 
 
Although gut microbial metabolites have a well-recognised role in obesity and 
cardiometabolic disorders (Delzenne and Cani, 2011; Jonsson and Backhed, 2017; Xu 
and Gordon, 2003), their targets and mechanisms are not fully understood. In this 
context, the human kinome - one of the pharmaceutical industry' s most important 
classes of drug targets - has remained mostly unexplored as a repertoire of transduction 
triggers for human metabolism.  
 
This work highlights the role of indoles as chemical messengers in the 
microbiome-kinome crosstalk: whereas indoxyl sulfate shows a putative kinome-wide 
effect and pro-adipogenic properties, indole-3-acetate selectively inhibits VEGFR-2 and 
subsequently angiogenesis. These results demonstrate how, by binding to human 
kinases, indoles can critically impact pathways and cellular processes relevant for the 
onset and development of obesity and cardiometabolic diseases. Angiogenesis, in 
particular, has been proposed as a key mechanism in several cardiometabolic disorders 
(e.g. obesity, arterial hypertension, diabetic retinopathy) – and, importantly, in cancer.   
 
 By unravelling the targets, mechanisms and consequences of indoles as gut 
microbial pharmaco-metabolites, this work not only contributes to a better 
understanding of the link between the gut microbiota, obesity and cardiometabolic 
disorders – but also opens novel avenues for the use of the gut pharmacopeia in risk 
stratification and personalised health care delivery. 
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